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Abstract 
 
This thesis addresses the transparency of weight of evidence-based analysis in the 
application of the IPCS Framework for Assessing the Human Relevance of a 
carcinogenic response to a chemical. This thesis also explores how, and to what extent, 
available toxicogenomics data can be incorporated into a cancer mode of action 
analysis.  
 
A systematic review was carried out on epidemiological data available for 
phenobarbital (PB). A positive association between liver cancer and PB was reported 
among a large Finnish cohort however the study was assessed to be unreliable on the 
basis of key limitations. However owing to the size of cohort investigated, the study 
could not be disregarded and the conclusions reached by the authors were considered 
to be associated with a high level of uncertainty. Studies of two smaller cohorts of 
patients, assessed to be of a high quality, reported no findings of such an association. 
The methods applied in this thesis illustrated the value of systematic review 
techniques in increasing the transparency of decisions made when applying a WOE 
based approach to assessing the human relevance of cancer mode of action and in 
helping to identify important data gaps. 
 
Comparative analysis of publicly available toxicogenomics data for PB using Pathway 
Analysis software led to the identification of perturbed pathways that were interpreted 
within the context of the key events for PB MOA for hepatocarcinogenesis. The 
analysis demonstrated that prior mechanistic knowledge about a compound under 
investigation is currently necessary before efficient interpretation of the biological 
relevance of perturbed pathways is possible. To realise the true potential for the 
application of toxicogenomics data in risk assessment, future toxicogenomics study 
designs will need to be more targeted (e.g. in their considerations of dose-response, 
time-response and species differences) before they can be applied to help fill the 
current gaps in mechanistic knowledge. The experience from the comparative analysis 
reported here suggests that at the present time, information on perturbed pathways 
obtained in this way is not sufficiently robust to be used as stand alone evidence in 
MOA analysis. The potential to read across toxicogenomics evidence for PB MOA to 
other compounds, which may act via the same MOA however deserves further 
exploration.  
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Chapter 1 
 
Introduction  
 
 
Humans are all exposed to chemicals on a daily basis from many different sources and 
at varying levels of exposure. The sources of these chemicals include, but are not 
limited to, drugs, agricultural chemicals such as pesticides, environmental pollutants, 
industrial chemicals and food additives. The regulation of these chemicals is often 
required to mitigate any potential risks to human health or the environment as a result 
of voluntary or involuntary exposure to these chemicals. The process of regulating 
these chemicals relies on the effective use of available but sometimes limited 
resources to characterise potential hazards as part of the chemical risk assessment 
process.  
 
In risk assessment, the overall evidence evaluated by a risk assessor is commonly 
referred to as the “weight of evidence” (WOE) [1]. Linkov et al [2] define WOE as “a 
framework for synthesizing individual lines of evidence, using methods that are either 
qualitative (examining distinguishing attributes) or quantitative (measuring aspects in 
terms of magnitude) to develop conclusions regarding questions concerned with the 
degree of impairment or risk”.   
 
 
1.1 Background to Chemical Risk Assessment 
 
Risk assessment is part of a risk analysis paradigm developed by the Codex 
Alimentarius Commission (CAC). The CAC was formed in 1963 by the Food and 
Agriculture Organization (FAO) and World Health Organization (WHO) to develop 
food standards, guidelines and codes of practice under the programme of the Joint 
FAO/WHO Food Standards Programme [3]. Risk analysis comprises of risk 
assessment, risk management and risk communication. Although the paradigm is split 
into three separate components, the process requires the interaction and 
communication between those responsible for each of the separate component [4]. 
Risk assessment describes the scientific process that consists of hazard identification, 
hazard characterisation, exposure assessment and risk characterisation. Risk 
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management describes the process of considering various policy alternatives in 
consultation with relevant stakeholders. The process also involves the consideration 
of issues identified from the risk assessment that are relevant for human health 
protection and factors that affect the promotion of fair trade practices. Finally, risk 
communication, requires the exchange of information and opinions among relevant 
stakeholders (risk managers, risk assessors, consumers, industry, members of the 
academic community etc)  on issues that relate to the different risk related factors 
and/or perceptions of risk. This process also requires the adequate communication of 
the findings from the risk assessment and justification for the basis for any risk 
management decisions made [4]. 
 
This thesis focuses on aspects that are considered as part of the risk assessment part of 
the risk analysis paradigm. The International Programme on Chemical Safety (IPCS) 
defines risk assessment as a "conceptual framework that provides the mechanism for 
a structured review of information relevant to estimating health or environmental 
outcomes" [5]. A major aspect of the risk assessment paradigm which consists of 
hazard identification, hazard characterisation, exposure assessment and risk 
characterisation, is the consideration of the hazard and the risk. The IPCS defines 
hazard as “an inherent property of an agent or situation having the potential to cause 
adverse effects when an organism, system or (sub)population is exposed to that 
agent”, while risk is defined as “the probability of an adverse effect in an organism, 
system or (sub)population cause under specific circumstances by exposure to an 
agent” [4]. 
 
Evaluation of the qualitative and quantitative evidence at the different stages of the 
risk assessment process allows for the consideration of all relevant information 
required to fully assess any potential risks associated with a chemical/substance, 
thereby facilitating the identification of any adverse health effects that may occur in 
humans [4]. The different aspects of the risk assessment paradigm are briefly 
discussed below.  
 
Hazard identification: during this first stage of the risk assessment process, the WOE 
available for the substance under review is evaluated in order to determine whether 
the substance has the potential to produce adverse health effects, the nature of those 
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effects and also to determine the conditions under which the substance might exhibit 
any hazards [6]. 
 
Hazard characterisation: the second stage of the risk assessment process involves the 
qualitative and quantitative assessment of the varying properties of the compound 
under evaluation and considerations for the circumstances where the compound has 
the potential to cause adverse health effects. This stage normally includes a dose 
response assessment and  consideration of any underlying uncertainties [6]. 
 
Exposure assessment: the third stage of the risk assessment process aims to define the 
nature of exposure and evaluate the different exposure levels for the compound (and 
its derivatives) to which humans are exposed or are likely to be exposed. The process 
also requires the consideration of the duration of exposure to the relevant 
chemical/substance [4]. 
 
Risk characterisation: in the final step of the risk assessment process, the WOE from 
the previous steps are summarised in a clear and transparent format that is aimed 
specifically at risk managers - to aid decision-making processes.  The result of this 
process is the qualitative and quantitative determination of the risks associated with 
exposure to this chemical after full consideration of the different scenarios to which 
humans might be exposed. At all stages of the risk assessment, the underlying 
uncertainties are considered thoroughly. Subsequently, it is the role of the risk 
manager to weigh the output of the risk assessment, together with all other relevant 
considerations to determine whether and what action should be taken to mitigate the 
risk [4]. 
 
 
1.2 Historical Approach to Risk Assessment 
 
An important consideration during the hazard characterisation stage of the risk 
assessment process is the dose response relationship.  The conventional approach is to 
characterise the shape of the dose response curve to determine the location of a 
putative threshold for a toxicological effect.  To establish whether a compound 
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exhibits a threshold effect requires consideration of the relevant underlying biological 
factors.   
 
For compounds that exhibit a threshold mechanism of effect it is assumed that a level 
of exposure exists below which no adverse health effects are likely to occur. Often, 
the no observed adverse effect level (NOAEL) is used as basis for estimating such a 
level in humans.  Toxicological effects thought to act in this way include most non-
cancer, organ-specific effects, neurological/behavioural effects, immunological 
effects and reproductive or developmental effects. Non-DNA reactive carcinogenic 
compounds are also considered to have a threshold for toxicological effect [6-8]. 
 
Fundamentally, the differences relating to the evaluation of compounds that exhibit 
either a threshold or non-threshold toxicological effect, relate to the determination of 
the ability of a compound to interact with DNA. The risk characterisation stage of the 
risk assessment process requires the use of different methods to estimate the risks 
associated with either DNA reactive or non-DNA reactive compounds. The traditional 
approach to dealing with non-DNA reactive compounds has been to derive a health 
based guidance value such as an acceptable daily intake (ADI) or acute reference dose 
(ARfD), by using a reference point (or point of departure), such as the no observed 
adverse effect level (NOAEL), and an uncertainty factor [8]. 
 
DNA-reactive carcinogens have generally been considered to exhibit no threshold in 
their effects, and the assumption is made that any level of exposure to these chemicals 
might result in an adverse health effect [6, 9, 10]. However, recent studies suggest that 
some DNA-reactive compounds display apparent thresholds at some low doses 
investigated [11].   Doak et al [11] investigated the low-dose-response relationship of 
four different DNA alkylating agents (methylnitrosourea (MNU), ethynitrosourea 
(ENU), methymethane sulfonate (MMS) and ehtylmethane sulfonate (EMS)) and 
assessed the induction of chromosomal damage and gene mutation. The authors 
demonstrated that both MMS and EMS displayed nonlinear dose response curves and 
observed the lowest observed effect level for the induction of chromosomal aberration 
at 0.85µg/mL and 1.40µg/mL for MMS and EMS respectively. Similarly, the lowest 
observed effect level for point mutations required 1.25µg/mL and 1.40µg/mL for 
MMS and EMS respectively before a mutagenic effect was observed. Such data 
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provide evidence that contradict the hypothesis previously for all DNA reactive 
genotoxic carcinogens that any level of exposure could result in an adverse health 
effect [4]. 
  
Qualitative and quantitative methods have previously been used to characterise the 
risks associated with DNA reactive compounds (compounds that act via a non-
threshold effect). For genotoxic carcinogens where the risk assessment can lead to the 
conclusion that there is no safe exposure level, risk management strategies have 
included the application of a qualitative approach such as the as low as reasonably 
achievable (ALARA) principle to minimise the risk levels by ensuring that exposure 
levels to these compounds are kept as low as reasonable/ achievable practicably.  
Quantitative methods of risk characterisation rely on the use of data obtained from the 
hazard characterisation stage of the risk assessment, particularly data from cancer 
bioassay, epidemiological data or estimates of exposure compiled to assess the dose 
response relationship.  Three different types of quantitative/semi-quantitative methods 
applied to the risk characterisation of DNA reacting chemicals are: the application of 
the threshold of toxicological concern (TTC); low dose extrapolation of data from 
rodent carcinogenicity bioassay (also referred to as linear extrapolation); and 
calculation of the margin of exposure (MOE) [7, 8].  
 
The TTC approach is applied for the risk characterisation of substances where 
biological data are lacking but the chemical structure of the substance being 
considered is known and there are also good exposure data for the substance [12]. If 
the substance of concern is known to be genotoxic or has a structural alert for 
genotoxicity (after exclusion of a small number of very potent structures), it is 
compared to a large database of carcinogens for which the distribution of doses 
estimated to be associated with a 1 in 10
-6
 risk of cancer has been determined.  If 
exposure is below the 5% value for this distribution (0.15µg/person/day), it is 
concluded that there is a low probability of harm to humans.  
 
The linear extrapolation approach involves the mathematical modelling of high dose 
carcinogenicity data obtained from animal experiments, to produce quantitative 
estimates of the risks of the cancer effects for humans who are normally exposed at 
doses several orders of magnitude lower than the lowest experimental dose 
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administered in an animal study [13, 14]. Extrapolation from the high doses observed 
in animals to the low doses to which humans are exposed can be carried out through 
the selection of reference points (RP) or so called “points of departure” (POD) on the 
modelled dose-response curve. The RPs/PoD normally selected for this approach 
include the benchmark dose (BMD10) or the statistical lower bound estimate of the 
95% confidence interval (BMDL10) for a 10% response, the lowest observed adverse 
effect level (LOAEL) or carcinogenic potency estimates such as TD50 or T25 
(simplistically, the effect dose for a 50% and 25% response, respectively, of the 
exposed population) [14-17]. This method of risk characterisation which can be 
applied to the evaluation of both threshold and non threshold substances provides an 
estimation of the level of exposure that is associated with an upper bound, lifetime 
risk of cancer of 1 in a million (1 X 10
-6
) or 1 in a hundred thousand (1 X 10
-5
). 
However one of the major limitations of this approach is that the models are highly 
conservative and there is sometimes the wrong assumption that the response observed 
in animals will also be seen in humans.  
 
The MOE approach for characterising the risks associated with genotoxic carcinogens 
is defined as the ratio between the dose leading to a specified tumour response in 
experimental animals and the human intake [18]. The MOE approach aims to inform 
risk managers on the relative risks associated with exposure from genotoxic 
carcinogens and also helps to prioritise risk management action for dealing with such 
compounds. The European Food Safety Authority (EFSA) and the World Health 
Organization (WHO) recommend the use of the BMDL10 as the POD when 
calculating a MOE from animal bioassay data [13, 14, 18]. 
 
 
1.3 Harmonisation of Approaches to Risk Assessment 
 
Different approaches to chemical risk assessment can lead to different conclusions 
using the same data and the same underlying assumptions.  In addition, assumptions 
have varied among risk assessment groups and there has been a lack of transparency 
such that the basis of a risk assessment sometimes cannot be determined or repeated. 
This highlighted the need for global harmonisation of basic scientific principles 
employed in risk assessment. In 1992, this issue was raised at the United Nations 
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Conference on Environment and Development (UNCED) in which the eco-friendly 
management of chemicals was addressed specifically in Chapter 19 of Agenda 21.  
The chapter highlighted the role of governments for developing and implementing 
national programmes for chemical management within the principles of sustainable 
development.  In highlighting the need for collaboration between international 
organisations such as the United Nations Environment Programme (UNEP), the 
International Labour Organisation (ILO), and the World Health Organisation (WHO) 
(represented by the International Programme on Chemical Safety, IPCS), IPCS was 
identified as the lead organisation to take forward the action plan to address issues 
relating to co-operation on the environmentally sound management of toxic chemicals.  
The role of IPCS was identified to be that of increasing co-operation between member 
states in an attempt to improve scientific knowledge in the area of chemical 
management [19, 20]. 
 
In 1993, IPCS initiated a project entitled Harmonisation of Approaches to the 
Assessment of Risk from Exposure to Chemicals (“Harmonization Project”), following 
the recommendations of UNCED [20] .  In 1994, the intergovernmental forum on 
chemical safety (IFCS) provided further support to IPCS in their lead role of 
promoting increased global harmonisation of scientific principles in chemical risk 
assessment.  The Harmonisation Project sought to "improve chemical risk assessment 
globally, through the pursuit of common principles and approaches and hence, 
strengthen national and international management practices which deliver better 
protection of human health and the environment within the framework of 
sustainability".  It is the ongoing aim of the Harmonisation Project to consider all 
issues related to the qualitative and quantitative stages of the risk assessment 
paradigms [21]. The Harmonisation Project aims to harmonize global approaches to 
risk assessment by: 
 Increasing understanding and agreement on basic risk assessment principles 
 Developing international guidance documents on specific issues [22]. 
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1.4 IPCS Mode of Action Framework  
 
Workshops organised by IPCS led to the identification of key areas of risk assessment 
that were in need of harmonization. These included: transparency, terminology, 
weight of evidence, flexibility and accessibility/ communication. The consideration of 
the WOE for mode of action (MOA) was identified as a key area for harmonization. 
Increased understanding of the carcinogenic process in both laboratory animals and 
humans has prompted a more evidence-based approach to the chemical risk 
assessment process in contrast to the previously simplistic and somewhat conservative 
techniques applied by different organisations, particularly in the field of cancer risk 
assessment. The increased availability of data relating to the pharmacokinetics and 
pharmacodynamics for specific agents has promoted the case for a chemical-specific 
approach [23, 24]. Efforts to address the types of criteria that should be considered 
when evaluating a MOA led to the development of a conceptual framework for the 
evaluation of an animal MOA.  One of the focus areas of the Harmonisation Project, 
where significant progress has been made and work is ongoing, relates to cancer risk 
assessment. 
 
In collaboration with the United States Environment Protection Agency (US EPA), 
Health Canada, and the International Life Sciences Institute Risk Science Institute 
(ILSI/RSI), IPCS published a conceptual framework for evaluating a mode of action 
for chemical carcinogenesis [24]. The term "Mode of Action" was introduced by the 
US EPA in acknowledgement that often only the key events in the carcinogenic 
process were known as opposed to the exact biochemical/molecular processes 
involved in the induction of cancer, as implied by the term "Mechanism of Action". 
The term MOA was, therefore, adopted for the IPCS framework in recognition of the 
fact that it was possible to reach conclusions about the key events that lead to specific 
carcinogenic endpoints without detailed mechanistic information [25]. A MOA is 
therefore defined as "a biologically plausible sequence of key events leading to an 
observed effect supported by robust experimental observations and mechanistic data”. 
It describes in a logical manner, the key cytological and biochemical events i.e. those 
that are both measurable and necessary to the observed carcinogenicity" [9]. The 
IPCS Conceptual Framework for Evaluating a Mode of Action for Chemical 
Carcinogenesis was published in 2001. The MOA framework is defined as "a tool 
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which provides a structured approach to the assessment of the overall weight of 
evidence for a postulated mode of action" [9, 24]. 
 
 
1.4.1  Mode of Action Approach to Cancer Risk Assessment  
 
The previously held default assumption for chemical risk assessment was that animal 
cancer data were always relevant to human risk. A move towards the use of the MOA 
approach for the evaluation of chemicals as illustrated through the evaluation of case 
study compounds, led to the acceptance that certain cancer MOAs are not relevant in 
humans. A noteworthy example of this is the MOA by which the chemical d-limonene 
causes renal tubular tumours in male rats. Evaluation of the evidence for d-limonene 
has shown that the accumulation of the protein α2u-globulin leading to induced 
toxicity and neoplasia is species- and sex-specific, i.e. to male rats and therefore not 
relevant to humans. As part of the effort to move away from applying default 
assumptions when using animal data in risk assessment, the MOA approach requires a 
thorough evaluation of the weight of evidence allowing for the provision of a 
biologically plausible explanation for the occurrence of a cancer [25, 26].   
 
The concept of using a MOA approach is not new to the field of chemical risk 
assessment. In the past, although not formally incorporated into risk assessment 
guidelines, the MOA approach consisted of evaluating available data relating to the 
biological events of observed toxicological endpoints from animal data to determine 
the relevance to human health. In attempting to harmonise scientific principles in the 
field of risk assessment, particularly in carcinogenic risk assessment, it was therefore 
essential to promote the incorporation of formal and systematic applications of the 
mode of action concept into risk assessment procedures. 
 
A significant development in the past few decades has been a recognition that 
carcinogens can act via a genotoxic or non-genotoxic (also referred to as epigenetic) 
mechanism. The process of mutagenesis as part of the carcinogenic process observed 
in experimental animals has also been useful in gaining wide acceptance by the 
scientific community that some chemicals can exhibit carcinogenic properties without 
direct interaction with DNA i.e. via a non-genotoxic mechanism. It is now accepted 
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that for most compounds acting via a non-genotoxic a threshold dose exists below 
which no adverse effects are observed [7]. The induction of tumours by non-
genotoxic carcinogens are considered to be a secondary adverse effect caused by an 
initial toxicological effect (which would exhibit a threshold) [7, 27]. Contrary to 
previously held default assumptions reserved for all carcinogenic chemicals,  it is now 
clear that thresholds do exists for non-genotoxic carcinogens as tumours are not 
induced at doses below the levels that do not cause the initial toxicological effect [28].   
More importantly, it has been realised that cancer and other toxicological effects 
result from a series of key events that reflect the structural changes occurring in the 
process of the final observed toxicological outcome. The need to thoroughly consider 
the effect that a foreign compound can have on disturbing the biological balance of 
key processes has become more pertinent. In the case of cancer, genotoxicity may be 
another key event that drives the mode of action and dictates the nature of the dose 
response curve [9]. 
 
 
1.4.2  Weight of Evidence Evaluation Based on the Bradford Hill Criteria 
 
The mode of action conceptual framework allows for the thorough assessment of the 
weight of evidence (WOE) in a systematic format.  The MOA framework provides, in 
the form of a stepwise approach, guidelines detailing the manner in which all WOE 
should be compiled and evaluated. This stepwise approach is intended to facilitate 
transparent decision making in the process of postulating the MOA in animals. The 
various points to be addressed in this format have been based on the criteria proposed 
by Bradford Hill [29] now commonly referred to as the "Bradford Hill criteria for 
causality". Hill identified nine different points to address when trying to determine 
whether a disease outcome was the result of an incidental association or, was in fact, 
causally related to a certain environmental exposure. While Hill was cautious to not 
refer to these points as criteria, the different points identified were intended to explore 
the idea of association before automatically assuming causality. The criteria for the 
evaluation of causality therefore included: strength of association, consistency of 
association, specificity of association, temporal relationship of the association, 
evaluation of the biological gradient or dose response curve, evaluation of the 
biological plausibility, the coherence of the observed effect, evaluation of 
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experimental evidence (e.g. the effectiveness of preventive steps towards observed 
associations) and the use of analogies in circumstances where evidence may be 
insufficient.   
 
In keeping with the Bradford Hill criteria for causality, the MOA framework suggests 
consideration of the weight of evidence in the following stepwise format: 
 
A. Postulated MOA. 
B. Key events; associated critical parameters. 
C. Dose Response Relationships. 
D. Temporal Association. 
E. Strength, Consistency and Specificity of Association of Key Events and 
Tumour Response.   
F. Biological Plausibility and Coherence.    
G. Possible Alternative MOAs. 
H. Uncertainties, Inconsistencies, and Data Gaps. 
I. Conclusion about the MOA. 
 
 
1.5 IPCS Human Relevance Framework 
 
In order to address the issue of how to evaluate the human relevance of the MOA(s) 
determined in animals, a working group comprising of representatives from ILSI/RSI, 
US EPA and Health Canada was assembled.  The working group discussed the issue 
of expanding the 2001 IPCS MOA framework to incorporate information relating to 
the determination of human relevance of a postulated animal MOA.  This 
collaborative work led to the development of the ILSI/RSI Human Relevance 
Framework (HRF) that provides guidance on how MOA information can be used to 
determine the relevance of animal tumours when carrying out human risk assessment.  
In 2003, the findings of the working group were published and provided details of the 
case studies evaluated, and also guidance on how to apply the ILSI/RSI HRF in the 
risk assessment process [26, 30, 31]. 
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Between 2004 and 2005, meetings and workshops were co-ordinated by the IPCS 
cancer working group to update the 2001 IPCS MOA framework.  The opportunity 
was also taken to refine the proposed ILSI/RSI HRF and, incorporate this information 
into the updated IPCS MOA framework.  This work has led to the most recent 
publication, IPCS Framework for Analysing the Relevance of a Cancer Mode of 
Action for Humans (IPCS HRF) [9].  
 
The IPCS HRF provides a structured approach to determining the human relevance of 
an animal mode of action. It provides a stepwise approach for determining whether 
the WOE is sufficient to form judgements regarding a postulated carcinogenic mode 
of action for a chemical and the relevance to humans. The framework is intended to 
further the understanding of the carcinogenic process, improve the transparency of the 
risk assessment process and improve the identification of data gaps, inherently 
making it easier to identify areas where study designs can be improved. It provides a 
stepwise approach to answering a series of three questions in the form of a narrative 
review on the basis of the weight of evidence, allowing for the documentation of all 
logical conclusions regarding the human relevance of the carcinogenic animal MOA.  
Question one of the framework requires the application of the IPCS MOA framework 
discussed above [9]. 
 
Question 1) Is the weight of evidence sufficient to establish the mode of action in  
       animals? 
Question 2) Can human relevance of the MOA be reasonably excluded on the basis of  
        fundamental, qualitative differences in key events between experimental  
        animals and humans? 
Question 3) Can human relevance of the MOA be reasonably excluded on the basis of  
        qualitative differences in either kinetic or dynamic factors between  
        experimental animals and humans?  
 
 
The IPCS HRF is being promoted to the wider scientific community who are 
encouraged to apply this framework approach when carrying out cancer risk 
assessment. The most recent publication that considers the human relevance of animal 
mode of action has been undertaken in partnership with various international 
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organisations. The involvement of representatives from different international 
organisations has added substantially to the credibility of this framework. The 
following sections discuss the extent to which some regulatory organisations have 
implemented the MOA framework within their own regulatory guidelines 
 
 
1.5.1 Application of the Mode of Action Approach by Different 
Organisations: United States Environmental Protection Agency 
 
The USEPA has been very active in workshops organised by IPCS to discuss issues 
related to cancer risk assessment and they have played a key role in the development 
of the IPCS MOA Framework. The timely revision of their “Guidelines for 
Carcinogen Risk Assessment” [32] led to incorporation of the MOA Framework 
approach to address carcinogen risk assessment. Previous US EPA cancer risk 
assessment guidelines promoted methods that relied heavily on the use of 
mathematical models to propose upper bound estimates of potential risks. Although 
these methods were intended to be protective of human health, they incorporated no 
chemical specific data and the methods were considered by many to be very 
conservative. 
 
The move towards a MOA approach when attempting to characterise the hazard and 
consider the dose response relationships, incorporates recent advances in the biology 
of cancer.  However, in the absence of chemical specific information, default 
assumptions are still applied. The US EPA recommends the MOA approach to help 
determine when to use linear or non-linear extrapolation methods and also to provide 
guidance on the considerations of MOA changes associated with the doses 
investigated [32]. 
 
The 2005 final draft of the US EPA guideline document has incorporated same 
concepts as in the 2001 IPCS MOA framework for animal carcinogenesis [24] and the 
ILSI/ RSI Human Relevance framework document [26]. The resulting EPA guidelines 
consider the overall hazard characterisation in animals and the relevance and cancer 
risks to humans. These guidelines incorporate the use of a MOA framework approach, 
and additionally, analysis of the human relevance for observed animal carcinogenicity.   
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Data compiled for the MOA analysis are intended to form part of the WOE evaluated 
to enable reasonable conclusions to be drawn about the carcinogenicity of an agent 
and, therefore, characterise any potential carcinogenic hazards. 
 
A similar MOA analysis format to IPCS has been adopted in the EPA cancer guidance 
document. Whilst a “check list” approach to compiling the information used for the 
MOA analysis is not endorsed, the guidance provided encourages a stepwise approach 
to cover specific points that are intended to facilitate a transparent and overall analysis 
of the evidence used to hypothesise a MOA. Similar to the IPCS framework, the 
format proposed below is provided in a stepwise manner and is based on the Bradford 
Hill criteria for causality. It provides a clear structure for laying out the scientific facts 
and the reasoning behind any conclusions drawn.  
 
1. Description of the hypothesised mode of action 
 Summary description of the hypothesised mode of action 
 Identification of key events 
2. Discussion of the experimental support for the hypothesised mode of action 
 Strength, consistency, specificity of association 
 Dose-response concordance 
 Temporal relationship 
 Biological plausibility and coherence 
3. Consideration of the possibility of other modes of action 
4. Conclusions about the hypothesised mode of action 
 Is the hypothesised mode of action sufficiently supported in the test 
animals? 
 Is the hypothesised mode of action relevant to humans? 
 Which populations or life stages can be particularly susceptible to the 
hypothesised mode of action? 
 
The first three steps of the US EPA MOA analysis are very similar to that proposed 
by IPCS as it encourages the risk assessor to carry out the analysis in a stepwise 
approach based on the Bradford Hill criteria for causality. The final step allows for 
conclusions to be drawn with regard to any hypothesised MOAs. A narrative review is 
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also required to address the issue of human relevance of observed animal carcinogenic 
MOAs. For observed key precursor events, it is recommended that an evaluation be 
carried out to critically examine any similarities and differences between laboratory 
animals and humans. It is recommended that analysis of the chemical specific data be 
undertaken to consider specific differences in toxicokinetics or toxicodynamics 
between animals and humans. 
 
The US EPA promotes the flexibility of its guidelines because it recommends the 
consideration of different MOAs for different routes/ patterns of exposure that include 
for example the intensity of exposures. The guidelines also go a step further by calling 
for the consideration of the potential susceptibility of different populations and life 
stages to the postulated MOAs. This is consistent with previous US EPA policy 
approaches to protect susceptible groups of the population and in fact a supplementary 
document, entitled: Supplemental Guidance Assessing Susceptibility for Early Life 
Exposure to Carcinogens, [32] has been produced by the agency to address this 
specific issue, although these are apply only to genotoxic carcinogens.    
 
 
1.5.2  European Union: European Food Safety Authority 
 
Within the European Union, the IPCS Mode of Action (MOA) Framework approach 
is currently being applied by the European Food Safety Authority (EFSA) scientific 
panel on Plant protection products and their Residues (PPR).  
 
Explicitly between May 2003 and May 2006, the EFSA PPR panel published opinions 
based on questions posed to them by the European Commission on issues relating to 
the human toxicology of six different pesticides: methamidophos, dinocap, 
daminozide, mepanipyrim, dichlorvos and alachor. A non-default approach was 
applied to evaluate the carcinogenicity of these compounds. In cases where the 
genotoxic potential of a compound was not sufficiently demonstrated in experimental 
studies carried out in vivo or in vitro, the panel concluded that the compounds were 
acting via a threshold mode of action regardless of whether there was sufficient 
evidence to actually demonstrate the specific non-genotoxic MOA for the observed 
tumour [33]. 
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The mode of carcinogenic action was considered for daminozide, alachor, 
mepanipyrim and dichlorvos. The focus of the MOA considerations was to confirm 
whether, on the basis of the evidence considered, the compounds acted via a threshold 
mechanism.  Although opinions were formed about the MOA of the chemicals on the 
basis of the WOE evaluated, for the majority of the compounds a structured approach 
was not applied in the evaluation of this evidence. The discussion of the WOE 
examined for alachor was however based on the IPCS Mode of Action Framework 
[33]. 
 
Although the IPCS mode of action approach was not applied to the evaluation of all 
the pesticides evaluated, the value of using the framework was noted by the PPR 
panel, including the extension of the framework to include addressing non-cancer 
endpoints [33]. 
 
 
1.5.3 International Agency for Research on Cancer (IARC) 
 
The International Agency for Research on Cancer (IARC), with the help of 
international working groups of experts, publish in the form of Monographs, critical 
reviews and evaluations of evidence on the carcinogenicity of a wide range of human 
exposures.  
 
Information provided in the monographs relates to that required for the hazard 
identification stage of the risk assessment. In addition, information regarding the 
dose-response assessment may also be addressed. The monographs make no attempt 
to carry out complete risk assessments and information relating to characterising an 
agent as a hazard is used mostly by national and international organisations as the 
starting point to carry out risk assessments.   
 
A preamble is produced at the beginning of each IARC monograph.  It describes the 
scientific principles and procedures applied in the development of the monograph. It 
also provides an overview of the types of scientific evidence considered and it lays 
down the criteria applied by scientists carrying out the evaluation.  The following 
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section reviews the methods used by IARC and attempts to make comparison with the 
IPCS MOA framework. 
 
When evaluating an agent, IARC review both animal and human studies and pay 
particular attention to the narrative review of the qualitative aspects of the following:  
1. Exposure data 
2. Studies of cancer in humans 
3. Studies of cancer in experimental animals 
4. Mechanistic and other relevant data 
5. Summary  
6. Evaluation and rationale 
 
The general stepwise approach of the IPCS MOA framework has not been adopted in 
the most recent revision of the preamble (January 2006). Rather, aspects of the MOA 
framework have been incorporated into the general structure addressed by the 
preamble in the format listed above.  
The IARC has built up an international reputation for producing strong evaluations of 
mechanistic data. Although not applying the format promoted by IPCS within the 
IPCS MOA framework under the definition of MOA, the IARC has previously 
produced internationally accepted criteria for some MOAs e.g.  species differences in 
thyroid, kidney and urinary bladder carcinogenesis [34] and peroxisome proliferation 
and its role in carcinogenesis [35]. 
 
The terminology utilised by IARC also differs somewhat from that of IPCS.  The term 
mechanism of action is used by IARC and it is assumed that the use of term 
mechanism in this context refers to the biological sequence of events that leads to 
cancer, inferred by MOA in the IPCS framework. In all IARC monographs and 
technical reports, the working group evaluates the findings of cancer observed in 
animals and humans.  Scientific data reviewed by the working group include those on 
toxicokinetics, mechanisms of carcinogenesis, susceptible individuals, populations 
and life stages, and other relevant data including adverse effects. In attempting to 
describe the mode(s) of action/mechanism(s) of action by which an agent may 
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increase the risk of cancer, the working group's objective is to summarise key 
mechanistic data obtained from studies carried out in animals and humans. 
 
Similar to the IPCS mode of action framework, IARC highlight the need for 
identifying the different mechanisms associated with the carcinogenic action of a 
single agent.  IARC recommend that for each identified mechanism of action the 
focus should be on identifying gaps in the data, reviewing and summarising key data 
that suggest that more than one mechanism may be operating and evaluating the 
relevance of postulated mechanisms to humans. In doing so, the aim is to identify the 
different mechanisms by which the agent might operate.  
 
Similar to the IPCS framework, IARC provide guidelines on how the working group 
carry out the narrative reviews of studies of cancer in humans and animals within the 
context of the Bradford Hill criteria for causality. Guidance is also provided for the 
interpretation of studies of cancer carried out in experimental animals and the 
determination of biological plausibility with relevance to observed carcinogenic 
effects in humans. 
 
 
1.5.4   United Kingdom 
 
Risk assessment in the UK is carried out by different governmental departments and 
agencies with the aim of informing policy makers, usually government ministers, 
tasked with the role of developing policies that are geared towards regulating 
individual chemicals, or clusters of chemicals, that have the potential to cause 
undesired health risks to humans.  Evaluation of scientific evidence is usually carried 
out by scientists within government departments and agencies who also prepare risk 
assessment dossiers for consideration by the relevant UK advisory committees.  The 
advisory committees include the Committee on Carcinogenicity of Chemicals in Food, 
Consumer Products and the Environment (COC), the Committee on Mutagenicity of 
Chemicals in Food, Consumer Products and the Environment (COM) and the 
Committee on Toxicity of Chemicals in Food, Consumer Products and the 
Environment (COT). The latter committees provide advice to the Department of 
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Health, the Food Standards Agency (FSA) and other government departments and 
agencies involved in dealing with issues relating to chemical safety [36]. 
 
The traditional UK approach to carrying out chemical risk assessment has been to 
evaluate scientific data relating to chemicals on a case-by-case basis.  Such an 
approach requires a thorough evaluation of the body of evidence. The most recent 
guidance document produced by the COC entitled, Guidance on a Strategy for the 
Risk Assessment of chemical Carcinogens [7], includes the consideration of the 
mechanisms of the potential carcinogens and whether a compound is acting via a 
genotoxic mechanism. The COC recommend that the latter be confirmed through the 
use of short-term mutagenicity tests which help to determine whether a compound is 
an in vivo mammalian mutagen, an approach endorsed by the COM [37]. 
Carcinogenic compounds found to be positive in vivo mutagens, should be regarded 
as potential genotoxic carcinogens. 
 
Compounds that cause cancer in laboratory animals and exhibit no mutagenic activity 
in-vivo are, therefore, assumed to be non-genotoxic carcinogens and thorough 
consideration of their modes of action is recommended by the COC.  The committee 
also endorses the use of the IPCS MOA framework and the ILSI/ RSI Human 
Relevance Framework as tools for considering the weight of evidence for 
carcinogenic chemicals, in particular non-genotoxic chemicals, their mode of action 
and subsequent relevance to humans [7]. 
 
 
1.5.5 Joint FAO/WHO Meeting on Pesticide Residues  
 
The Joint FAO/WHO Meeting on Pesticide Residues (JMPR) has applied the MOA 
framework to their evaluation of certain pesticides. The framework was applied by the 
2006 JMPR to provide a structured approach to the assessment of the WOE or the 
MOA analysis. The framework was applied specifically in their evaluation of 
pyrethrin extract and the framework was subsequently incorporated as part of the 
published monograph [38]. More recently, the IPCS HRF was incorporated into the 
WHO Environmental Health Criteria document which updates risk assessment 
methodologies for chemicals in food. The Environmental Health Criteria 240: 
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Principles and Methods for the Risk Assessment of Chemicals in Food included the 
IPCS HRF as part of its methodologies for the consideration of hazard identification 
and characterization in risk assessment [39].  
 
 
1.6           Weight of Evidence considerations for the application of the IPCS  
    MOA/HRF: transparency and data incorporation. 
 
 
The first part of the IPCS MOA/HRF which requires the risk assessor to address the 
question: “is the weight of evidence sufficient to establish a mode of action in 
animals?”, requires the consideration of different steps that are based on the 
considerations of causality proposed by Hill [29]. In this context, the use of the WOE 
approach for the consideration of the MOA is as an analytical tool required for the 
qualitative assessment of overall evidence to take into account the strength and 
specificity of association, dose-response concordance, temporal relationships and the 
biological plausibility and coherence amongst other aspects deemed relevant for 
consideration. Information relating to the WOE is then provided in the literature 
review to describe and summarise the extent to which the evidence reviewed supports 
a decision about a carcinogenic endpoint [2, 9].  
 
One of the main drivers of the use of a WOE approach in the IPCS HRF and indeed 
risk assessment in general, pertains to the need for greater transparency in the risk 
assessment process [9, 40, 41]. The EFSA Scientific Committee recently produced a 
guidance document to address the procedural issues that are considered beneficial to 
improve the transparency of the scientific aspects of risk assessment carried out by 
EFSA. The resulting document consisted of general principles for the identification 
and evaluation of data and issues relating to dealing with assumptions and 
uncertainties [42]. Similarly, the issue of transparency was also addressed by a 
committee of the ILSI Health and Environmental Sciences Institute (ILSI/HESI) who 
examined existing guidance and recommendations related to transparency in risk 
assessment as identified by different regulatory and advisory bodies  [40]. The ILSI/ 
HESI committee highlighted the different criteria cited for improved transparency in 
risk assessment and concluded that the transparency and documentation of the risk 
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assessment process were fundamental to credible risk assessment. Transparency was 
also identified as an essential component of a WOE based approach to risk assessment.  
 
Scientific data considered as part of the weight of evidence for the hazard 
characterisation of chemicals have traditionally relied on mutagenic and carcinogenic 
studies carried out in animals and where available, epidemiological evidence on 
carcinogenicity [43].   
 
Over the past decade however, technological advances in the field of genomics has 
led to the generation of vast amounts of data within the public domain and 
increasingly regulatory bodies are starting to address the question of what to do with 
the vast amounts of data being generated and how such data can be utilised as part of 
the risk assessment process [44, 45].  The incentive for the pharmaceutical industry 
who have invested significant amounts of money in the field of toxicogenomics is the 
hope of identifying candidate drugs more quickly and economically [46, 47].  
 
There have been many promises made about the potential benefits of toxicogenomics 
to chemical risk assessment.  Most significantly, has been the promise that it will aid 
the screening and prioritisation of chemicals and drug candidates that require further 
testing and development [46]. Alongside this, it is hoped that signature patterns of 
gene expression, so called biomarkers, can be developed to assess the similarities 
between chemicals to facilitate the prediction of adverse health outcomes [48]. This 
process involves the comparison of toxicogenomics profiles to databases of already 
known toxicants, whereby biomarkers of exposure and toxicity can be identified and 
used in the high-throughput screening [46].   
 
It is envisaged that toxicogenomics will have a significant impact on improving the 
mechanistic insight for chemicals under consideration. The prospect of identifying 
characteristic preneoplastic changes using gene-expression profiles that can be 
detected within hours or days (compared to conventional toxicity studies which can 
take months or years to observe evidence of toxicity) to predict a disease outcome is 
considered to be extremely advantageous. It is this identification of potential 
preneoplastic changes (which would be indicative of key events that lead to a final 
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toxicological outcome) that may enable the application of toxicogenomics data to the 
MOA analysis component of risk assessment [48].  
 
Even more important is the prospect for toxicogenomics data to be used in cross 
species extrapolation. It is thought that since genes are conserved between species, 
experiments carried out in human and animal cells can facilitate cross species 
comparisons of the level of response at the same exposure levels. Similarly, it is 
hoped that the generation of species specific data will enable the identification of the 
most appropriate animal models to predict human response. 
 
While supporters and investors within the field of toxicogenomics pledge that the data 
being generated in this field will revolutionise mechanistically based quantitative risk 
assessment and improve predictions of environmental and human safety [46, 49], 
there are still many challenges to be overcome. A survey carried out by the Health and 
Environmental Sciences Institute (HESI, part of the International Life Sciences 
Institute) Committee on the Application of Genomics to Mechanism-based Risk 
Assessment [50] to identify key issues and perspectives on the use of toxicogenomics 
for decision making within organisations and by policy makers, showed that the 
interpretation of toxicogenomics data and confidence in the results were considered to 
be a major hurdle for the increased  impact of such data.  The survey conducted by the 
HESI committee received a 30% response rate and participants included scientists 
from government, academia and industry, representing the chemical, consumer 
products and pharmaceutical industry.   
 
Respondents of the HESI survey considered the greatest impact of toxicogenomics 
would be the contribution to the understanding of biological mechanisms, 
identification of biomarker candidates and identifying species differences. However it 
was the opinion of all respondents of the survey that the biological interpretation of 
toxicogenomics data was at present a major hurdle in achieving a larger impact in 
these areas. It was felt that this result was an indication that more remains to be 
gained from toxicogenomics data in order to achieve a greater impact [50]. When 
questioned about the use of toxicogenomics data as supportive or supplementary data 
for decision making, it was therefore unsurprising that respondents from the 
pharmaceutical industry considered that the impact would be low. In contrast, 
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respondents from academia considered this to be a high impact area for the use of 
toxicogenomics data.  
 
The inclusion of toxicogenomics data in regulatory submissions was considered to be 
the benchmark by which to evaluate the successful impact of the use of such data in 
chemical safety assessment [50]. One of the main outcomes of the HESI survey was 
the identification of the need to improve both data quality and the quality of 
interpretation of the data.  
 
In response to the significant contribution anticipated to be gained in risk assessment 
from data generated in the field of toxicogenomics, regulatory bodies such as the 
United States Food and Drug Administration (USFDA) and Environmental Protection 
Agency (USEPA) actively encourage the use and submission of such data as part of 
their effort to establish formal guidelines and protocols for the inclusion of such data 
in submitted applications [46]. Most significantly in 2002, the USEPA issued its 
Interim Policy on Genomics [51] which outlined its intention to consider genomics 
data as part of their decision making process and as part of the WOE on a case by case 
basis. The US EPA defined genomics as the study of all the genes of a cell or tissue at 
the DNA, mRNA or protein level. Crucially however, the USEPA noted that such 
data could not be used in isolation as the basis for a risk assessment decisions as there 
were still research needs to improve the interpretation of genomic responses to 
adverse effects [44, 45, 51]. In 2004, the USEPA produced a White Paper entitled, 
“Potential Implications of Genomics for Regulatory and Risk Assessment at EPA” 
[52]. 
 
A workshop was organised by IPCS to address the issue of the use of toxicogenomics 
data in chemical risk assessment [53]. Participants of the workshop discussed and 
acknowledged the generally held views about the contributions expected to be made 
from data generated using toxicogenomics technologies and identified areas in which 
they felt more collaborative work was necessary to facilitate successful application of 
toxicogenomics data in risk assessment. The workshop participants identified the need 
for greater collaboration among those generating the data and traditional toxicologists 
and risk assessors who would be responsible for interpreting the data within the 
context of risk assessment. In addition it was felt that more involvement was 
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necessary from academic institutions to improve the understanding of the broader 
applications for toxicogenomics data. The involvement of experts from a range of 
backgrounds that included epidemiology, molecular and clinical genetics and 
bioinformatics was considered to be essential. One of the recommendations of the 
workshop was that a collaborative effort should be undertaken to develop case studies 
for chemicals with known MOAs and available toxicogenomics data. 
 
 
1.7 Aims and objectives  
 
Fundamental aspects of the application of a WOE-based approach to risk assessment, 
relate to the collection and presentation of evidence that forms the basis for 
conclusions about a chemical of concern or conclusions about an animal MOA and 
subsequent relevance to humans, in the case of the IPCS HRF  [9, 54]. This research 
thesis aims to address both these aspects as part of the general consideration of the use 
of WOE approach in MOA analysis within the context of human relevance as part of 
the more general consideration of how such approaches could be refined. 
 
1. Improved Transparency of WOE-based risk assessment 
 
An important part of the WOE-based approach to applying the IPCS framework is the 
compilation of the scientific data that informs the narrative review for each section of 
the MOA/HRF framework. While the IPCS framework goes a long way to 
formalising the process of transparent decision-making, an objective approach to 
evaluating the weight of evidence would greatly improve the transparency of different 
stages of the risk assessment process that currently relies solely on the provision of a 
narrative review.  
 
To address the issue of the improvement of transparency in the application of a WOE-
based approach to the IPCS HRF, the use of systematic review techniques will be 
explored to illustrate how such techniques can improve the transparency of evidence 
evaluated as part of the application of a MOA/HRF framework.  
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Objective: 
 Demonstrate the use of systematic review techniques for the evaluation of 
epidemiological evidence for a chosen case study compound, as a means of 
improving the transparency of evidence that will form part of the MOA/ HRF 
analysis. 
 
2. Incorporation of non conventional data into MOA/HRF analysis 
 
An IPCS workshop organised to discuss the potential application of toxicogenomics 
data in risk assessment recommended that more case studies should be developed for 
chemicals with known MOAs and available toxicogenomics data [53].  
 
To address the current disconnect between the large amounts of toxicogenomics data 
being generated and the contribution of such data to framework approaches to hazard 
characterisation, a data based approach will be applied to investigate the extent to 
which toxicogenomics data can be used to inform the MOA/HRF analysis.  
 
Objectives: 
 Conduct a comparative analysis of publicly available toxicogenomics data to 
investigate the extent to which the observed changes can provide evidence for 
key events of the MOA for the hepatocarcinogenic effects of the case study 
compound. 
 Conduct a critical appraisal of the state of the science for the use of published 
toxicogenomics data in MOA analysis. 
 Provide recommendations for the effective utilisation of toxicogenomics data 
as part of a MOA/HRF analysis.  
 
Phenobarbital (PB) was selected as the case study compound to carry out the 
objectives outlined above. PB has been administered to patients for long term 
treatment of epilepsy. Long-term experiments carried out in rodents in the 1970s 
showed that liver tumours were induced after administration of PB.  In order to 
determine whether this same effect were observed in humans, epidemiological studies 
of groups of patients that were administered PB were carried out to investigate 
whether these patients were more likely to develop liver cancer than similar groups of 
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individuals within the general population. The use of this drug in a clinical setting 
allowed for ease in identifying a cohort of patients that could be followed up, in order 
to investigate whether there was any association between the occurrences of liver 
cancer among patients exposed to this drug  [55].  
 
PB was considered to be an ideal case study compound for this investigation owing to 
the fact that the same outcome of disease could be investigated in both experimental 
animals and in humans. Evidence obtained from human studies, depending on its 
reliability and robustness, are fundamental to the overall evaluation of the human 
relevance of the toxicological effect. Irrespective of the information obtained from 
animal studies, good quality epidemiological evidence is generally preferred over 
animal data in a risk assessment. In the case of carrying out the human relevance 
analysis, PB provides a unique example of a compound where the cumulative dose 
observed in humans after long-term administration of PB for epilepsy treatment is 
similar to the doses required to induce a carcinogenic effect in long-term animal 
studies [9, 56].  
 
PB is considered to be the prototype of several rodent hepatocarcinogens e.g. 
oxazepam and DDT [56]. Over the past few decades there has been a considerable 
amount of data generated on PB to investigate its mechanisms of action for 
hepatocarcinogensis in rodents. The vast amount of knowledge accumulated for PB 
means that it is readily employed as a positive control in mechanistic studies. It is 
therefore not surprising that PB has also been employed in toxicogenomics 
investigations.  With the increased promotion of genomics technologies, 
toxicogenomics data on PB is becoming more readily available within the public 
domain.   
 
The next chapter provides a brief summary about mechanistic evidence supporting the 
postulated mode of action for PB induced hepatocarcinogensis. The remaining 
chapters in this thesis describe the efforts and methods applied to compile and 
evaluate epidemiological and toxicogenomics evidence for PB obtained from the 
public domain.  
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Chapter 2 
 
Phenobarbital 
 
 
Introduced in 1912, phenobarbital (PB) has been used as a sedative or hypnotic and 
for the long term treatment of epilepsy [57]. Its use has decreased since the 1960s but 
it is still used extensively worldwide.  
 
The International Agency for Research on Cancer (IARC) evaluated PB in 1977, 1987 
and again in 2001. IARC concluded that there was sufficient evidence for the 
carcinogenicity of PB in animals but inadequate evidence for the carcinogenicity of 
PB in humans. Based on evidence evaluated by IARC, PB was assessed to be possibly 
carcinogenic to humans (Group 2B) [58].  
 
In a battery of genotoxicity tests, PB has been observed to be generally negative 
overall. It has also been observed to be negative in tests for DNA damage, leading to 
conclusions that PB is not genotoxic. In addition it has been shown to act as a liver 
tumour promoter when administered after different initiating carcinogens [59]. 
 
PB is thought to induce tumours via its tumour promoting effects. Its ability to induce 
tumours in rats when administered alone has been demonstrated only in aged animals, 
which are thought to already possess considerable numbers of spontaneously 
occurring initiated cells [60, 61]. This evidence in addition to the lack of observed 
mutagenicity, have led to the assumption that PB‟s promoting activity is the result of 
epigenetic interactions as opposed to genomic interactions [60]. 
 
The non-genotoxic effects of PB have been studied extensively for decades. PB is 
considered to be the prototype of several rodent hepatocarcinogens. Compounds like 
oxazepam and DDT are referred to as “PB-like carcinogens” in reference to their 
characteristic effect on hepatocytes [56, 58]. As a prototype of many compounds, PB 
provided excellent case study for this research. PB is one of a few compounds for 
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which the human exposure (for patients administered PB) results in circulating levels 
similar to those observed after doses producing carcinogenic effects in study animals. 
Phenobarbital is reported to have been administered to epileptic patients at doses of 3-
4 mg/kg/day with the target plasma PB concentration of 10-25 µg/mL [59, 62]. An 
epidemiological study carried out by Clemmesen and Hjalgrim-Jensen [63] reported 
that PB was routinely administered at doses of 100-300 mg/day to prevent seizures in 
epileptic patients. Studies reviewed by Whysner et al [59] show that doses of between 
2 to 150 mg/kg were administered to rodents (rats and mice). 
 
 
2.1 Postulated Key Events for PB M2ode of Action for Liver Tumour Formation 
in Rodents 
 
Mechanistic information accumulated for PB has enabled the identification of key 
toxicological responses that are postulated to be crucial to PB induced tumourigenesis. 
These include increased cell proliferation, inhibition of apoptosis, hypertrophy and 
hyperplasia and development of altered hepatic foci (resulting in advance liver 
tumours). It has also been suggested that factors such as oxidative stress and the 
inhibition of gap junction intercellular communication may also be associated with  
PB‟s MOA for liver tumour formation  [56, 59, 64, 65]. Exposure to PB elicits a wide 
range of biological responses and processes in rodents. The key events for PB are 
discussed in more detail below.  
 
 
2.2 Activation of the Nuclear Receptor CAR 
 
One of the first key events for the PB MOA is the activation of the nuclear receptor,  
constitutive androstane receptor (CAR) [56].  
 
A characteristic effect of PB is its ability to induce members of cytochrome (CYP) 
P450 family in vivo. Members of the CYP family shown to be induced in rats by PB 
include 2A1, 2C6, 2C7, 2C11, 3A1 and 3A2, however the CYP forms most affected 
by PB are members of the 2B sub-CYP family, (CYP2B1 and CYP2B2 in the rat [59, 
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66]. Selective induction of CYP2B forms is considered diagnostic of CAR activation 
in rodents [56].  
 
Evidence for the regulation of CYP2B10 gene by PB in mouse has been obtained in 
experiments carried out using CAR knockout mice.  These have show that the mRNA 
levels of CYPB10 is greatly increased in CAR wild-type mice after treatment with PB, 
whereas the gene was not expressed in the CAR-null mice [67].  
 
PB has also been shown to induce other enzymes that include aldehyde 
dehydrogenase, epoxide hydrolase, NADPH:P450 reductase, some forms of UDP-
glycuronyl transferase and several members of the glutathione-S-transferase family 
[59].  Microarray studies carried out by Ueda et al [67] have shown that CAR is 
involved in the upregulation of many of these genes particularly NADPH-cytochrome 
P450 reductase, sulfotransferases, glycuronosyltransferases and glutathione S-
transferases, as well as genes encoding various enzymes and transporter proteins that 
are not only involved in metabolism but also in the secretion of steroid and thyroid 
hormones, bilirubin and bile acids.  
 
Studies carried out in rodents showed that upon exposure to PB, CAR translocates 
from the cytoplasm into the nucleus where it forms a heterodimer with the retinoid X 
receptor alpha (RXRα) and binds to a DNA sequence identified as an enhancer region 
upstream of the targets gene.  This enhancer region, termed the phenobarbital 
responsive enhancer module (PBREM), is present in a number of genes that include 
cytochrome P-450s, UDP-glucuronosyltransferases, sulfotransferases and drug 
transporters Indeed studies in CAR knockout mice confirm its role in the up 
regulation of genes that encode the latter group of proteins [64, 67-71].  
 
The activation of CAR has been demonstrated to be essential for the induction of 
CYP2B10 in the mouse (and CYP2B6 in humans and CYP2B2 in rats), the 
development of cell hypertrophy and observed increased liver weight. These effects 
have been clearly demonstrated to be associated with the activation of CAR through 
the use of CAR knockout mice models. Wei et al [64] observed that the liver weight 
in wild type mice administered PB was significantly increased compared to mice 
lacking the CAR gene (CAR
-/- 
) that were also administered PB. Yamamoto et al [72] 
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also investigated the effects of PB in CAR knockoutmice and demonstrated that CAR 
was essential for PB induced liver tumour development. The authors administered 
CAR
-/-
 and CAR
+/+
 mice with the initiator diethylnitroasmine (DEN) followed by 
chronic treatment with PB. After 32 weeks the authors observed  that only CAR
+/+
 
mice had developed hepatocellular carcinoma  and similar to Wei et al [64] they also 
observed increases in liver weight in the wild type mice compared to CAR
-/-
  mice. By 
52 weeks, PB treated CAR
+/+
 mice had all died and had developed tumours. The 
authors did not observe any tumours or deaths among the CAR
-/-
 mice.  
 
 
2.2.1 Increased Liver Weight Characterised by Hypertrophy and Hyperplasia 
 
PB exposure has been shown to result in the increase of rodent liver size 
(hepatomegaly) after a few days to weeks of continued exposure. Chronic exposure of 
PB in mice resulted in 40-70% increase in liver size thought to be the result of both 
hypertrophy
1
 and hyperplasia
2
  [59, 73-76]. The effects were observed to a lesser 
extent in rats and shown to be reversible following withdrawal of PB [77].  
 
Increased hypertrophy or hyperplasia resulting in an increase in liver size can occur 
independently of each other. Carthew et al. [76] observed that rats treated with PB led 
to significant increases in hypertrophy at both 2 and 12 weeks of treatment compared 
with controls. In contrast, the authors observed that PB induced hyperplasia was not 
significantly increased until after 12 weeks of PB exposure. Similarly, Ross et al [78] 
carried out experiments using humanised knockout models for CAR and PXR and 
demonstrated that mice treated for 4 days with PB developed liver hypertrophy 
without hyperplasia in the huPXR/huCAR models. This was in contrast to the CAR 
and PXR knockout mice in which no increases in liver weight were observed and 
there was no induction of the target genes for both CAR and PXR (CYP2B10 and 
CYP3A11 respectively). 
 
Evidence for hyperplasia was also reported by Jupundzic et al [79] who observed that 
the mitotic activity of parenchymal liver cells from rats treated with PB were 4.9 
                                                 
1
Increase in liver caused by an increase in the size of cells. 
2
 Increase in liver size caused by the increase in the  number of cells as a result of increased cell 
division. 
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times higher than control groups. Plant et al [80] observed similar findings in rat 
hepatocytes but reported mitogenic activity 2-3 fold above control levels.   
 
 
 
2.3 Cell proliferation 
 
Exposure to PB results in the stimulation of cell proliferation [59]. Evidence reviewed 
by Whsyner et al. [59] showed that the observed increase in cell proliferation occurs 
in both normal hepatocytes and cells of altered foci.  
 
Cell proliferation has been observed to be much higher in foci compared to normal 
cells even without PB treatment [81]. The data suggests that PB stimulates cell 
proliferation in normal cells but this stimulation only lasts a few days and may even 
be inhibited. Upon the development of hepatic foci after continuous exposure to PB,  
the proliferation in altered hepatic foci have been observed to be sustained at a much 
higher rate for a prolonged period of time compared to the proliferation in normal 
cells. The enhanced cell proliferation in foci compared with normal hepatocytes is 
thought to be contribute to the mechanism by which PB promotes tumour formation 
[59]. 
 
Plant et al [80] reported that PB could induce DNA synthesis in cultured rat 
hepatocytes and observed a peak of PB induced DNA synthesis after 36 hours of 
dosing. Similar observations were reported by Peraino et al [82]. It has been 
suggested that the observed foci growth is not solely the result of stimulated cell 
proliferation but also a result of the stronger expression of phenotypic changes that 
render the foci more detectable [83]. Schulte-Hermann et al [83] observed an increase 
in the amount of detectable foci during PB treatment and concluded that these results 
implied that the foci populations studied in control and PB treated animals were not 
identical. The body of evidence reviewed by Whysner et al [59] showed that PB 
induced cell proliferation was caused by direct mitogenic effect rather than 
regeneration due to cell loss.  
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2.4 Inhibition of apoptosis 
 
Inhibition of apoptosis has been observed to be an important part of PB‟s ability to 
promote liver tumours. Evidence reviewed by Whysner et al [59] showed that a 
marked reduction in the level of cell death as measured and demonstrated by the 
observed decrease in the numbers of apoptotic bodies (AB) was observed in different 
strains of rat and mouse following the administration of an initiator.  Plant et al [80] 
treated  primary rat hepatocytes with PB over a period of 14 days and observed that 
the inhibition of apoptosis occurred in a dose dependent manner.  
 
The inhibition of apoptosis has been observed to be reversible following the 
withdrawal of PB administration [59]. Bursch et al [77] observed a 10-fold increased 
excess of ABs within the focal cells compared to normal tissues after withdrawal of 
PB. This led the authors to conclude that the focal cells appeared to have a shorter life 
span than normal cells and appeared to be more sensitive than normal cells to 
apoptosis.  
 
The resumption of apoptosis following withdrawal of PB suggests that the inhibition 
of apoptosis is a key aspect of PB tumour promotion. The inhibition of the cell death 
of initiated cells by PB exposure enables cell survival and continued proliferation 
until further alterations in the genome occur [59].   
  
 
2.5 Development of Altered Hepatic Foci 
 
PB is a known tumour promoter and enhances the development of liver tumours 
particularly if it is administered following initiating agents such as 2-
acetylaminofluorene (AAF) or N-nitorosodiethylamine (NDEA). It is therefore used 
extensively as a tumour promoter in initiation-promotion protocols [59]. Following 
the administration of an initiator, PB has been shown to lead to the increased numbers 
and size of altered foci.  
 
Altered hepatic foci (AHF) are morphologically and histochemically distinguishable 
from normal liver parenchyma [84]. Differences have been observed in the genetic 
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expression of specific enzymes such as adenosine triphosphate (ATP), glucose-6-
phosphatase (G6P) and γ-glutamyltranspeptidase (GGT) and these are used as 
histochemical markers to determine the cellular populations of hepatocytes that are  
involved in carcinogenesis. Determination of enzyme expression levels for GGT(+),  
G6P(-) and ATP(-) and histohemical staining for these enzymes are used to monitor 
the number and growth of hepatic foci during neoplastic development [85] 
 
Altered foci are the preneoplastic lesions that preceed tumour formation [59]. Peraino 
et al [82] observed significant increases in the incidence of hepatomas following the 
administration of 0.05% PB to rats in the diet either simultaneously or after 
administration of AAF. Mechanistic studies carried out in rodents have shown that 
chronic exposure to PB led to the rapid increase in both the number and size of liver 
foci which subsequently developed into adenomas and hepatocellular carcinomas in 
different strains of both the rat and mouse [59, 81].  
 
 
 
2.6 Toxicological Events Associated with the Observed Key Events 
 
2.6.1 Oxidative stress 
 
It has been suggested that reactive oxygen species (ROS) and other free radicals that 
are generated during oxygen activation might play a part in the epigenetic effects of 
the observed promoting activity of PB [60, 86, 87].    
 
Reactive oxygen species can be generated by both endogenous and exogenous sources 
and have been shown to produce single or double stranded DNA breaks. Where DNA 
damage persists, the resulting effects can be cell arrest, induction of transcription, 
induction of signal transduction pathways, replication errors and genomic instability; 
all of which are observed in carcinogenesis [87, 88]. 
 
ROS can be generated during normal metabolic processes and many forms of ROS 
are able to form oxidised bases [87]. The role of cytochrome P450 enzymes in the 
production of ROS was proposed by Parke et al [89] and this has since been 
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demonstrated in different studies. Dostalek et al [90] showed that some cytochrome 
P450 enzymes contributed to the process of oxidative stress as a result of exposure to 
PB in vivo in mice [90] and in rats [91]. Hydroxy radicals have also been shown to 
produce oxidized DNA lesions. An in vivo mouse study carried out by  Kinoshita et al 
[92] demonstrated the formation of oxidative stress after exposure to PB. The authors 
measured the levels of hydroxyl radicals generated in liver microsomal fraction and 
attributed the observed DNA damage to the increased protein and activity levels of 
CYP2B1/2 and CYP3A2. Similar findings were obtained from a study in the rat after 
PB exposure [93]. 
  
 
2.6.2 Inhibition of Gap junction Intercellular Communication 
  
The regulation of cellular homeostasis is accomplished by the passage of low 
molecular weight molecules such as neurotransmitters, calcium ions and hormones 
through cell transmembrane channels or so called gap junctions that consist of 
aggregated channels that link to the interior of neighbouring cells enabling cell to cell 
communication in a process known as gap junction intercellular communication 
(GJIC) [94, 95]. The gap junctional proteins, connexins play a prominent role in the 
process by allowing the intercellular passage of negative and positive homeostatic 
elements. GJIC therefore plays an important role in biological processes that include; 
cell growth, differentiation, embrogenesis and neoplastic development [94-96]. 
 
GJIC has been shown to be modulated during the carcinogenic process [96] and the 
inhibition of GJIC can lead to a disruption of cell homeostasis resulting in an increase 
in cell proliferation [94, 96, 97].  
 
PB has been demonstrated to inhibit the intercellular communication in rat [98] and 
mouse [97] hepatocytes. Similar findings were observed by Kolaja et al [94] who 
observed inhibition of GJIC in intact rat liver following exposure to PB. The 
inhibition of hepatic GJIC occurred at the same time as the observed decrease in 
apoptosis and an increase in hepatocyte proliferation.  
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2.7 Concordance of Dose response  
 
Some of postulated key events described above have been observed to occur in a dose 
dependent manner. Jones et al [99] demonstrated that exposure to PB led to an 
increase in liver weight and replicative DNA synthesis. Male and female C57BL/10 J 
strains of mice treated with 200 and 1000 ppm PB showed increased liver weight and 
a transient increase in replicative DNA synthesis. These effects were also observed 
after 99 weeks of exposure and the effects occurred in a dose dependent manner. In 
addition Jones et al [99] observed that the male mice treated with PB for up to one 
month led to increases in relative liver weight while replicative DNA synthesis was 
increased only after 3, 8 and 15 days of treatment at 1000 ppm PB [99]. The authors 
only observed altered hepatic foci and liver tumours after 1000 ppm PB.  
 
 
2.7.1 Temporal Association 
 
The key events are an essential element for carcinogenesis and their occurrence must 
precede the appearance of tumours [9]. As already discussed above CAR activation, 
liver hypertrophy and increased cell proliferation are all early events while key events 
like altered hepatic foci occur only after chronic treatment with PB as demonstrated 
by Jones et al [99].  
 
2.7.2  Species differences 
 
PB has been studied extensively in rodents. Studies reviewed by Whysner et al [59] 
showed that PB was investigated using different strains of rat (wister rats, inbred 
Fischer rats, aged and young F344) and mice (CF-1, B6C3F1 hybrid mice, C57, C3H 
and (C3H X VY)F-1 hybrid mice).                                                                                                         
 
The investigations of the effects of PB showed that chronic oral exposure to PB 
resulted in the increased incidence of liver foci in several strains of rat but no 
increased incidences of adenomas were observed in any of the strains of rat [59]. 
Mice were observed to respond more sensitively to the exposure to PB. PB 
administered to the different strains of mice via chronic oral exposure or by dietary 
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exposure resulted in an increase in liver foci and subsequent increases in 
hepatocellular adenomas and carcinomas [59]. The C57 mice were reported to be 
more resistant to tumours compared to the other strains of mice. Investigations have 
also been carried out using syrian hamsters. Diwan et al [100] administered PB in 
drinking water (500 ppm) to Syrian hamsters and observed that exposure of the 
hamsters to PB did not lead to the induction of liver tumours.  
 
The effects of PB in humans have also been investigated in various epidemiological 
studies owing to the fact PB was administered for decades within a clinical setting. 
These studies will be reviewed in detail in the following chapter.  
 
 
2.8 Summary 
 
In summary the postulated key events for the MOA for PB induced 
hepatocarcinogenesis includes: 
 Activation of CAR and associated effects 
o Induction of CYP2B 
o Cell hypertrophy 
o Increased liver weight. 
 Increased cell proliferation 
 Inhibition of apoptosis 
 Development of altered hepatic foci 
 
Other associated events include: 
 Oxidative stress 
 Inhibition of Gap junction Intercellular Communication 
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Chapter 3 
 
Systematic Review of Epidemiological Data for PB 
 
 
The need for a more systematic review of the evidence used in risk assessment 
processes and the incorporation of diverse evidence is widely acknowledged [31, 36, 
101, 102]. The application of systematic methods to evaluate scientific evidence is 
common in the field of medicine and epidemiology where systematic review or meta-
analysis are employed to provide a more transparent and objective appraisal of the 
scientific evidence [103, 104].  Meta-analysis provides a means of systematically 
appraising scientific evidence and where relevant, it enables different results to be 
combined so that conclusions can be reached more objectively [105].   
 
A systematic evaluation of the weight of evidence using a conceptual framework 
approach will inevitably identify key data gaps in the information available to 
postulate a mode of action in animals. While experimental data required to identify 
key events in humans may be lacking, well conducted epidemiological studies have 
the potential to bridge data gaps between an animal mode of action and the key events 
in humans. 
 
This chapter describes the systematic review undertaken to evaluate epidemiological 
evidence available for PB. The aim was to review whether there is any association 
between the administration of PB for long term treatment of epilepsy and the 
occurrence of liver cancer in patients taking this drug.  
 
A systematic evaluation of the evidence available was carried out broadly applying 
guidelines provided by the NHS Centre for Reviews and Dissemination [43, 101]. 
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3.1 Methodology for Epidemiology Review 
 
3.1.1 Development of Search Strategy for the Identification of Epidemiological 
Studies 
 
Epidemiological studies were identified by searching electronic databases that 
included: PubMed, EMBASE, Cochrane library, Toxline and Web of Science. In 
order to develop a robust search strategy, an initial broad search was carried out in 
PubMed using keywords associated with PB and disease outcome of interest (liver 
tumours). Keywords used to describe the compound of interest and the disease 
outcome by the individual publications were used as the starting point to determine 
other synonyms under which these keywords may have been indexed or catalogued in 
the search databases.  Using facilities available in PubMed and Web of Science 
(MeSH terminology, term exploding facilities or subheading trees) the different 
terminology associated with the keywords of interest was compiled and used to 
generate the search strategy.  Rather than using Medial Subject Headings (MeSH) 
terminology alone to search for papers in the relevant databases, where applicable, 
efforts were made to consider other terminology not included in the MeSH database, 
for example where the nomenclature had changed for certain keywords.  This was 
carried out with the aim of capturing all relevant papers necessary for a complete 
evaluation of the weight of evidence for a compound under investigation. Other 
relevant publications were identified by citation searching (searching the reference 
provided in of all relevant publications identified from the initial search using the 
different electronic databases). A full list of the search terms applied is provided in 
Appendix III. 
 
Criteria were developed to enable the selection of relevant publications. The searches 
were limited to studies published in English and published at any time or at least from 
1970
3
 to the present date 
 
Inclusion criteria: 
 studies carried out in humans 
                                                 
3
 Experimental studies evaluating the hepatotoxicity effects of PB in animals were first published in the 
1970s. It was therefore reasonable to assume that studies to evaluate the effects of liver cancer in 
humans would not have been published prior to this period.  
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 Observational studies ( these included: case series, cross sectional, cohort, 
case-control or nested case control studies) 
 publications that mentioned a combination or all of the keywords4  in the 
title or abstract: "PB" /"liver cancer"/"epileptic patients" 
Exclusion criteria: 
 studies carried out on human cells 
 in vivo and in vitro animal studies 
 
 
3.1.2 Study Quality Assessment Scoring 
 
Lists of criteria were developed to evaluate the quality of the studies reviewed. A 
study was considered to be of good quality on the basis of how well the quality 
criteria identified were addressed by authors of the individual studies. Criteria was 
developed using key guidelines available from the public literature to identify various 
aspects that were essential for the qualitative evaluation of the relevant studies. Using 
guidelines provided by the NHS Centre for Reviews and Dissemination [43, 101] and 
the principles of a qualitative scoring method applied by Key et al [106], a qualitative 
scoring system was developed and scores of good, adequate or poor were applied to 
the rating of each study.  Quality considerations for each study related to: how well 
issues of bias and confounding were considered and adjusted for by the authors, 
mechanisms used to identify and select patients treated with PB, methods used to 
define the exposure or exposure assessment and methods used to confirm the disease 
outcomes (Table 3.1).  The scores were assigned on the basis of the strengths and 
weaknesses reported from each study. A score of 1, 2, or 3 corresponding to the 
qualitative rating of poor, adequate or good respectively were then assigned to give an 
overall qualitative score. The total of the assigned scores for the individual paper was 
then obtained. The score weightings assigned to the individual studies were used as 
part of the overall assessment of the quality of the published study and as part of the 
critique of and evaluation of the findings and conclusions reached by the individual 
authors of the papers evaluated. 
                                                 
4
 Includes any other associated synonyms identified in the search strategy using the search 
methodology.  Details of the full search strategy for the identification of epidemiological evidence for 
PB are detailed in Appendix 3. 
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Table 3.1: Quality assessment criteria and scoring system applied to the individual  
     studies 
 
 
Quality 
Criteria 
Quality score  
 
Good 
(Score = 3) 
Adequate 
(Score = 2) 
Poor 
(Score = 1) 
 
Consideration 
of bias and 
confounding 
in the study 
 
 
The authors addressed 
any limitations to the 
study design by 
identifying any sources 
of bias and how these 
were managed.  Any 
confounding factors 
were also highlighted 
by the authors and 
efforts were made to 
adjust the results to 
account for any 
confounders. 
 
 
The authors identified 
any limitations and bias 
inherent in the study 
design.  Potential 
confounding factors 
that may have 
influenced the results 
observed were also 
highlighted by the 
authors however no 
effort was made to 
adjust for any of these 
factors.   
 
 
No effort was made by the 
authors to address any 
issues of bias, confounding 
or limitations to the study. 
 
 
Identification 
of patients 
treated with 
PB 
  
 
 
Authors were able to 
use medical records to 
identify epileptic 
patients within the 
cohort that were 
predominately treated 
with PB. 
 
 
Authors were able to 
identify epileptic 
patients that were 
treated with 
antiepileptic drugs 
which included PB 
although not 
exclusively.  
 
 
Authors were unable to 
identify specifically or 
failed to mention which 
drugs were administered to 
epileptic patients within the 
cohort. 
 
 
Methods used 
to estimate 
dose levels of 
PB exposure 
 
 
 
Authors applied well 
defined quantitative 
methods to estimate 
cumulative dose 
exposure to PB using 
patient drug 
information obtained 
from medical records or 
other appropriate 
patient records. 
 
Where no quantitative 
methods of exposure 
assessment were used, 
any surrogate methods 
used to estimate drug 
exposure was clearly 
defined by the authors.   
 
No clear definition of 
methods used to estimate 
levels of patient exposure to 
PB.  
 
Confirmation 
of disease 
status of liver 
cancer in 
epileptic 
patients. 
 
 
 
Authors carried out 
histopathological 
examinations on 
available tissue samples 
to confirm diagnosis of 
liver cancer as indicated 
by medical records or 
Cancer Registry 
records. 
 
Authors used only 
medical records or 
Cancer Registry records 
to confirm patient 
diagnosis of liver 
cancer. 
 
The diagnosis of liver 
cancer could not be 
adequately confirmed as a 
result of grouped recording 
of diseases into medical 
records or cancer registry 
records. 
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3.2 Results 
 
Application of the search strategy and selection of the relevant studies using the 
predefined inclusion criteria identified eight studies for the review.  Figure 3.1 below 
details the number of studies that were identified for the review. 
 
   
Figure 3.1: Flowchart detailing the number of studies identified for the review 
 
 
 
 
The initial search from the electronic databases using the derived search strategy 
identified 11,096 publications. Studies were selected on the basis of the inclusion and 
exclusion criteria leading to the identification of 31 potentially relevant studies. Only 
five of these were actually observational studies and therefore considered to be 
relevant for the investigation of the association between liver cancer and PB. Citation 
searching of these potentially relevant studies identified a further three relevant 
studies. The search therefore identified eight relevant studies to be included in the 
review.  
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There were eight epidemiological studies investigating the association between the 
exposure of epileptic patients to the drug PB/and or any other antiepileptic drug (in 
cases when it was not clear what drug was administered to the patients) and the 
occurrence of liver cancer. Table 3.2 gives details of the characteristics of the 
identified studies, Table 3.3 gives the quality scores and Table 3.4 summarises the 
main findings for liver cancer. All studies reviewed were observational studies using a 
cohort or a nested case-control study design.  Four of the eight studies were based on 
a cohort of patients identified from the Neuropsychiatric Hospital of Filadelfia, Centre 
for Epilepsy Treatment in Denmark that had been followed up over time [63, 107-
109]. The remaining four studies reviewed were cohorts of epileptic patients 
identified from institutional treatment centres for epileptic patients [110, 111] or were 
epileptic patients identified from within the general community [112, 113]. 
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Table 3.2: Summary of included epidemiological studies  
 
 
 
 
First 
Author 
Date 
Published 
Period of 
Study 
Country 
Study 
Design 
Study Subjects 
Controls / Reference 
Population 
Antiepileptic Drugs 
Administered 
 
Methods used to 
Collect Data 
Other Risk 
Factors 
Investigated 
Methods of Measure of Exposure to 
PB 
 
Clemmesen 
[114] 
 
1974 
 
1933 
to 
1962 
 
Denmark 
 
Cohort 
study 
 
Epileptic patients admitted 
to the Neuropsychiatric 
hospital of Filadelfia,  
centre epilepsy treatment 
(n= 9136) 
 
Men= 4201 
Women = 3957 
 
 
Morbidity rates for 
all of Denmark 
 
 
1920s: PB 
1940s: phenytoin 
from 1954: 
primidone 
 
Danish Cancer Registry 
and death certificates. 
 
 
 
Exposure to 
thorotrast. 
 
 
 
Period of therapy defined as the 
remaining lifetime of the patients. 
 
Deaths verified by checking against 
national register for deaths for the 
years up to and including 1967. 
Clemmesen 
[63] 
 
 
 
1978 
 
Follow up 
study to  
Clemmesen 
1974 
1933 
to 
December 
1972 
Denmark 
 
Cohort 
study 
Epileptic patients admitted 
to the Neuropsychiatric 
hospital of Filadelfia,  
centre epilepsy treatment 
n= 8078 patients 
 
Men= 4268 
Women = 3810 
 
 
 
 
Cancer incidence 
rates for all of 
Denmark 
PB, phenylhydantoin, 
primidone 
 
Death files and Danish 
Cancer Registry 
 
Effect of epileptic 
patient exposure to 
thorotrast 
Not clearly defined although this has 
been assumed to be the period of 
follow up; i.e. the follow-up period 
until the last month of contact, the 
period up until death or until 
December 1972 when the follow-up 
period ended. 
 
Doses administered to patients were 
noted. PB: 100 - 300 mg; 
phenylhydantoin: 100 - 400 mg; 
primidone: 1.5 - 1.5 g 
 
Olsen J. H. 
[108] 
1989 
 
 
The follow-
up to 
Clemmesen  
1978 
1933 to 
1962; 
 
1976 to 
1984 
Denmark 
 
Cohort 
study 
Epileptic patients admitted 
to the Neuropsychiatric 
hospital of Filadelfia,  
centre epilepsy treatment 
n=8004 
 
Men=4246 
Women= 3758 
 
The general 
population 
1920s: PB 
1940s: phenytoin 
1950s: primidone 
1960s: 
carbamazepine 
 
** 
medical records, Danish 
Cancer Registry, 
Central Population 
Registry 
 
The effect of 
thorotrast 
Time since hospitalisation was taken 
as a surrogate for a cumulative drug 
exposure . 
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White SJ 
[111] 
1979 
1931 to 
1971 
Chalfont, 
Buckingh
amshire, 
England 
Cohort 
study 
2099 patients admitted to 
the Chalfont Centre for 
epilepsy and taking 
anticonvulsants only 
patients, medically 
diagnosed as having 
epilepsy were included in 
the study. 
1448 men and 651 women 
Comparison of 
mortality with that in 
the general 
population in 
England and Wales 
in the same period. 
Most of the epileptic 
patients in this study 
were treated with PB, 
phenytoin and 
primidone. 
 
Medical records for all 
patients living in the 
centre in 1931.  Death 
certificates,.  Follow-up 
through the national 
health service central 
register (NHS CR) 
None. 
This was not made clear although it 
was noted that the type and duration 
of drug therapy was noted.  It was 
assumed that this was taken as the 
period of follow up for each patient. 
 
Shirts 
[113] 
1986 
1935 to 
1979 
Rochester 
MN, 
America 
Cohort 
study 
All patients with seizure 
disorders in the Rochester 
area. 959 patients were 
included in the cohort of 
730 had epilepsy 
(classified as having two 
seizures or more). 
The general 
population in 
Rochester.  
Comparison was 
made on the basis of 
age and sex and 
specific incidence 
rates for Rochester 
by means of SMR. 
No mention of 
exactly what 
anticonvulsants 
medications the 
cohort was under. 
 
 
 
 
 
 
 
 
 
Medical records, all 
records with the 
diagnosis. 
None. 
The number of person-years of the 
cohort while on anticonvulsants 
medication.  The dates of initiation 
and discontinuation of prescribed 
drugs were obtained from the medical 
records. 
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** Individual exposures to anticonvulsants drugs could not be quantified, time since hospitalisation was taken as a surrogate cumulative drug exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
First 
Author 
Date 
Published 
Period of 
Study 
Country 
Study 
Design 
Study Subjects 
Controls / Reference 
Population 
Antiepileptic Drugs 
Administered 
 
Methods used to 
Collect Data 
Other Risk 
Factors 
Investigated 
Methods of Measure of Exposure to 
PB 
 
McLean 
AEM 
[110] 
 
1992 
 
Study one: 
follow up 
from White 
et al 1979. 
 
 
 
1951 to 
1977 
 
Chalfont, 
Buckingh
amshire, 
England 
 
Cohort 
studies 
 
Study one: patients with 
severe epilepsy at the 
National Centre for 
epilepsy, Chalfont (636 
deaths observed). 
 
Study two: people with 
well-controlled epilepsy 
(4488 persons with 
epilepsy; car driving 
licence holders). 
 
The general 
population in 
England and Wales. 
 
PB 
 
UK system of 
registration of deaths 
and diagnosis of cause 
of death in the death 
certificates as the office 
of population Census 
and survey (OPCS, 
formerly the registrar 
General) and the central 
National Health Service 
records. 
 
 
 
None addressed. 
 
Study one: not stated although it is 
assumed that this would be have been 
the same as in the White et al 1979 
paper since the information was 
based on the same dataset. 
 
Study two: none stated studies has 
been assumed to be the period of 
follow up. 
Lamminpaa 
[112] 
2002 
1979 to 
1997 
Finland 
Cohort 
study 
All patients seeking 
reimbursement of 
antiepileptic drugs from 
the Finnish social 
insurance institution in 
1979 to 1981 
 
14,487 men and 13,932 
women. 
Corresponding 
cancer incidence in 
Finland 
Enzyme inducing 
epileptic drugs used 
in the 1980s, these 
included the 
carbamazepine, 
phenytoin, PB and 
primidone 
Finnish Cancer Registry 
The effect of 
alcohol as a liver 
enzyme inducer 
was discussed by 
the authors. 
Not stated. 
This was therefore assumed to be the 
number of years of reimbursement for 
each drug. 
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3.2.1 Study Quality Assessment 
 
 
Table 3.3: Quality assessment based on the Quality Criteria 
 
Quality 
criteria 
 
Author and year of publication 
Lamminpaa 
et al [112] 
McLean et 
al [110] 
Olsen et al 
[109] 
Shirts et al 
[113] 
White et al 
[111] 
Consideration 
of bias and 
confounding 
in the study 
 
Adequate 
 
Poor 
 
Good 
 
Poor 
 
Poor 
 
 
Identification 
of patients 
administered 
PB 
 
 
Adequate Adequate Good Poor 
Good 
 
 
 
Methods used 
estimate 
cumulative 
dose levels of 
PB exposure 
 
Adequate 
 
 
 
Poor Good Adequate Adequate 
Confirmation 
of disease 
status of liver 
cancer in 
epileptic 
patients. 
 
Adequate Poor 
Good 
 
Adequate Adequate 
*Quality 
Score 
(scores are 
additive) 
8 5 12 6 8 
 
*Good =3; Adequate = 2; Poor = 1 for each criterion, summed 
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Table 3.4: Summary of the main findings from the individual studies 
First Author 
Date 
published 
Major findings 
for liver cancer 
Strengths/weaknesses Conclusion Additional comments 
 
Clemmesen 
[114] 
 
 
 
 
1974 
 
 
Slight excess for liver cancer was not 
considered to be statistically significant. 
When the values were combined the total 
number of liver cancers observed among 
patients treated with anticonvulsants for less 
than 10 years was 2 (Exp.= 1.5;  RR= 1.33). 
Total number of liver cancers observed 
among those treated for more than 10 years 
was 8 (Exp = 3.5; RR= 2.3). 
 
One of the cases of liver cancer observed in 
1964 and diagnosed with cholangiocarcinoma 
of a cirrhotic liver was confirmed to have 
received thorotrast.   
 
Large study of patients evaluated using complete 
dataset compiled from the Cancer Registries and 
based on notifications from hospitals and 
supplemental information from death certificates. 
 
No adjustments were made for exposure to alcohol 
and tobacco because the patients were considered to 
have had a sheltered life and obtained relative 
protection against exposure to alcohol and tobacco at 
the treatment centre. 
 
The study evaluated the associations between the 
cumulative exposure from combined anticonvulsants 
drugs rather than PB exposure only.  
 
The observed cases of liver cancer was not 
considered to be statistically significant as some 
of these results may have been confounded by 
exposure of the patients to  thorotrast  a known 
liver carcinogen.  The authors concluded that the 
observed neoplasms were not causally linked to 
anticonvulsants therapy. 
 
Community-based study.  
Institutionalised epileptic 
patients. 
 
 
   
 
Clemmesen & 
Hjalgrim-
Jensen 
[63] 
 
 
1978 
 
 
Follow up of 
original 
cohort 
compiled by 
Clemmesen 
et al, 1974 
 
A significant excess of liver cancer was 
observed among the study group 
 (Obs = 11;Exp= 2.8, p<0.001; RR = 3.9).   
8 of the 11 cases of liver cancers had received 
injections of thorotrast.  Exclusion of the 
thorotrast cases lead to the observed cases of 
liver cancer being very similar to the numbers 
expected (Obs. =3; Exp. =2.8; RR = 1.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This was a large study with a further five-year 
follow-up compared to the original 1974 study by 
Clemessen et al. 
 
All observed cases of liver cancer were verified using 
histological techniques. 
 
Analysis was not carried out on the basis of the 
different types of drugs taken in comparison with the 
observed neoplasms. 
 
 
 
 
 
 
Histological evaluation of 8 thorotrast cases 
confirmed that the neoplasms were histologically 
similar to the type of liver neoplasms observed in 
thorotrast related liver cancer cases, leading the 
authors to concluded that the observed liver 
cancer cases was therefore likely to have being 
associated with exposure to thorotrast rather than 
PB. 
 
Owing to the lack of difference between the 
observed in the first of non-thorotrast cases and 
the expected numbers for occurrence of liver 
cancers, the authors noted that the latter results 
provided a good basis for argument against any 
measurable effects of PB on the occurrence of 
liver cancer. 
 
Although the title suggests 
that the study examined on 
the effects of PB among 
follow-up of 8078 
epileptic patients, it is 
impossible to determine 
with any certainty that the 
11 observed cases of liver 
cancers were only exposed 
to PB.  Although PB was a 
primary drug introduced 
in the 1920s, its 
administration may have 
been substituted by other 
anticonvulsants drugs or 
administered in 
combination with another 
antiepileptic drug.   
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First Author 
Date 
published 
Major findings 
for liver cancer 
Strengths/weaknesses Conclusion Additional Comments 
 
Olsen J. H. 
[108] 
 
1989 
 
 
Follow up 
front cohort 
compiled by 
Clemmesen 
& Hjalgrim-
Jensen 
(1977) and 
based on 
original 
cohort 
compiled by 
Clemmessen 
et al, 1974 
140 patients known to have received 
thorotrast were excluded from the study (n= 
7864 non thorotrast patients with epilepsy). 
Eleven cases of liver cancer were observed 
compared to the expected seven.  Statistical 
analysis was carried out on observed cases of 
liver cancers and other cancers. Non-
statistically significant elevations were 
observed for liver cancers   
(RR or O/E=1.9; n= 9; expected = 4.7; 95% 
CI= 0.9 - 3.6). 
 
Elevations were observed for patients 10 
years after hospitalisation (RR= 2.4) and the 
risks were significantly increased after 30 
years of the first admittance (RR= 2.9*; *P< 
0.05).  The latter however only marginally 
exceeded the expected value for the same 
period (O=6; E= 2.1). 
 
The study had an over 90% follow-up success rate 
and a long follow up over 30 years.  The authors 
attempted to identify epileptic patients exposed to 
thorotrast in an effort to consider any potential 
confounding factors.  This was done by linking 
available data from Cancer Registry with the Danish 
thorotrast study. 
 
Inherent errors were highlighted by the author such as 
the use of patient hospitalisation as a surrogate to 
drug exposure. Although PB was the primary drug 
administered to patients the observed cancers could 
not solely be attributed to the effects from PB. 
 
No detailed drug and alcohol histories were compiled 
for the individual patients. No information was 
provided on smoking and alcohol intake for the 
epileptic patients at Filadelfia.  Although it was noted 
by the authors that the physicians and nurses at the 
Centre for Epilepsy , previously a religious home, 
discouraged smoking and drinking alcohol. 
 
The authors concluded that the non-significant 
elevations of liver cancer observed may have 
been related to undocumented exposure to 
thorotrast. 
 
It was noted that there were some limitations in 
the Danish thorotrast study which would have 
meant an incomplete data set on the compilation 
of patients administered thorotrast. 
 
Overall the site-specific analysis did not appear 
to suggest causal associations with 
anticonvulsants drugs. 
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First Author 
Date 
published 
Major findings 
for liver cancer 
Strengths/weaknesses Conclusion Additional Comments 
 
Olsen  
[109] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1995 
 
Nested case-
control 
study into 
the cohort 
compiled by 
Olsen et al, 
(1989). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
26 cases of primary liver cancer were 
observed among a cohort of 8004 epileptic 
patients.  Only nine of these patients however 
were known not to have received thorotrast 
and only 6 of these 9 non-thorotrast exposed 
patients were actually treated with PB. 
 
19 cases of patients with liver cancers who 
had received PB were identified and 
compared to 29 controls (OR = 2.0; 95% CI = 
0.5- 7.2).  The latter values were further 
analysed to exclude any patients that had also 
received thorotrast. Six cases fitting this 
criteria were identified and matched with 11 
controls (cases: controls = 6: 11; OR= 1*; 
95% CI= 0.1- 8.0). 
The restriction of the analysis to patients not 
exposed to thorotrast significantly reduces the 
number of the cases available for analysis 
thereby reducing the stability of the risk 
estimation. 
 
In the absence of thorotrast, overall 
administration of PB was associated with non 
significant increased risks for liver cancers. 
 
 
* matched analysis unadjusted for other 
anticonvulsants therapy due to small numbers 
 
The study specifically identified cases of epileptic 
patients with liver cancers who had received long-
term treatment of PB. 
 
Where tissue samples were available, the authors 
carried out histopathological examinations and x-ray 
analysis for thorium residuals.  This analysis was 
carried out on the tissue samples of the non-thorotrast 
cases, receiving PB and diagnosed with primary liver 
cancer. 
 
Potential confounding factors were efficiently 
addressed by the authors. 
 
Thorotrast: separate analysis was carried out to 
consider the effects of thorotrast on the patient's with 
liver cancers. 
 
The authors attempted to identify cases of liver 
cancer specifically associated with PB exposure on 
the basis of biological relevance as observed in 
experimental rodent studies. 
 
The small numbers of cases investigated were 
identified by the authors as a limitation to their study.  
To address issues of bias, medical records were 
abstracted without knowledge of case control status 
of study subjects.  All assumptions made by the 
authors were discussed in the study and this included 
the reasoning behind the use of cumulative exposure 
as a surrogate estimation of the actual dose of PB 
exposure. 
 
 
 
Although histopathological examinations were 
carried out on the tissue samples where 
available, only one of the histopathologically 
examined tissue samples (in cases receiving PB 
and with no exposure to thorotrast) confirmed 
that the cancer was the result of hepatocellular 
carcinoma, a subtype of neoplasm associated 
with PB administration in experimental rodents. 
The results obtained in the latter were on the 
basis of a tissue sample from a metastasis in the 
lung, therefore it was not possible for the authors 
to determine whether there was underlying liver 
disease.   
 
The authors found no significant association 
between the treatment with PB and human liver 
cancer.  It was therefore concluded that the 
increased risk for cancers of the liver observed 
among Danish epileptic patients were due to 
other factors other than anticonvulsant treatment, 
including thorotrast administration and 
conditions relating to cirrhosis of the liver. 
 
This was a well-designed 
study that sought to 
identify any issues of bias 
and confounding as well is 
clearly stating the 
reasoning behind any 
assumptions made.  
Efforts were made to 
confirm all diagnosis 
using histopathological 
examinations. 
 
The study also specifically 
identified cases of patients 
with liver cancer that had 
been treated with PB. 
 
To calculate the 
cumulative exposure, the 
assumption was made that 
the epileptic patients were 
exposed to the daily doses 
until the date of the cancer 
diagnosis (or equivalent 
equivalents date for 
matched controls) or at the 
end of 1960 whichever 
came first.  The median 
cumulative dose of 750 g 
was chosen to differentiate 
from high exposure. 
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First Author 
Date 
published 
Major findings 
for liver cancer 
Strengths/weaknesses Conclusion Additional Comments 
 
White SJ 
[111] 
 
1979 
 
There were no observed cases of primary liver 
cancer with the observed frequency of 0, the 
underlying value was estimated to live 
between 0 - 3.7 (95% confidence limit). 
 
The expected mortality rate for liver cancer 
was estimated by the authors to be 0.3. 
Although there were no observed deaths from 
liver cancers in the study, the range for the 
mortality ratio was estimated to be between 
approximately 0 and 12. 
 
 
The authors could only estimate the mortality rates 
expected in the general population because the 
number of deaths caused by primary liver cancer was 
not separately recorded from gallbladder cancer 
before 1958. 
 
The only conclusion that could be reached by the 
authors was that the limits for the mortality ratios 
were approximately 0 to 12, signalling that the 
risk of death from primary liver cancer for 
epileptic patients could be less than that for the 
general population or up to 12 times greater. 
 
 
 
Shirts 
[113] 
 
1986 
 
65 primary cancers were diagnosed among 
patients followed up.  No cases of liver 
cancers were observed although the expected 
number for the area of study was 0.2. 
(Obs. = 1; Exp. = 0.2) 
 
One of the positive aspects of the study was that the 
authors followed up a cohort of patients from initial 
seizure of diagnosis rather than only including 
patients with established seizure disorders prior to 
entry into the cohort.   
 
One of the main limitations of this study was the lack 
of discussion of the actual antiepileptic drugs taken 
by the epileptic patients within the cohort study.  
Owing to the lack of observed cases of liver cancer, 
there was no discussion about the results. 
 
 
 
 
There were no observed cases of liver cancer 
among the cohort investigated. 
 
      
 
 
 
 
 
     
70 
 
 
 
 
      
First Author 
Date 
published 
Major findings 
for liver cancer 
Strengths/weaknesses Conclusion Additional Comments 
 
McLean AEM 
[110] 
 
1992 
 
Study 1: statistically significant results were 
obtained in the first study seeking to examine 
the number of deaths in patients with epilepsy 
in Chalfont treatment centre for epileptic 
patients (Obs. = 1; Exp. = 0.6; RR = 1.5; 95% 
CI = 0.0 - 8.5, for liver and gall bladder 
cancer). 
 
Study 2: two deaths were observed from liver 
or bile tract cancer were observed among 
4488 epileptics holding driving licences (Obs. 
=2; Exp. = 1; RR= 2.0).   
 
The authors noted that one of the disadvantages of 
carrying out a community-based study was the fact 
that people living within these institutions were likely 
to be exposed to very different environmental factors 
when compared to the general population. They 
therefore identified a group of well-controlled 
epileptics; people within the UK diagnosed as having 
epilepsy but also have a driving licence for a motor 
vehicle.  The latter group of individuals were only 
permitted to have a driver's licence if they could 
prove they had not had an epileptic fit for over two 
years, such documentation could only be provided by 
a family practitioner or consultant physician who 
would normally state that the patient's epilepsy was 
under control and also state what medication the 
patient was under. 
 
Both study designs included a well-defined 
population of people taking PB as long-term 
treatment for epilepsy.  These cohorts were then 
followed up using the UK system of registration of 
deaths and diagnosis of cause of death. 
 
There was no distinction in the reporting of results in 
the second study between the observed mortality rates 
from cancer of liver or bile tract.  It was therefore 
impossible to determine whether the death (s) was 
attributed to liver cancer or bile tract cancer. 
Although the disease classifications were also 
grouped in the first study, owing to the fact that the 
data was the same as that reported in the White et al 
study, the observed case was confirmed to be gall 
bladder cancer and not liver cancer. 
 
Study 1: on the basis of the results obtained the 
authors concluded that the risk of liver cancer to 
people from taking PB must be very small 
though it could still be up to eight times the risk 
found in the general population in the UK, 
without having shown up in the studies. 
 
As the authors observed no increase in liver 
carcinoma in people taking PB, the overall 
conclusion reached was that there was no 
significant cancer risk to man as a result of 
taking anticonvulsants drugs especially in 
comparison with the other cases causes of 
mortality. 
 
This study had a clearly 
defined group of people 
taking PB for long term 
treatment of epilepsy.  
 
The study also attempted 
to follow up a cohort of 
individuals that were more 
comparable to the general 
population in terms of 
exposure to similar 
environmental factors. 
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First Author 
Date 
published 
Major findings 
for liver cancer 
Strengths/weaknesses Conclusion Additional Comments 
 
Lamminpaa 
[112] 
 
 
 
 
 
 
 
2002 
 
An overall significant increased risk of liver 
cancer (1.71) was reported by the authors 
(Obs.= 37; Exp.= 22; SIR= 1.71; 95% CI= 
1.20 - 2 .35).  Similar increased risks were 
also reported for patients aged 60 years or 
above as well as in younger patients.  It 
should be noted however that the increased 
relative risk was on a statistically significant 
in patients above 60 years (Age <60 years: 
Obs.=9; SIR= 2.2; 95% CI= 0.97- 4 .02. 
Age > 60 years: Obs.= 28; SIR= 1.6; 95% 
CI= 1.0 6 - 3.31) .  No cases of liver cancer 
were observed in patients less than 30 years 
of age. 
 
 
 
A large cohort of over 28,000 people taking 
antiepileptic drugs.  The study allowed for a long 
follow-up period in order to study the risk of cancer 
among patients taking AEDs.  Each patient was 
identified using a personal identification number, 
therefore followed up until death or until the study was 
completed.  The authors noted that the cancer registry 
system in Finland was also complete therefore linking 
the datasets allowed for a precise follow-up of all such 
patients within the cohort in order to establish any 
disease outcomes. 
 
The authors assumed compliance of regular use of the 
antiepileptic drugs by patients within the cohort since 
treatment of epilepsy in Finland also resulted in the 
regular monitoring of blood concentrations of the drugs.  
It was noted that lack of compliance resulting in under 
use of the antiepileptic drugs would if anything, result 
in an underestimation of the cancer risks. 
 
 
Alcohol was identified as a major risk factor 
for liver cancer.  The authors noted that more 
than 20% of newly diagnosed epilepsy cases 
in adults are alcoholic epilepsies, therefore it 
was acknowledged that alcohol might be a 
contributing factor for increased risk of liver 
cancer in epileptic patients. 
The authors concluded that the study showed 
that there was an increased risk of some 
cancers among users of enzyme inducing 
antiepileptic drugs. 
 
It was noted however that the excesses 
observed for liver cancers may be associated 
with lifestyle but the role of enzyme inducing 
antiepileptic drugs could not be ruled out. 
 
Thorotrast was used in 
Finland in one hospital as 
the beginning of the 1950s 
although but was not 
considered by the authors 
to have contributed to 
their findings. 
 
The exposure assessment 
was very poorly defined in 
this study. 
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3.2.2 The Danish Cohort of epileptic patients 
 
 
 
1932 1943 1962 1972 1984
Admission 
period
Timeline 
(year)
Clemmesen & 
Hjalgrim-Jensen, 1977
Follow-up: + 5 years
Clemmesen, 1974
Initial follow-up
Olsen et al., 1989
Follow-up: + 22 years
Olsen et al., 1995
Nested case-control 
study
9136 patients were admitted 
with epilepsy from 1933 to 
1962. 
Patients who had had brain 
tumours removed were 
excluded.  
The data from these patients 
were compared with the 
Danish Cancer Registry data 
during 1943 - 67.
Deaths during 1933- 42 were 
verified by the follow-up 
files of the hospital
A cohort of 8078 patients 
were selected for  follow-up 
until 1972 out of the original 
9136 patients admitted 
between 1933 and 1962.  
Exclusions: 1058 patients
-Aliens (n= 160)
- Deaths before 1943
(n= 131)
- Patients that could not be 
traced (n = 340)
-Duplicate registrations
(n= 106)
- Patients whose diagnosis 
could not be "sustained" and 
who were also discharged 
less than four weeks after 
admission (n= 321).  
A cohort of 8004 patients 
were selected as eligible for 
follow-up until 1984.
9085 patients were identified 
out of the original 9136 
patients. The authors chose to 
include 321 patients whose 
hospitalisation stays were less 
than four weeks.  
Exclusions: 1081 patients
- Any additional duplicate 
admissions (n= 217) 
-Aliens and untraceables 
(n= 844),
- Patients with an unavailable 
admission date (n= 20).
Start of
follow-up
9136 epileptic  
patients  identified 
for follow up
Start of Danish 
cancer registry
Case-control study nested in 
the cohort of 8004 epileptic 
patients identified by Olsen et 
al. (1989).
This study specifically 
investigated the 26 identified 
cases of primary liver cancers 
and matched them with 
suitable controls.
Detailed drug use for these 
cases were abstracted from the 
medical records to address the 
cases on the basis of the levels 
of exposure to phenobarbital 
and any exposures to thorotrast.
Figure 3.2: The relationship between the different epidemiological studies carried out using data on patients 
admitted to the Filadelfia  
      Centre for epilepsy treatment in Denmark between 1933 and 1962 
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Figure 3.2 summarises the relationship between the four Danish papers reporting 
results from studies of a cohort of epileptic patients identified from the 
Neuropsychiatric Hospital of Filadelfia, Centre for Epilepsy Treatment. In the initial 
follow up study by Clemmensen [107, 114], the occurrence of cancer (ascertained 
from the cancer registry for 1943-67) was determined among 9136 patients admitted 
to hospital with epilepsy. Five cases of liver cancer were observed among the patients 
identified compared to 3.5 expected to occur among the general population. The slight 
excess reported for liver cancer was not statistically significant. In addition clemessen 
reported that one of the cases, a man of 61 who died in 1964 with cholangiocarcinoma 
of a cirrhotic liver had received thorotrast [114].  
 
Clemmesen and Hajalgrim-Jensen [63] followed up 8078 out of the initial 9136 
patients identified by Clemmesen [114] for an additional five years to combined with 
a reassessment of the data to provided strength and clarity to conclusions drawn from 
the initial follow up study.  The study led to the exclusion of 1058 patients and the 
exclusion of a further three cases (patients treated with thorotrast) from the original 
five observed cases of liver cancer. The authors concluded that the remaining three 
cases were close to the expected number.  
 
Olsen et al [108] identified a cohort of 8004 epileptic patients. As the majority of the 
patients identified were from the initial 9136 patients identified by Clemmesen [114], 
the follow up of the initial cohort was therefore extended by a further  22 years. The 
author observed liver cancer to be elevated ten years after hospitalisation and was 
significantly increased among 30 year survivors. The authors reported a relative risk 
of 2.9 (n=6). Following this study a case control study was nested in the cohort of the 
8004 patients identified in the previous study. The study carried out by Olsen et al 
[109], the most recent publication from this Danish cohort, was chosen for evaluation 
in this review in order to avoid duplication of results documented in previous studies 
published by these authors.   
 
Olsen and colleagues identified 26 cases of primary liver cancers among the Danish 
cohort of 8004 epileptic patients and these cases were matched with suitable controls.  
In order to identify the number of patients with liver cancers among the cohort who 
had also received thorotrast (identified as a potential confounder by the authors) for 
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other treatment, the authors linked this dataset with the Danish thorotrast study to 
confirm that 17 of the 26 epileptic patients had been administered thorotrast. Patients 
known to have received thorotrast were therefore evaluated separately from the other 
patients with liver cancers that were known to have not received thorotrast. Out of the 
latter nine remaining cases of liver cancers, only six were in fact receiving PB 
treatment for epilepsy.  Analysis of these observed six cases when compared to the 11 
matched controls showed no increased risk for liver cancer among epileptic patients 
(OR: 1.0, matched analysis unadjusted for other anticonvulsant therapy; 95% CI: 0.1- 
8.0).  Further histopathological examinations were carried out on 4 available tissue 
samples from the observed cases of patients defined as having being exposed to PB.  
Epileptic patients were defined as having been "exposed" if they had received more 
than 5g (50 tablets) of PB or more than 10g (40 tablets) of primidone
5
 lifelong. The 
authors chose a median cumulative dose of 750g to separate low from high doses of 
exposure to PB, see table 3.5.  
                                                 
5
 Primidone is extensively metabolised to PB, which is responsible for much of its therapeutic effect 
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  Table 3.5: Primary Liver cancers among the 6 Danish epileptic patients exposed to PB with no evidence of Thorotrast exposure by  
histopathological examination and X-ray analysis for thorium residuals (Source: Olsen et al [109]) 
Gender 
and Year 
of birth 
Age at 
diagnosis 
(Year) 
Source of 
verification 
 
Original diagnosis 
Results of re-evaluation Cumulative dose* 
of PB (g) 
Histocytological 
review 
Comments 
F, 1899 65 
 
Death 
certificate 
 
Liver cancer 
 
No tissue available  
 
824 
M, 1904 81 
Death 
certificate Liver cancer No tissue available  647 
M, 1905 61 Autopsy Cholangiocarcinoma Cholangiocarcinoma  1079 
M, 1908 67 Autopsy 
 
Hepatocellular 
carcinoma Cholangiocarcinoma  1589 
 
M, 1913 
 
65 
Autopsy 
Hepatocellular 
carcinoma 
Hepatocellular 
carcinoma 
 
Tissue from a 
metastasis to 
the lung 
2200 
F, 1920 59 Autopsy Cholangiocarcinoma 
 
Possibly secondary 
tumour 
 1065 
  * Estimated as a cumulative dose from date of initial treatment till end of 1964 
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The original diagnosis of the four liver cancer cases among the Danish cohort 
subject to histopathological assessment included two cases of hepatocellular 
carcinoma (the neoplasm subtype confirmed in animal experiments to be linked 
with exposure to PB) and two cases of cholangiocarcinoma.  Further 
histopathological examination by the authors confirmed that one of the cases of 
hepatocellular carcinoma was in fact a case of cholangiocarcinoma.  Since the 
latter was not biologically consistent with exposure to PB, the authors concluded 
that these three observed cases could not be biologically associated with 
exposure to PB and that the observed disease outcome was the result of some 
other risk factor. 
 
It should be noted that, for the two remaining cases of liver cancer for which no 
tissue samples were available, the doses to which these two patients were 
exposed was almost three times less than that received by the patient with the 
histopathologically confirmed diagnosis of hepatocellular carcinoma. By 
application of the authors‟ classification of low and high exposure, the exposure 
of patient M; 1904 was assessed to be low. In addition, the only tissue sample 
available for analysis in the latter case was a metastasis to the lung; the authors 
therefore concluded it was not possible to determine whether there was any 
other underlying liver disease.  Without tissue samples to confirm the diagnosis 
in the remaining two epileptic patients, one can only interpret the findings by 
taking into account the levels of uncertainty associated with the observed results. 
The actual number of PB receiving patients that actually developed 
hepatocellular carcinoma could be a minimum of one or a maximum of three.   
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3.2.3 The English cohort of epileptic patients 
 
Two papers were published on cohort studies carried out on epileptic patients 
identified from the Chalfont Centre for Epilepsy, Buckinghamshire, England. The 
cohort was originally assembled by White and colleagues in 1979 and the dataset later 
re-evaluated by McLean et al [110]. The paper published by McLean et al [110] also 
sought to define a population of free-living people taking PB for long-term treatment 
of epilepsy. The cohort of institutionalised patients studied by McLean and colleagues 
was the same as that defined by White et al [111]. Although both papers reported the 
same result of no observed cases of primary liver cancer, a decision was made to use 
the results reported in the 1979 paper for this review because unlike the results 
provided by McLean et al, White et al, provided an estimation of the confidence limits 
and of the standard mortality ratio based on the estimated expected number at general 
mortality rates. These results could therefore be used for comparison with the results 
reported from the other studies. 
 
McLean et al [110] also sought to define a non-institutionalised epilepsy cohort.  
Their aim was to examine the mortality rates from liver cancer among a defined 
"well-controlled" group of epileptic patients taking PB. The results obtained from this 
new cohort were also included in this review as this newly defined group was separate 
from the group of patients previously identified from the Chalfont Centre for Epilepsy. 
 
About 1980 epileptic patients admitted to the Chalfont Centre for epilepsy were 
followed up for a total of 32,873 person-years between 1951 and 1977 by White et al 
[111].  During this period there were no observed deaths from primary liver cancer 
among the epileptic patients. The authors estimated that the frequency of death from 
liver cancer was between 0 and 3.7 and the 95% confidence limits for the mortality 
ratio was estimated to be between 0 - 12. The authors concluded that the risk of death 
from liver cancer among epileptic patients could be less than that observed among the 
general population or 12 times higher. 
 
McLean et al [110] identified 4488 persons suffering from epilepsy and permitted to 
hold a driving licence due to the fact that their epilepsy was well-controlled (i.e. 
people who had not had a fit for more than two years and were motivated to continue 
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taking their treatment with PB for their epilepsy). No significant increases in liver 
tumours were observed among this identified group of epileptic patients taking PB 
(observed: 2; expected: 1; O/E: 2.0).  The liver cancers were grouped with those from 
bile tract cancer so it was difficult to determine whether the two cases observed were 
actually true cases of liver cancer.  
 
 
3.2.4 The American cohort of epileptic patients 
 
Shirts et al [113] identified a cohort of 959 residents of Rochester, MN suffering from 
seizure disorders, between 1935 and 1979. This cohort was followed up until death or 
to the end of the study period in 1982. There were no observed cases of primary liver 
cancer among this group of people suffering from seizure disorder; this was in line 
with the expected number of cases for liver cancer estimated to be 0.2. Although there 
was no direct mention of which anticonvulsant medications were actually prescribed 
to the patients, the dates of initiation and discontinuation of prescribed anticonvulsant 
medications were used to calculate standard morbidity rates for the observed cancer 
incidences.  While the cohort of patients was identified using medical records similar 
to the Danish and English cohorts, this study differed in that the identification of 
patients was not restricted to that of hospitalised or institutionalised patients. Instead, 
authors followed up the cohort of epileptic patients within the community from the 
onset of their diagnosis until the end of the study.  
 
 
3.2.5 The Finnish Cohort of epileptic patients 
 
Lamminpaa et al [112] identified a cohort of Finnish patients who had received 
monetary reimbursement for antiepileptic drugs between 1979 and 1981; 14,487 men 
and 13,932 women were followed up until 1997 or until death.  Thirty seven cases of 
liver cancer were observed compared to an expected number of 22 within the general 
population (Standardised Incidence Ratios, SIR: 1.71; 95% CI: 1.2 - 2.35). There was 
a statistically significant increased risk for liver cancer among patients receiving 
antiepileptic drugs.  Similar findings were observed among patients aged 60 years or 
more (observed: 28; SIR: 1.60; 95% CI: 1.0 6 - 3.31).  However, there were no 
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observed increased risks of liver cancer observed among patients that were less than 
60 years of age (observed: 9; SIR: 2.12; 95% CI: 0.9 7 - 4.02).   
 
The authors were unable to identify any patients that had obtained reimbursement for 
the drug PB.  The aim of the study was to investigate whether an association existed 
between enzyme induction and liver cancer. The records utilised by the authors, 
grouped antiepileptic drugs according to their enzyme inducing properties.  PB was 
among this group of compounds. The cases of liver cancers observed in the cohort of 
patients followed up were therefore not necessarily associated with PB exposure. In 
addition, the authors noted that initial methods of recording data into the 
reimbursement registers were not as thorough in excluding some anti-enzyme 
inducing drugs such as valproate. The authors however noted that as valproate is 
mostly prescribed to paediatric patients, it was unlikely that the cancers observed 
would have been influenced by valproate. Although a lifestyle study was not carried 
out to examine the direct influence of alcohol consumption among the cohort 
investigated, alcohol consumption was also suggested by the authors as a potential 
contributing factor for the observed increase risks of liver cancers, owing to the fact 
that it was acknowledged that 20% of newly diagnosed epileptic adults were linked to 
alcohol consumption [112, 115].  It was concluded that there was an increased risk of 
liver cancer and other cancers among epileptic patients exposed to enzyme inducing 
antiepileptic drugs. 
 
It was noted that thorotrast was administered to patients in one Finnish hospital during 
the 1950s; however, this was not considered by the authors to have greatly influenced 
the observed results.  Table 3.6 summarises the risk estimates from the five studies. 
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Table 3.6: Summary of overall results reported in the studies evaluated 
 
*1 
Estimated values 
a 
Not clear whether these cases were due to liver cancer or bile tract cancer 
 b 
Estimated frequency of the occurrence of deaths from liver cancer thought to lie between 0 and 3.7 (95% CI) and the limits for the mortality ratio were 
estimated to be between 0 and 12. 
*2
Out of identified 26 primary liver cancer patients in the cohort, 17 were known to have received thorotrast and only 6 out of the remaining 9 patients 
actually received PB. 
 
 
Cohort studies 
 
 
First author 
 
Year 
Estimation of risk 
 
 
n 
Observed cases of liver 
cancer/  deaths from liver 
cancer 
Expected 
number of 
cases 
SMR/ 
SIR 
95% Confidence 
Interval 
Lamminpaa 2002 
Standardised 
Incidence Ratio 
Patients 
14,487 men 
13,932 women 
 
37 
 
22 
 
1.71 
 
1.2 – 2.35 
McLean 1992 
 
Observed/ 
Expected 
4488 epileptic driving 
licence holders 
 
2
a
 
 
1 
 
2.0 
 
Shirts 1986 
Standardised 
morbidity ratio 
959 residents with seizure 
disorders 
 
0 
 
0.2
*1
 
  
White 1979 
Standardised 
mortality ratio 
Patients 
1448 men 
651 women 
 
0 
 
0.3
*
 
 
0
b
 
 
 
Nested case control study 
  
First author  
 
Year 
 
Estimation of risk  
 
n 
 
Observed cases of 
liver cancer  
 
Number of 
controls 
 
Odds Ratio 
95% Confidence 
Interval 
 
Olsen 
 
1995 
 
Odds ratio 
26 out of the cohort of 8004 
patients 
 
6
*2
 
 
11 
 
1.0 
 
0.1 - 8.0 
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3.3 Discussion 
 
One of the main objectives of this research project is to illustrate, through the 
evaluation of selected case study compounds, the means by which to carry out a 
systematic evaluation of the weight of evidence for a specific chemical using a 
conceptual framework approach to facilitate the development of such methodology.  
Using a conceptual approach proposed by the IPCS HRF, such an analysis is intended 
to inform the hazard identification and hazard characterisation steps of the risk 
assessment for a chemical or substance under investigation. 
 
This chapter documented the systematic review and evaluation of epidemiological 
data available for PB.  The aim was to critically examine the weight of 
epidemiological evidence through the application of quality assessment methods to 
thoroughly evaluate evidence available for the investigation of the association of PB 
with liver cancer.  Using set criteria to evaluate the studies, qualitative score 
weightings were assigned for each study evaluated in order to determine the reliability 
and robustness of any findings reached by the authors of the individual studies.  The 
result of this initial assessment is intended to form an integral part of the human 
relevance framework analysis for PB.   
 
Narrative reviews of the weight of evidence for PB have been carried out in the past 
in an effort to investigate the different types of cancers induced in animals and 
considered to be associated with exposure to humans [55, 56, 58]. Most relevant to 
this report has been the paper published by Singh et al [55] which reviewed available 
human evidence investigating the carcinogenic effect of PB as well as other 
antiepileptic drugs.  While this 2005 review paper discussed the findings of studies 
that investigated the occurrence of liver cancers among epileptic patients taking PB, 
the latter issue only formed a small aspect of the overall aim of the review paper 
which was to address the issue of general cancer risks among people with epilepsy 
and the association of the of these risks with antiepileptic drugs.   
 
Eight relevant publications were identified using the search strategy developed.  This 
was identical to the same studies identified by Singh et al [55] in their review.  A 
more in-depth assessment of the epidemiological evidence was carried out in this 
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report in contrast to other reviews. Using set criteria for evaluating the studies, a 
qualitative assessment was carried out to assess the reliability of the available 
evidence and in turn the relevance and robustness of the study.  The focus of the 
quality assessment was to evaluate how well the studies were able to address the 
review question. The studies were therefore qualitatively assessed on how well the 
authors: addressed issues of bias and confounding; defined their cohort of patients 
taking PB, confirm observed cases of liver cancer and what types of methods were 
used to assess exposure to PB. 
 
 
Methodological Considerations  
 
3.3.1 Methods of Exposure Assessment 
 
Owing to the fact that exposure had already occurred in the subjects of study, various 
methods were employed by the different authors to determine the levels of PB to 
which they would have been exposed. Depending on the type of information available 
and the completeness of the records for individual patients, the authors had to make 
various assumptions regarding the actual drug therapy administered to each patient 
and also, the duration of the drug administration. Since the individual exposure levels 
to anticonvulsants drugs could not be adequately quantified with absolute certainty, 
surrogates were therefore used to estimate drug exposure.  In rare cases and when 
available, information could be abstracted from the medical records of the actual 
duration of drug therapy [110, 111]. However, in most studies reliance was placed on 
abstracting patient admission and discharge dates from medical records or any other 
available information in order to estimate the duration of exposure; this was usually 
taken as the length of time of hospitalisation (Olsen et al., [108, 114, 116] or 
alternatively the number of person-years while taking relevant medication was used as 
a measure for cumulative exposure [112, 113]. Olsen and colleagues [109] attempted 
to quantify the actual cumulative doses of exposure by using computational methods.  
By obtaining information relating to the daily doses of PB that was prescribed to 
patients (100 - 300 mg) from the medical records, assumptions were then made about 
the drug-taking patterns of each individual patient and the cumulative doses were 
computed. 
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 3.3.2 Measures of Effects 
 
In all studies reviewed, the authors attempted to estimate the cancer incidence or 
mortality rates in the established epilepsy cohorts. The Danish [109] and one of the 
English cohorts [110] accomplished the latter by comparing the data obtained for the 
epileptic patients with data available through cancer registries or demographic 
databases. Methods of indirect standardisation were applied for the American [113], 
Finnish [112] and the second English [111] cohort of patients. For the latter, the 
observed numbers of incident cases or deaths were compared to the number of cases 
expected among the general population (standardised for age, sex and calendar 
period). Where possible, results of the original diagnosis were confirmed by carrying 
out histological evaluation of tissue samples from the relevant patients.   
 
 
3.3.3 Identification of cohort of patients treated with PB 
 
An overview of the available epidemiological evidence highlighted the 
methodological difficulties associated with trying to investigate the risks of liver 
cancer in epileptic patients receiving long term treatment of PB.  Only a few studies 
were able to specifically identify cohorts of epileptic patients receiving predominantly 
PB as treatment and even in these circumstances some of the datasets were 
incomplete owing to the fact that some medical records had incomplete information 
and omitted vital information relating to the type of drug therapy administered and the 
duration of drug therapy.  Cohorts established on the basis of relatively good quality 
data on epileptic patients administered PB included the English and Danish cohorts.  
 
For the majority of the studies reviewed it was not possible to determine with absolute 
certainty whether PB was the only treatment administered for the long term treatment 
of epilepsy.  In most cases PB was presumed by the authors to be the primary drug 
administered although it is more likely that PB would have been administered in 
combination with other antiepileptic drugs.  The literature suggests that the practice of 
"polypharmacy" was common in Europe especially for the treatment of epilepsy 
whereby multiple drugs were administered even when PB was the main drug on the 
market [117].  When phenytoin and primidone were introduced into the market it was 
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common to have dosing regimens that included caffeine + phenytoin + phenytoin 
sodium salt + PB administered as a combined pill or as separate pills.  Another 
combination of dosing regimen may have been the dosing of similar classes of 
compounds like PB + primidone [117].  
 
The English and Danish cohorts investigated patients admitted to institutional centres 
for epilepsy treatment.  The follow-up of these patients by the study investigators was 
relatively easy as the treatment centres maintained good patient medical records.  The 
English cohort compiled data on patients admitted to the Chalfont Centre for epilepsy 
between 1931 and 1971 and mortality rates were examined during the period 1951 to 
1977 [110, 111]. The Danish cohorts followed up patients admitted to the Filadelfia 
Epilepsy Centre in Denmark between 1933 and 1962. The original dataset was 
compiled and evaluated by Clemmesen [114]. However, three further papers were 
published and further analysis was carried out on the original dataset.  The later 
publications extended the follow up period of each preceding paper and refined the 
dataset somewhat to take into account any patient deaths or exclusions due to loss of 
patient information resulting therefore in the loss of patient follow up [63, 108, 109]. 
The publication by Olsen et al [109] was the only Danish study included in the 
qualitative assessment to avoid duplication of results and also because its publication 
specifically identified patients within the Danish cohort that were administered 
predominantly PB. 
 
 
3.3.4 Methods of dealing with confounding 
 
One of the major difficulties in interpreting findings associated with increased risks of 
liver cancers among epileptic patients is the lack of thorough investigation into how 
varying lifestyles of epileptic patients may have impacted on the disease outcomes 
being evaluated.  Owing to the retrospective designs of the studies evaluated, the 
authors could only rely on information available through public and medical records. 
Important confounding factors such as smoking, alcohol consumption and other 
lifestyle characteristics are not normally recorded in such documents; therefore the 
impact of such factors on the outcome of diseases observed among the epilepsy 
cohorts have not been thoroughly investigated or adjusted for using statistical 
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techniques in most of the studies reviewed.  The consideration of such factors are 
important because disease outcomes such as cirrhosis of the liver may be an 
underlying cause of tumour formation in the liver and the former is most likely to be 
associated with alcoholic liver disease or viral hepatitis [109]. 
 
Another important confounding factor among epileptic patients treated with PB is the 
exposure of these patients to thorotrast (thorium-232).  During the 1930s and 1940s 
thorotrast, a radioactive colloidal solution of thorium dioxide was used in many 
countries including Europe, North America and Japan during radiological procedures.  
During this period it is likely that many epileptic patients may have been exposed to 
thorotrast while undertaking procedures such as cerebral angiography.  Injection of 
thorotrast leads to lifelong accumulation of the compound in the body, the majority of 
which is deposited in the liver (60%) and to lesser extents in the spleen (30%) and 
bone marrow (10%).  Patients injected with thorotrast would have been exposed to 
low doses of radiation emitted from thorium-232 at the organs of accumulation.  
Growing concerns for the toxicity exhibited by thorotrast led to its withdrawal from 
the market in the 1950s. Epidemiological studies instigated as a result of the concerns 
raised resulted in the follow up of patients known to have received thorotrast. The 
results obtained from the studies showed that patients exposed to thorotrast had 
significantly increased risks of developing liver cancer compared to the groups of 
patients who had not been exposed to this compound [118-120].  The different 
confounding factors addressed above were considered to different extents by the 
different authors in the studies reviewed. 
 
 
3.3.5 Findings for the association between PB and liver cancer 
 
Three out of the five studies reviewed reported findings of liver cancer among their 
respective cohort of epileptic patients.  Shirts et al [113] observed no cases of liver 
cancers among a cohort of 730 people suffering from epilepsy. This study received a  
low quality assessment score of 5 as they did not consider issues of bias, confound or 
limitations in the study nor did they mention any of the drugs that were administered 
to the patients with seizure disorders. 
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White et al [111] also reported no deaths as a result of primary liver cancer among 
636 patients who died during the period of their study. This study received a quality 
score of 8. Although the authors made a poor attempt to address any issues of bias, 
confounding or limitations in the study, the authors were able to use patient drug 
records to identify patients that had be treated with PB. 
 
Although McLean et al [110] observed two cases of liver cancers the authors 
concluded that these observations did not demonstrate a significant increase in cases 
of liver cancer. In addition the study assessed to be of low quality (score = 5) 
compared to the other studies reviewed. Although the authors adequately identified a 
cohort of patients that were treated with PB, the methods used to confirm the disease 
status was however considered to be of poor quality because it was not possible to 
determine whether the patients were suffering from liver cancer or bile tract cancer. 
  
The remaining two studies were the largest epilepsy cohorts and both reported 
unequivocal findings of cases of liver cancer.  Olsen et al [109] reported six cases of 
liver cancer matched with 11 controls (nested in a cohort of 8004 Danish epileptic 
patients). The study was judged to be of a high quality (score = 12) as the authors 
thoroughly addressed sources of bias and confounding. In addition the authors were 
able to identify patients that were treated with PB and were able to confirm the 
original diagnosis of the cases of liver cancers described. Lamminpaa et al [112] 
observed 37 incidents of cancer out of a total of 28,419 people reimbursed for anti-
epileptic drugs during the study period. This study was assessed to be adequate and 
received a quality score of 8. These two studies will be discussed in more detail in the 
following sections. 
 
 
3.3.6 The Finnish cohort: Lamminpaa et al, 2002 
 
The study carried out by Lamminpaa et al (2002) based on the Finnish cohort of 
epileptic patients reported statistically significant increased risks of liver cancer 
associated with exposure to antiepileptic drugs (SIR: 1.7; CI: 1.2-2.35).  This study 
had the largest cohort of all the studies reviewed, following up almost 30,000 
epileptic patients for a minimum of 17 years and potentially up to 30 years. 
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Although this study obtained a quality score of 8, one of the main limitations of the 
study was the inability of the authors to relate the observed incidences of liver cancer 
with the different types of drugs consumed, owing to methods used to record data.  
The authors noted that antiepileptic drugs used in the 1980s included carbamazepine, 
phenytoin, PB and primidone. The review previously carried out by Singh et al [55] 
noted that the main exposure could be presumed to be PB.  However, it is difficult to 
conclude with any certainty that the incidences of liver cancers observed were 
associated with exposure to PB. A review carried out on the use of antiepileptic drugs 
in Europe (Loiseau, 1999) confirms that the main antiepileptic drugs to have 
dominated the market between 1912 and 1963 were; PB, marketed in most countries 
from 1920, phenytoin available from the 1940s and primidone introduced in the 1950s.  
Carbamazepine was introduced in most European countries in 1963 and its efficacy 
was considered as comparable to that of both PB and phenytoin. By the 1970s 
carbamazepine was considered to be the drug of choice in most Scandinavian 
countries.  The latter is an important point to consider when one bears in mind the 
date at which point the Lamminpaa study was initiated (1979-1981).   
 
Although the methods of estimating exposure to PB/antiepileptic drugs were clearly 
stated in the papers (taken as the number of years reimbursed antiepileptic drugs), a 
limitation associated with this type of exposure assessment method includes, as noted 
by the authors, the impossibility of estimating a dose response relationship. 
Confounding issues were not thoroughly addressed by the authors investigating this 
cohort of patients.  Although it was noted that thorotrast was used in Finland in the 
1950s at one hospital it was not considered to have impacted on the observed 
incidences of liver cancers among the cohort. The authors, however, provided no 
justifications for this reasoning or confirmation that any of the patients within the 
cohort were treated at this hospital.  There was also no mention of any additional 
methods employed by the authors to confirm the diagnosis of liver cancer observed 
among the cohort. 
 
 
 
 
  88 
3.3.7 The Danish cohort: Olsen et al, 1995 
 
The authors evaluating the association of PB with liver cancer found no increased 
risks (Odds Ratio: 1.0, unadjusted for other anticonvulsants therapy due to small 
numbers; 95% CI: 0.1-8.0) for this disease outcome among this cohort of epileptic 
patients. One of the limitations of the study however, was the small number of liver 
cancer patients matched with control subjects to be included in the study. 
 
This study was assessed to be of a high quality and received a quality score of 12. The 
main strength of the study was its ability to identify the group of patients that were 
administered PB out of the original cohort of patients that were admitted between 
1933 and 1962.  Owing to the period that the patients were recruited for the study, it 
can be presumed that PB was predominantly the main antiepileptic drug administered 
to the patients.  Data relating to this cohort of epileptic patients has been reviewed in 
the past in three separate publications, each author in turn refining the data and 
excluding any patients lost to follow up.  Olsen et al [109] through the use of a nested 
case-control study design, carried out a thorough investigation of all observed cases of 
liver cancer identified among this cohort. The authors also applied quantitative 
methods to estimate the cumulative dose of PB to which the patients may have been 
exposed, allowing for the potential use of this analysis for dose response assessments. 
 
The authors carried out a thorough evaluation of the potential confounders for liver 
cancers.  Patients that were exposed to thorotrast were identified and excluded from 
the analysis and where tissue samples were available, histopathological evaluations 
were carried out for the liver cancer cases. The latter approach allowed for the 
confirmation of the original diagnosis of liver cancer as stated in the medical records 
and confirmed the status of "non-exposure to thorotrast" by confirming the absence of 
thorium residuals in the tissue samples.  This served the purpose of also allowing for 
the consideration of the biological relevance of the tumours by determining whether 
the types of tumours observed were similar to those observed in rodents that had been 
administered PB. 
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3.4 Conclusions 
 
This systematic review set out to evaluate the epidemiological evidence designed to 
investigate the association of PB with liver cancer. The search strategy that was 
developed identified relevant studies that sought to address this review question. 
Among the studies able to specifically investigate the occurrences of liver cancers 
among patients predominantly treated with PB, the study by Olsen et al [109] scored 
highly against the quality assessment criteria. It was therefore considered to be 
reliable and robust in its investigation of the association of PB with liver cancer. An 
unfortunate limitation of the study was however the small study size of patients 
investigated and upon which the conclusions were based. 
 
The study by Lamminpaa et al [112] reported a statistically significant increased risk 
of liver cancer associated with antiepileptic drugs (SIR; CI: 1.2-2.35) however the 
results have to be interpreted with caution. While this study obtained a quality score 
of 8 as a result of the scores of “adequate” for the different pre defined criteria for the 
quality scoring, what this score actually reflected was the ability of the study to 
attempt to address the different criteria considered to play an important factor in the 
investigation of the association of PB and liver cancer. However the study did not go 
far enough to address important areas of confounding and more crucially, the study 
was not able to identify the patients that were actually treated with PB.  
 
Quantitative systematic review methods such as meta-analysis could not be applied to 
the assessment of the epidemiological evidence owing to the heterogeneity of the 
studies reviewed and the lack of sufficient data for such an analytical approach. The 
systematic qualitative methods employed however, allowed for the application of 
qualitative scores as a way of facilitating the transparent justification of any 
conclusions from the studies reviewed; this was in keeping with the objectives of the 
IPCS human relevance framework.   
 
This review has highlighted the methodological difficulties associated with trying to 
investigate the association between PB and liver cancer.  It also identified the 
limitations associated with current epidemiological evidence investigating the 
potential cancer risks associated with antiepileptic drugs.  While it may not be feasible 
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to establish any new cohorts of epileptic patients taking PB, where possible, it may be 
useful to extend the work already done in the identified cohorts of epileptic patients.  
The latter could include the refinement of the data collected for the Finnish cohort in 
order to establish if possible, the number of reimbursements that were actually made 
for PB, therefore allowing the determination of the true number of liver cancer cases 
linked to patients that were taking PB. Such an attempt would add further weight to 
the currently available evidence and address issues of small sample sizes.   
 
Regardless of the limitations highlighted from the study carried out by Lamminpaa et 
al [112], the large cohort investigated in this study makes it difficult to disregard the 
positive findings of association reported by the authors. The focus for any conclusions 
to be drawn has to be placed on this larger study. However, it is currently difficult to 
draw any firm conclusions about the effects of PB from potential patients exposed for 
reasons already stated. 
 
These findings highlight the need for this study to be revisited. A nested case control 
study on the cohort identified by Lamminpaa et al [112] would enable the 
identification of patients that were exposed to PB and go a long way to refine the 
results obtained to enable conclusions to be drawn about the association of PB with 
liver cancer among the epileptic patients exposed.  
 
This systematic review of the epidemiological data for PB has enabled the thorough 
and transparent evaluation of the weight of epidemiological evidence available for PB. 
Although no conclusions have been drawn about the association of PB with liver 
cancer owing to the unreliable evidence evaluated; the limitations associated with the 
interpreted findings have been explicitly described and the rational for assessing the 
individual studies have been thoroughly described. The application of the systematic 
approach applied here would go a long way to improve the transparency of evidence 
evaluated as part of the IPCS MOA/HRF.  
 
As discussed earlier in the introductory chapter, in addition to exploring the use of 
systematic review techniques for as a way of improving the transparency of evidence 
considered as part of the IPCS HRF, another important factor to consider in the 
development of the IPCS HRF, is the investigation of the extent to which non 
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conventional data can be incorporated into the MOA/HRF analysis.  The latter will be 
explored in the next two chapters.  
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Chapter 4 
 
 
Toxicogenomics: Methodology for the Transcriptional 
Analysis of the Hepatocarcinogenic effects of PB 
 
 
 
This chapter provides a brief background to the subject area of toxicogenomics and 
details the methodology developed for the evaluation of publicly available 
transcriptomics (microarray) datasets to investigate the hepatocarcinogenic effects of 
phenobarbital (PB). The aim was to develop a methodology for the investigation of 
the effects of PB on gene expression changes in different species. In addition, the 
extent to which non-commercial or commercially available pathway analysis software  
could be used to investigate statistical and biologically relevant pathways was 
evaluated and the relationship between these functional pathway changes and clinical 
pathology end-points investigated. More importantly, this methodology was 
developed to evaluate how the results output from the pathway analysis software 
could be used to inform mode of action and human relevance analysis. More broadly, 
this methodology was developed to investigate the extent to which readily published 
information on toxicogenomics could be utilised meaningfully in risk assessment and 
how this might be improved. 
 
 
4.1 Brief Background to Toxicogenomics  
 
Technological advancements in the field of genomics has allowed for increased 
efficiency and speed in the sequencing of DNA allowing for complete sequencing of 
prokaryotic and eukaryotic genomes.  One of the greatest achievements in recent 
history was the sequencing of the entire human genome, accomplished in 2001 [121-
123]. These achievements has increased scientific understanding of biological and 
toxicological processes resulting in the study of the function of a genome in relation 
to gene expression (transcriptomics), protein levels (proteomics) or metabolites 
(metabonomics) [124].  Genomics technologies have been used for decades to aid the 
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mechanistic evaluation of adverse toxic effects. Traditionally the approach to 
evaluating the mechanism of action relied on evaluating a few genes at a time with the 
aim of discovering the gene function in relation to the observed toxic effect [124, 125]. 
Associated technological advancements surrounding these -omics approaches have led 
to the field of "toxicogenomics" which can be defined as the study of the structure 
and output of the entire genome as it relates and responds to adverse xenobiotic 
exposure [126].  Toxicogenomics involves the application of various aspects of 
functional genomics i.e. mRNA (transcriptomics/gene expression profiling), protein 
(proteomics) and metabolite (metabolomics) analysis and its associated technologies 
in toxicological assessments [124, 125, 127].  
 
The technology behind transcriptomics is the DNA microarray. The DNA microarray 
consists of a small glass or a membrane to which potentially thousands of known 
gene-specific sequences are fixed at specific points. The mRNA extracted from 
biological samples (treated with chemicals of interest at specific doses and time points) 
are treated to enable hybridisation with the complimentary DNA strand on the glass or 
a membrane which enables the hybridised complex to be detected [128]. The 
advantage of DNA microarrays is that they enable the measurement of the gene 
expression of tens of thousands of genes at one time taking within the context of dose 
and time, thereby identifying genes that are associated with the relevant disease at the 
time and dose of measurement [127]. Some of the limitations associated with DNA 
microarrays are that the measurements are semi quantitative owing to issues such as 
cross hybridisation and sequence specific binding anomalies. The number of samples 
that can be processed at any one time is also a limitation, as well as the amount of 
time it takes to process and analyse samples (it can take several days to generate the 
data required and take a considerable amount of time to analyse the data generated) 
[127].  
 
Unfortunately gene expression profiling alone is insufficient to enable a thorough 
understanding of disease outcomes. Exposure to toxicants results in abnormalities in 
protein production and function.  Owing to the fact that there is no direct functional 
correlation between the expression of individual genes and their corresponding 
proteins, other toxicogenomics tools such as proteomics are employed to  investigate 
the expression of proteins that are affected by toxicant exposure [127].  Proteomics is 
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defined as the “systematic analysis of expressed proteins in tissues, by isolation, 
separation, identification and functional characterisation of proteins in a cell, tissue 
or organism” [127]. Proteins perturbed by toxicant exposure are functionally 
annotated and validated. Proteomics requires the use of 2-dimesional (2-D) gel 
electrophoresis for protein separation followed by mass spectrometry analysis of the 
relevant proteins. One of the main limitations of the technology used in proteomics is 
the low sensitivity of 2-D gel electrophoresis. The detection of low abundance 
proteins can be difficult owing to the presence of high abundance proteins (e.g. 
albumin and immunoglobulin) [127]. To mitigate against this problem, these high 
abundance proteins have to be removed from the protein samples using 
immunoaffinity techniques which allow more samples to be loaded onto the gels 
thereby enabling the visualisation of the lower abundant proteins[127, 129].  
 
Notwithstanding the benefits of both transcriptomics and proteomics (especially when 
used in combination), neither technique provide insight into the metabolic and cellular 
functions of the whole organism under investigation in response to toxicant exposure. 
The final tool applied in toxicogenomics is metabonomics which is based on the idea 
that exposure to toxicants leads to changes in the relative concentrations of 
endogenous biochemicals [127]. Metabonomics is defined as the “quantitative 
measurement of the dynamic multiparametric metabolic response of living systems to 
the pathophysiological stimuli or genetic modification” [130]. Metabolites found in 
bodily fluids (e.g. urine, blood, cerebrospinal fluid) are affected by toxicant exposure 
as these metabolites are in equilibrium with surrounding cells and tissues [127]. One 
of the main advantages of metabonomics is that samples are more readily from human 
subjects to enable the analysis of the different metabolites.  High resolution NMR 
spectroscopy is used for the detection of metabolites in biological samples. Results 
obtained from metabonomics analysis is intended to complement information 
obtained from gene expression profiling and proteomics [127, 129]. 
 
Owing to the availability of publicly available data for the selected case study 
compound (PB), this thesis will address only issues associated to transcriptomics. The 
following sections describe briefly some of the techniques and methods involved in 
the identification and evaluation of gene transcripts. 
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4.1.1 Microarray Study Design 
 
The main goals of microarray studies are to identify genes that are differentially 
expressed under given conditions.  As such, microarray study designs can be grouped 
into three different categories;   
 Class comparison: these studies aim to identify differentially expressed genes 
between two or more groups.   
 Class prediction: these studies aim to predict the class membership of a given 
sample on the basis of its gene expression profile.  
 Class discovery: the aim of these studies is to be able to group together 
samples or sets of genes on the basis of shared similar gene expression profile.   
 
Regardless of the study objectives, the main steps of microarray data analysis involve 
the identification of differentially expressed genes (presented in the form of lists of 
up/ down regulated genes or patterns of gene expression) and the evaluation of the 
biological relevance of the differential expression of individual or sets of genes 
(Figure 4.1) [128, 131].   These are discussed in more detail in the sections below. 
 
 
Figure 4.1: Steps of Microarray Analysis 
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data
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Functional 
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Pathway
Network
 
 
 
4.1.2  Identification of differentially expressed genes 
 
The analysis of microarray data begins with the normalisation of the available data 
using different statistical methods that aim to reduce the experimental variability in 
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the dataset [132].  Different methods are used to compare datasets (i.e. comparison 
between experimental and control sample) to enable the identification of differentially 
expressed genes. The latter include identification of the level of fold change or the use 
of statistical methods to identify differentially expressed genes.   
 
 
Fold Change 
 
One of the simplest approaches for determining whether genes are differentially 
regulated is to compare the fold change between the experiment and control genes.  A 
fold change of between two and three is normally considered to be indicative of a 
biological significant change between experiment and control. The main disadvantage 
of this simplistic approach to identifying differentially expressed genes lies in the 
methods used to decide on the threshold of significance.  The arbitrarily chosen 
threshold level may not always be appropriate for every microarray experiment. The 
latter is especially true in cases where genes are affected below this two-fold 
threshold so they would not otherwise be selected as significantly different from the 
control. Under these circumstances, this can lead to reduced experimental sensitivity 
[132]. 
 
 
Use of Comparison Statistics 
 
The use of the fold change method provides no idea of the reproducibility of the data 
observed.  To address this, a statistical approach is used to identify genes that are 
observed to be perturbed compared to controls.  The use of experimental replicates 
(biological
6
 or technical
7
) facilitates the consideration of the levels of variability in the 
data and therefore enables a confidence level or a p-value to be assigned.  The choice 
of comparison statistics is dependent on the number of replicates and factors under 
consideration.  The t-test is used for comparisons between two groups and ANOVA 
for comparisons of three or more groups [128, 131]. 
                                                 
6
 Biological replicates measure different samples on different arrays-this allows for the measurement 
of biological variability such as genetic variability or environmental effects. 
7
 Technical replicates measure the same sample on different arrays-this focuses on addressing the 
variations inherent in the techniques applied. 
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In addition to the use of comparison statistics, experimental techniques are sometimes 
employed to provide independent validation of results obtained from microarray 
experiments. Qualitative polymerase chain reaction (PCR) techniques are commonly 
applied for the validation of microarray experiments to test whether or not a particular 
gene (at mRNA or DNA level) is present or not [133]. Real Time Quantitative PCR 
(qPCR) is fast becoming the most accepted form of experimental validation. It 
requires only a small amount of biological material and the speed in which the 
experiments can be performed (30-45 minutes) and the user is able to carry out 
multiple gene expression measurements in a single reaction enabling the validation of 
multiple genes in a single reaction  [133].   
 
 
Correcting For Multiple Testing 
 
The derivation of a p value for each individual gene often results in multiple tests 
being performed.  In order to validate the statistical results obtained, it is therefore 
necessary to correct for multiple testing. Storey and Tibshirani [134] propose the 
calculation of the Q value to represent the "false discovery rate" (FDR).  The FDR is 
"the rate that truly null features are called significant".  The p value measures the 
level of significance in terms of the false positives rate for each individual gene, the Q 
provides a measure of the significance of each individual p value, thereby accounting 
for any multiple testing.  When interpreting statistical results to identify differentially 
regulated genes or pathways (in the case of pathway analysis), a 5% Q value cut-off 
(as a cut-off criterion to identify differentially expressed genes) therefore provides a 
better indication of the proportion of significant genes (or pathways) that turnout to be 
false positives [131, 134]. 
 
4.1.3  Biological Relevance of Differentially Expressed Genes 
 
To provide a means of analysing lists of genes within a biological context, annotation 
methods have been developed to facilitate biological function analysis of individual 
genes (or sets of genes) among researchers. A controlled vocabulary has been 
developed for this and is called “ontology”.  Ontology in the context of gene 
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annotation, can be defined as “comprising a set of well-defined terms within well-
defined relationships” [135]. Depending on the availability of supporting literature, 
the annotations reflect biological knowledge about the particular genes as well as 
providing the basis and structure for which new genes can be annotated. 
 
Ontologies have been developed to aid the conceptualisation of the biological 
functional underpinnings of gene expression. The latter have included Gene Ontology 
(GO) [135], GeneX (http://ncgr.org/genex/), eVOC [136] and KEGG orthology (KO) 
[137]. Gene Ontology (http://www.geneontology.org) is the most widely used. The 
GO project provides an expert curated public database that attributes genes to the 
various biological categories including biological processes, molecular function and 
cellular components. 
 
 
Pathway analysis  
 
Although lists of differentially expressed genes can be created using methods 
described previously, it is more relevant to consider these genes in the context of their 
biological significance.  Gene changes do not always relate directly to the 
experiments carried out since genes do not operate independently of each other but 
rather, operate within the realms of many functional contexts in an interdependent 
manner [138]. By placing the emphasis on the evaluation of the relationship between 
different genes under specific experimental conditions, the evaluation of single 
genes/proteins on an individual basis would also result in the loss of information.   
 
Pathway analysis of microarray data allows for the integration of normalised array 
data with their functional annotations such as gene ontology. Analysis involves 
placing significantly regulated genes that have been functionally annotated using gene 
ontology or other suitable functional terms, into pre-compiled pathways. This allows 
for the consideration of the physical and functional interactions between genes rather 
than the assessment of individual genes on the basis of functional annotation alone 
[138, 139].  The latter can potentially lead to the identification of more subtle changes 
in gene expression rather than just compiling lists of differentially expressed genes. 
There are various commercial and academic web-accessible tools available for 
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investigating pathways. Pathways are manually compiled on the basis of available 
literature. Considerable effort is required on the part of curators whose job it is to 
continually update pathways on the basis of new evidence [138].  
 
 
4.2  Development of Methodology for Transcriptomics Analysis 
 
4.2.1  Search Strategy to Identify Relevant Microarray Studies for PB 
 
The search for microarray data for PB focused on two microarray repositories; 
ArrayExpress managed by the European Bioinformatics Institute (EBI) and Gene 
Expression Ominibus (GEO) managed by the National Institute for Biotechnology 
Information (NCBI). Both repositories comply with Minimum Information about a 
Microarray Experiment (MIAME); a set of guidelines that outline the minimum set of 
information that are required to describe adequately a microarray experiment [140]. 
  
The single search term “phenobarbital” was used to search the datasets in 
ArrayExpress.  No filters were applied to the search to limit the search to any species 
or type of array.  This search identified 6 studies. 
 
Datasets within the GEO database were found using the search terms: 
[“phenobarbital” AND “liver”]. The search produced 17 different studies. 
 
 
Selection of Studies 
 
Although the main emphasis was on obtaining studies that primarily focused on 
investigating PB, where available, studies that employed PB as a positive control were 
also selected for further investigation. Five out of the six studies found in 
ArrayExpress and 7 out of the 17 studies found in GEO were considered relevant for 
the purposes of the investigation. The 5 relevant studies obtained from ArrayExpress 
were found to be the same as that obtained from GEO.  
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In addition to the data obtained from ArrayExpress and GEO, unpublished data linked 
to one of the studies deposited in GEO was obtained via personal communication 
from the study investigators [141]. 
 
 
Selected Dataset 
 
The datasets were exported from GEO. The 7 different experiments classified as GEO 
series are summarised in Table 4.1. Microarray data for five different time points 
(10hrs, 12hrs, 2, 4 & 30 days) were obtained from four separate mouse experiments, 
four time points (6hrs, 1, 3 & 5 days) were obtained from two separate rat 
experiments and only one time point from one human hepatocytes experiment were 
obtained from the repository. A full summary of the experiments from which the data 
were obtained is provided in Appendix IV (A4.1).   
 
 
 
4.2.2 Pre-processing of Microarray data (Statistical Analysis of Microarray Data) 
 
The statistical manipulation of the microarray data was carried out in consultation 
with and based on the advice from Susan Hester, PhD, a Genomics expert at the 
United States Environmental Protection Agency.  
 
The raw datasets downloaded from the GEO repositories comprised the signal 
intensities from the respective microarray scans. The files were imported into the 
Gene Expression Data Analysis system Rosetta Resolver (Version 7.1) (Rosetta 
Inpharmatics, Kirkland, WA). The software was used to identify sequences within the 
treatment groups (PB) that were statistically different from the control groups for each 
study. Using the Rosetta Resolver error model, the microarray scans were converted 
to sets of normalised data called “intensity profiles” [142]. 
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Table 4.1:  Summary of experimental data exported from GEO 
 
GEO series 
(Experiment) 
 
Authors/ study 
contributors 
Species  
& 
strain  
Type of 
study 
Time points 
investigated 
 
Route of PB 
administration 
 
Dose 
Biological replicate 
samples per  time 
point investigated 
GSE6721 
 
Rezen et al [143] 
Mouse 
(C57BL/6) 
In vivo 10hrs 
Intraperitoneal 
injection. 
50mg/kg in 
vehicle (5% 
DMSO in corn 
oil 
4 PB samples: 4 
controls samples 
GSE16777 Nesnow et al [144] 
Mouse 
(CD-1) 
In vivo 2
8
, 4 & 30 days Diet 5.9 mg/kg/day 
5 PB samples: 5 
controls samples 
GSE14712 
Ren et al [145] 
 
Rat 
(Sprague- 
dawley) 
In vivo 
6hrs, 1 & 5 
days 
Gavage 100 mg/kg 
5 PB samples: 5 
controls samples 
GSE9387 
No publication from 
study 
 
Rat 
(information 
on strain 
used not 
available) 
In vitro 3 days 
In vitro exposure 
via medium 
200µM 
3 PB samples: 3 
controls samples 
GSE10410 Goetz et al [146] Human In vitro 3 days 
In vitro exposure 
via medium 
1000µM 
4 PB samples: 4 
controls samples 
GSE12489* 
 
Tamasi et al [147] 
Mouse 
(C57BL/6J) 
In vivo 12 hours 
Intraperitoneal 
injection. 
100 mg/kg 
6 PB samples: 6 
controls samples 
GSE12529* Tamasi et al [147] 
Mouse 
(C57BL/6J) 
In vivo 12 hours 
Intraperitoneal 
injection. 
100 mg/kg 
6 PB samples: 6 
controls samples 
                                                 
8
 The Day 2mouse dataset from experiment GSE16777 was obtained via personal communication by one of the study investigators involved in the published study by 
Nesnow et al., 2009. Although the dataset at Day 2 was not published, the treatment of the mouse followed the same protocol for in-life procedures, mRNA isolation and 
hybridization, as that of the treatment of the mice at Days 4 and 30. 
 
*The datasets obtained for GSE12489 and GSE12529 were excluded from the studies owing to errors in the file obtained from GEO and the resulting pre-processing 
difficulties encountered in Rosetta Resolver (V7.1). 
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One-way ANOVA with Error-Weighting 
 
Analysis of Variance (ANOVA) is used to test for difference between two or more 
independent groups and is based on comparison of the variation between the different 
groups with variation within groups.  In the processing of the microarray data, 
ANOVA also measures the within-group variance. The use of small numbers of 
biological replicates in microarray studies can lead to small within-group variance 
resulting in a large P-value and high false positive rates, whereby genes are 
highlighted as differentially expressed when they are in fact not. To mitigate this 
problem, the Resolver software enables the user to select the error-weighting one-way 
ANOVA test function for the statistical analysis. The error weighting within Resolver 
provides a conservative estimate of the measurement errors attributed to factors such 
as sample preparation, labelling and dye related bias, hybridization, chip quality 
variation, chip scanning and image feature extraction. Carrying out error weighting as 
well as the ANOVA test therefore serves the purpose of improving the variance 
estimation [142] (Rosetta Inpharmatics, Kirkland, WA). 
 
The one-way ANOVA was performed on the intensity data associated with the 
different treatment groups (PB or controls) and factor levels (number of groups under 
comparison = 2; PB & control). The one-way ANOVA test compared the between-
group variance to the within-group variance of the measurements. The calculated 
within-group variance was the variation of replicated measurements within individual 
treatment groups. The between-group variance was measured among the mean 
measurements of the different treatment groups. The means of the treatment groups 
were identified as significantly different if the between-group variance was 
significantly larger than the within-group variance (Rosetta Inpharmatics, Kirkland, 
WA). 
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Multiple Test Correction (Benjamini and Hochberg FDR) 
 
Multiple test correction was carried out on the different microarray datasets to reduce 
the chances of false positives (genes identified to be statistically different from 
controls when in reality they are not). The Benjamini and Hochberg false discovery 
rate (FDR) was applied to all datasets investigated to adjust the p-values derived from 
the multiple statistical tests and correct for the occurrence of false positives. 
 
 
Differentially Expressed Genes (DEGs) 
 
Statistically filtered sequences were identified by carrying out the one-way ANOVA 
with a false discovery rate (Benjamini-Hochberg test) of p ≤ 0.05. For smaller 
datasets (rat, all time points and mouse 10 hrs) the applied p-value of 0.05 for FDR 
was observed to be to too stringent (producing exceptionally small numbers of DEGs), 
as such a p ≤0.25 was applied instead (the justifications for this approach and the 
associated limitations will be discussed in detail chapter 5, see section 5.6.7.). 
 
 
4.2.3 Selection of Pathway Analysis Tools 
 
A considerable amount of time was spent investigating the applicability of various 
freely available academic web-accessible tools to evaluate the data obtained. Two 
non-commercial pathway analysis tools tested included KOBAS
9
 and DAVID
10
. The 
KOBAS software required the annotation of the genes in KEGG
11
 orthology (KO) and 
the first step of using KOBAS involved the annotation of the genes with KO terms. 
The non-commercial database KEGG, available on the public domain, was developed 
to combine genomic information with functional information (also known as 
enrichment analysis). KEGG functionally assigns genes into networks of interacting 
                                                 
9
 KOBAS - KEGG Orthology-Based Annotation System (http://kobas.cgi.pku.edu.cn) 
10
 DAVID - Database for Annotation, Visualization and Integrated Discovery 
(http://david.abcc.ncifcrf.gov). 
11
 KEGG - Kyoto Encyclopaedia of Genes and Genomes  (http://genome.jp/kegg) 
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molecules, to take into account the fact that biological functions are the result of 
interacting genes.  Three databases exist within KEGG:  
 PATHWAY which represents various functions in the form of a network of 
interacting genes,  
 GENES which provides a database to catalogue completely sequenced and 
partial genomes and  
 LIGAND which is a database for chemical compounds in the cell enzymes and 
enzymatic reactions.  
The KO has also been applied to functionally annotate each molecule or gene [148]. 
 
While KOBAS could be used to find the most frequent and statistically significant 
enriched pathways [149], one of the major shortcomings of the software and the 
annotation system was the unavailability of the KO terms for all the genes of interest 
and therefore the inability of KOBAS to annotate all the genes uploaded onto the 
system. This led to the loss of significant numbers of genes that would have otherwise 
being analysed. In addition, KOBAS could only be used for pathway analysis so a 
separate software was required to carry out the network analysis.  
 
Consideration of the interactions of individual genes (using pathway analysis) is just 
one aspect of the overall biological process.  Interactions of more than one pathway 
result in the formation of a regulatory network. The components of each network 
change according to the biological context, therefore, the pathways involved may 
sometimes contain only a few genes as it is entirely context dependent [150]. It was 
therefore essential to carry out network analysis in order to consider the interactions 
of individual pathways since biological pathways often involve more than one 
pathway. 
 
Similar problems were encountered using the DAVID software, which annotates 
genes using Gene Ontology (GO). The software was unable to analyse the large lists 
of genes uploaded and often resulted in the loss of significant numbers of genes 
presumably because all the genes could not be annotated to GO. In addition, the 
software could not be used to carry out analysis to determine the statistical 
significance for the association of the genes of interest with pre-compiled pathways 
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(groups of genes grouped a priori according to their functions) as defined by GO. It 
was therefore difficult to determine which genes were most important and which 
pathways were more significant than others [151, 152].  
 
Owing to the problems encountered using the non-commercial tools, the commercial 
software Ingenuity Pathway Analysis, IPA (www.ingenuity.com) was employed to 
carry out the analysis of the genes of interest. IPA enabled the evaluation of both the 
biological pathways and networks that featured genes of interst. The methodology 
associated with the analysis is discussed in greater detail in the following sections.  
 
 
4.3 Pathway and Network Analysis of DEGs Using Ingenuity Pathway Analysis 
(IPA) 
 
The DEGs obtained from Rosetta Resolver were evaluated using Ingenuity Pathway 
Analysis [153]. IPA was used to gain a better understanding of the biology and the 
significant interactions involved within groups of genes found to be differentially 
expressed. The biological significance of the changes observed within the DEGs 
identified was investigated through the use of tools within IPA such as network 
analysis generation, canonical pathways and toxicological function/ lists analysis.  
 
 
4.3.1 Core Analysis in IPA 
 
IPA was used to run a Core Analysis of the dataset. This analysis enabled the rapid 
assessment of the signalling and metabolic pathways, molecular networks and 
biological processes that were most significantly perturbed, within the dataset 
uploaded. The Analysis in IPA enabled groups of genes to be mapped onto Canonical 
Pathways (well characterized cell signalling and metabolic pathways that were most 
relevant to the uploaded dataset), IPA Tox Lists (sets of genes known to be perturbed 
upon compound treatment that will eventually lead to a measurable pathology) and 
Toxicity Functions (functions that relate to hepatotoxicity and marked clinical 
endpoints). The selected results outputs provided in the form of the Tox lists, 
Canonical Pathways and Tox functions were all different options available in IPA to 
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view the results. The outcome provided by the three results outputs relate to each 
other in the sense that each output enables the user to view and interpret the results 
with the desired biological context. The direct and indirect relationships between the 
genes were also explored using tools that enabled the functional representation of 
genes that were involved in relevant Toxicity functions [153].  
 
It is important to note that regardless of the selection of the type of species dataset 
selected under the general settings when creating a Core Analysis (Figure 4.2), the 
human orthologs for each gene were provided as the default in the result outputs. This 
was unchangeable in IPA and it meant that genes produced as part of the results from 
the rat and mouse experiments had to be changed manually where necessary. 
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Figure 4.2: Screen shot showing the analysis page in IPA which allowed the different criteria for the analysis for each dataset 
 
 
 
Source: Ingenuity Pathway Analysis™ 
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4.3.2 Levels of Significance/ P-value Calculated for Functions and Pathways in IPA 
Significance values are provided in Functional Analysis for a dataset as a measure of the 
association between a set of Functional Analysis genes in the uploaded experiment and a 
given process or pathway. IPA applied the default of p-value ≤ 0.05 which was left 
unaltered [153]. 
 
4.3.3 IPA Result Output: Functional Analysis of dataset 
 
The functional analysis identified the biological functions and/or diseases that were most 
significant to the dataset. Genes from the dataset that met the p-value cut off and were 
associated with biological functions and/or disease in the IPA knowledge base were 
considered for the analysis. Fischer‟s exact test was used to calculate a p-value 
determining the probability that each biological function and/or disease assigned to that 
dataset was due to chance alone [153]. 
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Figure 4.3: An example of the results output for the functional analysis in IPA. The bar 
chart produced shows the different toxicological functions into which the datasets were 
grouped.  
 
 
 
Source: Ingenuity Pathway Analysis™ 
(The figure shows the Toxicity Function analysis from the mouse day 2 dataset). 
 
 
4.3.4 IPA Result Output: Toxicology Lists (Tox List) 
 
The toxicity lists produced by IPA comprised of molecules known to be involved in a 
particular type of toxicity. The lists of genes were grouped according to critical biological 
processes and adaptive or reparative responses as observed upon exposure to xenobiotic 
chemicals. The Tox Lists enabled closer examination of the functional changes across the 
different time points studied for genes exposed to PB [153] . 
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Figure 4.4: An example of the results output for the Toxicity List in IPA. The bar chart 
produced shows the different types of toxicities into which the datasets were grouped. 
 
 
 
Source: Ingenuity Pathway Analysis™ 
(The figure shows the Tox List from the mouse day 2 dataset). 
 
 
4.3.5 IPA Result Output: Canonical Pathways  
 
Canonical pathway analysis identified the pathways from the IPA library of canonical 
pathways that were most significant to the dataset. Genes from the dataset that met the p-
value cut off and were associated with a canonical pathway in the IPA knowledge base 
were considered. The significance of the association between the dataset and the 
canonical pathway was measured in two ways: 1) A ratio
12
 of the number of genes that 
map to the canonical pathway was displayed. 2) Fisher‟s exact test was used to calculate 
a p-value determining the probability that the association between the genes in the dataset 
and the canonical pathway is explained by chance alone [153].  
 
 
 
                                                 
12
 The ratio is the number of molecules in a given pathway that meet the cut criteria divided by the number 
of molecules that make up that particular pathway. 
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Figure 4.5: An example of the results output for the Canonical Pathways produced in IPA. 
The bar chart produced shows the different pathways into which the datasets were 
grouped. 
 
 
 
Source: Ingenuity Pathway Analysis™ 
(The figure shows the apoptosis signalling canonical pathway from the human day 3 
dataset). 
 
 
4.3.6 Graphical representation of Networks  
 
The displayed genes that form a network or pathway represented the molecular 
relationships between genes/gene products. Genes or gene products were represented as 
nodes, and the biological relationship between two nodes was represented as an edge 
(line). All edges were supported by at least one reference from the literature, from a 
textbook, or from canonical information stored in the IPA knowledge base. Human, 
mouse and rat orthologs of a gene were stored as separate objects in the IPA knowledge 
base, but were represented as a single node in the network. The intensity of the node 
colour denoted the degree of up-(red) or down-(green) regulation. Nodes were displayed 
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using various shapes that represented the functional class for the gene product. Edges 
were displayed with various labels that described the nature of the relationship between 
the nodes (e.g. P for phosphorylation, T for transcription) [153].  An example of such a 
diagram is A4.2.1 located in Appendix IV.  
 
 
4.4 Biomarkers for Non-genotoxicic Carcinogenicity and Reference Genes for 
Hepatocellular Carcinoma  
 
A list of gene signatures for predicting non-genotoxic carcinogenicity were obtained from 
2 separate investigations that attempted to identify biomarkers for non-genotoxic 
carcinogenicity.  Fielden et al [154] identified 37 gene signatures that were independently 
tested against 47 chemicals. The authors reported assay sensitivity and specificity of 86% 
and 81%. Nie et al [155] identified 6 signature genes to predict nongenotoxic 
carcinogenicity and reported 88.5% prediction accuracy estimated by cross-validation. A 
review carried out by Pei et al [156] investigating the use of omics-based methods 
applied to the study of hepatocellular carcinoma identified 19 genes that had been 
highlighted in hepatocellular carcinoma microarray studies. 
 
The 62 genes identified from the 3 different studies were converted to Entrez Gene 
identifiers using tools in PubMed and the corresponding mouse, rat or human orthologs 
were identified. The different gene symbols/names associated with each gene identifier 
were also obtained to enable efficient comparison between the different datasets. The 
DEGs from all time points investigated for each species were combined, duplicates were 
removed and then they were compared with the biomarkers and reference genes 
identified using the VLOOKUP tool in Microsoft Excel. 
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Chapter 5 
 
Results of Transcriptional Analysis to Investigate the 
Hepatocarcinogenic Effects of Phenobarbital 
 
 
This chapter details the results of the transcriptional analysis carried out on publicly 
available transcriptomics (microarray) data to investigate the hepatocarcinogenic effects 
of PB.  The aim of this comparative analysis of microarray data was to investigate the 
effects of PB on gene expression changes in different species and to determine how the 
functional pathway changes observed, could be related to clinical pathology endpoints for 
the liver (e.g. proliferation, necrosis/inflammation or Cholestasis) and more importantly, 
how these results could be used to inform mode of action and human relevance analysis. 
More broadly, this was an investigation into how readily published information on 
toxicogenomics could be utilised meaningfully in risk assessment and how this might be 
improved. 
 
 
5.1 Analysis of Differentially Expressed Genes (DEGs) using Ingenuity Pathway  
           Analysis (IPA) 
 
Groups of DEGs generated from Rosetta Resolver (Table 5.1) were analysed using the 
Core Analysis function in IPA. This allowed the interpretation of the dataset within the 
context of biological processes. The evaluation of the results focused on assessing the 
relevance of the toxicity functions associated with the datasets of interest.  
 
Table 5.1: Statistically significant DEGs obtained from analysis carried out in Rosetta  
     Resolver  
 
Species Rat Mouse Human 
Type of study In vivo In vitro In vivo In vitro 
Time Point 6hrs 1d 5d 3d 10hrs 2d 4d 30d 3d 
Number of 
DEGs 123 321 305 25 327 3045 3771 1268 1663 
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5.2 Toxicology Lists (Tox List) 
 
The lists of genes from the different time points available for the datasets from different 
species were mapped onto the IPA Tox List
13
 upon the application of the Core Analysis
14
 
function in IPA. The analysis identified a series of 46 different Tox Lists that were 
associated with the genes obtained from one or more of the different species at different 
time points. The IPA Tox Lists were produced in the form of bar charts. On the basis of 
evidence obtained from the literature (with regards to the basis of known mechanisms of 
hepatotoxicity and their involvement in the postulated key events that are involved in PB 
induced MOA for liver tumour formation as described in chapter 2), 18 out of the 46 
observed Tox Lists were selected for further investigation. The transcriptional changes 
across the 18 selected Tox Lists were investigated and the temporal relationships of the 
key gene changes examined. The transcriptional changes of the genes involved in the 
different Tox Lists were summarised in tables that were essentially simplified heat maps.  
 
Table 5.2 provides a summary of the Tox Lists produced by IPA and their occurrence 
within the rat, mouse and human datasets. The gene changes involved in a selection of 
toxicities/biological processes relating to hepatotoxicity were represented in table format 
to enable closer examination of the temporal relationships of the gene changes across the 
different datasets.  
 
A full list of the temporal comparison of the genes involved in the selected Tox Lists, are 
provided in Appendix V (A5.1.1 to A5.1.20). 
 
                                                 
13
 See Chapter 4, section 4.3.4 for a description of the IPA Tox Lists 
14
 See Chapter 4, section 4.3.1 for a description of the IPA Core Analysis function 
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Table 5.2:  Table showing Ingenuity Pathway Analysis (IPA) Toxicity Lists produced from all datasets 
 
Ingenuity Toxicity Lists 
Time points studied  
Rat Mouse Human  
6hrs 1d 3d 5d 10hrs 2d 4d 30d 3d 
Oxidative Stress Response Mediated by Nrf2 X
* X
*
   X
*
 X
*
 X
*
 X
*
 X
*
 X
*
 
CAR/RXR Activation X
*
 X
*
 X
*
 X
*
 X
*
 X
*
 X
*
 X
*
 X
*
 
Aryl Hydrocarbon Receptor Signalling X X
*
   X
*
 X
*
 X
*
 X
*
 X
*
 X
*
 
PXR/RXR Activation X
*
 X
*
 X X
*
 X
*
 X
*
 X
*
 X
*
 X
*
 
Xenobiotic Metabolism X
*
 X
*
 X X
*
 X
*
 X
*
 X
*
 X
*
 X
*
 
Fatty Acid Metabolism X
*
 X
*
 X
*
 X
*
 X
*
 X
*
 X
*
 X
*
 X
*
 
LPS/IL-1 Mediated Inhibition of RXR Function X
*
 X
*
   X
*
 X
*
 X
*
 X
*
 X
*
 X
*
 
PPARα/RXR Activation   X   X X
*
 X
*
 X
*
 X
*
 X
*
 
G2/M Transition of the Cell Cycle           X
*
 X X
*
   
p53 Signalling           X
*
 X X   
FXR/RXR Activation X X
*
 X X
*
 X
*
 X
*
 X X
*
 X
*
 
G1/S Transition of the Cell Cycle           X
*
   X   
Mechanism of Gene Regulation by Peroxisome Proliferators via PPARα   X
*
   X X
*
 X
*
 X X
*
 X 
Hypoxia-Inducible Factor Signalling   X
*
   X X X X X   
TR/RXR Activation   X
*
 X X X X
*
   X X
*
 
Mitochondrial Dysfunction X X
*
   X X
*
 X
*
 X X   
Cytochrome P450 Panel - Substrate is a Xenobiotic (Human) X X
*
   X X
*
 X
*
 X X X
*
 
Hepatic Cholestasis   X
*
   X X
*
 X
*
 X X
*
 X
*
 
Oxidative Stress   X
*
   X
*
 X
*
 X
*
 X
*
 X
*
 X
*
 
Cytochrome P450 Panel - Substrate is a Xenobiotic (Mouse) X X
*
   X
*
 X
*
 X
*
 X
*
 X X
*
 
RAR Activation X X
*
       X
*
 X X   
NFkB Signalling Pathway           X
*
   X X 
Cytochrome P450 Panel - Substrate is a Xenobiotic (Rat) X
*
 X
*
   X
*
 X X
*
 X
*
 X
*
 X 
Cytochrome P450 Panel - Substrate is a Fatty Acid (Mouse)       X
*
 X X
*
   X X 
Cholesterol Biosynthesis           X
*
 X X X 
Anti-Apoptosis           X
*
 X X   
TGF-β Signalling   X   X X X
*
 X X   
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Ingenuity Toxicity Lists (continued) 
Time points studied 
Rat Mouse Human  
6hrs 1d 3d 5d 10hrs 2d 4d 30d 3d 
Cytochrome P450 Panel - Substrate is a Fatty Acid (Human)       X
*
 X X
*
   X X 
Negative Acute Phase Response Proteins   X   X
*
 X X
*
 X X X
*
 
Cytochrome P450 Panel - Substrate is a Fatty Acid (Rat)       X
*
 X X
*
   X X 
Cytochrome P450 Panel - Substrate is an Eicosanoid (Human)         X
*
 X     X 
Cytochrome P450 Panel - Substrate is an Eicosanoid (Rat)         X
*
 X     X 
Positive Acute Phase Response Proteins   X
*
 X
*
 X   X   X
*
 X 
Cytochrome P450 Panel - Substrate is an Eicosanoid (Mouse)       X X X     X 
Pro-Apoptosis           X X X X 
Hormone Receptor Regulated Cholesterol Metabolism           X X X X
*
 
LXR/RXR Activation   X
*
 X
*
 X X X   X X
*
 
Hepatic Stellate Cell Activation       X   X X X X
*
 
VDR/RXR Activation X X X   X X   X X 
Cytochrome P450 Panel - Substrate is a Vitamin (Human)           X   X   
Cytochrome P450 Panel - Substrate is a Vitamin (Mouse)           X   X   
Cytochrome P450 Panel - Substrate is a Vitamin (Rat)           X   X   
Cytochrome P450 Panel - Substrate is a Sterol (Human)   X
*
         X X X 
Cytochrome P450 Panel - Substrate is a Sterol (Mouse)   X
*
         X X X 
Cytochrome P450 Panel - Substrate is a Sterol (Rat)   X
*
         X X X 
Hepatic Fibrosis X X X X
*
 X   X
*
 X X 
 
NB: The crosses at the different time points indicate that the genes within that particular dataset are involved in the indicated toxicity.   
X
* – Indicate the statistically significant (p-value ≤ 0.05) association of the genes within the species at the time point and the toxicity 
indicated. 
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5.2.1.1  CAR/ RXR Activation (Appendix A5.1.1) 
 
The constitutive androstane receptor (CAR) is part of a steroid family of nuclear 
receptors. Following activation by compounds like PB, CAR binds to the retinoid X 
receptor (RXR) forming a heterodimer, which binds to upstream enhancers of target 
genes, including CYP2B genes and others that are involved in drug metabolism [71]. The 
“CAR/ RXR activation” list consists of genes associated with CAR/ RXR activation 
[153].  
 
Although no common genes were found across the different datasets, the majority of the 
genes involved in the CAR/ RXR activation Tox List across all species were up-regulated 
and involved in phase I and II drug metabolism. The latter included the cytochrome P450 
enzymes (CYP2B, CYP2C), aldehyde dehydrogenase (ALDH1A1), sulfotransferases, 
glutathione S- transferases (GST). Changes in CAR (NR1I3) itself were only observed at 
Day 2 carried out in the mouse where it was down-regulated. Retinoid X receptor alpha 
(RXRa) was observed to be down-regulated in the mouse at two days but upregulated at 
Day 30. The latter was also down-regulated in the human dataset at Day 3. 
 
 
5.2.1.2  PXR/ RXR Activation (Appendix A5.1.2) 
 
The pregane X receptor (PXR) is a nuclear receptor activated by compounds such as PB. 
It forms a heterodimer with RXR, which binds to enhancer regions of target genes such 
as some cytochrome P450 enzymes involved in drug metabolism [71].  
 
Phase I and II drug metabolising enzymes were consistently up-regulated across all 
species and time points. The nuclear receptor pregane X receptor (PXR, NR1I2) was also 
up-regulated but only at day 4 in the mouse. 
 
Genes found to be down-regulated at one or more days were those known to play a role in 
hepatic energy metabolism. The latter were only observed in the mouse and included the 
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forkhead transcription factor (FOXO1), glucose-6-phosphatase (G6PC) and 3-hydroxy-3-
methylglutaryl-Coenzyme A synthase 2 (HMGCS2).  In addition, hepatocyte nuclear 
factor 4α, insulin-like growth factor binding protein 1, peroxisome proliferator-activated 
receptor γ co-activator 1 α, peroxisome proliferator-activated receptor α (HNF4A, 
IGFBP1, PPARGC1A, PPARA) and protein kinase, cAMP-dependent, regulatory, type I, 
α (PRKAR1A) were down-regulated at one or more days. RXRa was also down-
regulated in both the mouse and human datasets at days 2 and 3 respectively.  
 
 
5.2.1.3  PPARα/ RXR Activation (Appendix A5.1.3) 
 
The perixosome proliferator-activated receptor alpha (PPARα) is a ligand activated 
transcription factor that belongs to the family of nuclear receptor and forms a heterodimer 
with RXR [157]. 
 
The majority of the gene changes observed were from the dataset collected from the 
mouse. Genes found to be up-regulated within this list of genes included the cytochrome 
P450 family of enzymes (CYP2C) involved in drug metabolism, synthesis of cholesterol 
steroids and other lipids. Other genes found within this list of genes fell predominantly 
within the roles of cellular growth, proliferation, fatty acid metabolism and apoptosis. 
 
RXR was observed to be down-regulated in both the mouse (days 2 & 30) and human 
(day 3) dataset. 
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5.2.1.4  Mechanism of gene regulation by Peroxisome Proliferators via PPARα  
(Appendix A5.1.4) 
 
One response to exposure to foreign compounds is the occurrence of peroxisomal 
proliferation.  Peroxisomes are microbodies that are abundant in hepatocytes and have 
been observed to increase after exposure to certain compounds [158]. The induction of 
peroxisome proliferation is mediated by the ligand dependent nuclear receptor, PPARα. 
 
Changes in genes involved in this Tox List occurred predominantly in the mouse between 
days 2 and 30. There were 31 different observed gene changes in the mouse compared to 
10 and two from the rat and human dataset, respectively. Although the results of the two 
genes in the human dataset (RXR, IKBKG) were similar to the results observed in the 
mouse, they were not specific to PPAR as these genes were observed to occur across 
many of the other Tox Lists evaluated. Three out of the 10 genes in the rat dataset 
showed contrasting results to the mouse. The transcription regulator CITED2 was down-
regulated in the rat at day 1 but up-regulated in the mouse at day 4. The heat shock 
protein, HSP90AA1 (known as HSP86 in the rat) was down-regulated in the rat at day 1 
and observed to be up-regulated in the mouse at 10 hrs and 2 days. The RAF1 gene was 
up-regulated in the rat at day 5 but down-regulated in the mouse at 10hrs and at days 2 
and 30.  
 
With the exception of one gene (GRB2), which was up-regulated at day 2 and down-
regulated at day 4, all other genes maintained a consistent direction of regulation at either 
1 or more days within the mouse dataset. 
 
Most of the genes identified in this list are involved in lipid metabolism, cell proliferation, 
apoptosis and oxidative reduction.  
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5.2.1.5  Oxidative Stress & Oxidative Stress Response Mediated by Nrf2  
(Appendix A5.1.5 & A5.1.6) 
 
In the presence of foreign compounds like PB, reactive oxygen species may be produced. 
The oxidation and reduction cycle that ensues, results in the donation of an electron to 
oxygen to produce superoxide. Oxidative stress results from an imbalance between the 
production of reactive oxygen species produced and the detoxification of reactive 
intermediates [87].  
 
IPA identified 133 genes within the Tox List of genes involved in Oxidative Stress 
mediated by NRf2. This comprised of 86 genes from the mouse, 29 from the rat and 18 
from the human. In addition, IPA grouped another 25 genes within a separate Tox List, 
Oxidative Stress which comprised of 18 genes from the mouse, 11 from the rat and 5 
from the human dataset.  
 
Metabolising enzymes with key roles in the detoxification of xenobiotics to reduce 
cellular stress were observed to be up regulated. The latter included glutathione 
transferases (GSTs), dehydrogenases (NQO), reductases (AKR, TXN) and peroxidases 
(PRDX). Glutathione S-transferase theta-2 (GSTT2) was down-regulated at 6hrs in the 
rat but up-regulated at several time points in the mouse. For genes common to both the 
mouse and the human, the direction of gene regulation was found to be the same.  
 
The key genes identified from the general literature to be involved in the regulation of 
this pathway included NQO1, KEAP1, MAFG and NFE2L2 (NrF2). KEAP1, involved in 
the regulation of NrF2 (Nguyen et al. [159] & Pi et al. [207]), was observed to be up-
regulated from days 2, 4, and 30 in the mouse data only. The gene encoding NrF2 
(NFE2L2) was up-regulated in the mouse at Day 2 and also in the human dataset. 
NADPH: quinine oxidoreductase 1 (NQO1) which possesses antioxidant response 
elements (ARE) within the promoter region of its sequence, was observed to be up-
regulated in the rat (Days 1 and 5) and mouse at Day 2 [159]. The gene encoding the 
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small MAF protein (MAFG) was only observed to be up regulated in the human data. 
The latter is known to form a heterodimer with NrF2 to amplify its signalling [160].  
 
 
5.2.1.6  Aryl Hydrocarbon Receptor Signalling (Appendix A5.1.7) 
 
The aryl hydrocarbon receptor (AhR) is involved in the mediation of numerous biological 
processes that result from exposure to foreign compounds [161]. 
 
In total 66 genes were grouped into the Aryl Hydrocarbon Receptor Signalling Tox List, 
of which 62 genes were from the mouse dataset, 16 from the rat and 11 from the human 
dataset. Most of the genes across all datasets were up-regulated and included phase I 
metabolizing enzymes (CYP, ALDH), phase II metabolizing  enzymes (GSTs, NADPH-
quinone oxidoreductases), different other nuclear receptor co-activators (NCO) and 
proteins and growth factors involved in cell cycle progression (CCN, CDK) and apoptosis 
(BAX). 
 
The aryl hydrocarbon nuclear translocator (ARNT) known to dimerize with AHR was 
only present and observed in the mouse list, where it was down-regulated at days 2 and 4. 
AHR observed only in the mouse dataset and it was up regulated at all time points 
investigated.  
 
 
5.2.1.7  P53 signalling (Appendix A5.1.8) 
 
P53 is a tumour suppressor protein involved in the regulation of cellular stress such as 
DNA damage, UV radiation and hypoxia [162] 
 
The P53 Tox List was only identified in the mouse dataset at Days 2, 4 and 30 and 
comprised of 28 genes and proteins. IPA did not produce this Tox List from the datasets 
uploaded for both rat and the human datasets. 
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Most of the genes and proteins in this list were up-regulated especially at Day 2. The 
majority of the genes within this list are those involved in cell cycle progression (KAT2B, 
MDM2, CCND1, CDK4, PCNA, CCNG1, PLAGL1 and PTEN) and almost all are 
involved in apoptosis and cell proliferation and growth.  
 
 
5.2.1.8  G2/M Transition of Cell Cycle (Appendix A5.1.9) 
 
Gap 2 (G2) is one of four phases of the cell cycle of a proliferating cell. The four phases 
include: Gap 1 (G1), Synthesis (S), Gap 2 (G2) and Mitosis (M). During G2, cells grow 
and prepare for division [163]. 
 
The G2/M transition of the cell cycle Tox List was identified from the mouse dataset only 
The results produced from the analysis in IPA did not identify this Tox List from the rat 
or human datasets. 16 genes and proteins from Days 2, 4 and 30 were identified to be part 
of this Tox List and the regulation of the G2/M transition of the cell cycle. Most genes 
were up-regulated particularly at Day 2.  
 
Most of the genes in this list were identified in IPA to play a role in apoptosis and cell 
proliferation. In addition genes have more specific roles in G2 and mitosis (CDC, CCNB, 
GADD45A, PLK1, WEE1, YWHAE). The genes within the list are also involved in 
segregation of cells (TOP2A), DNA damage response  (CHEK1) and cell cycle 
progression (MDM2, KAT2B, CDC, GADD45A, PLK1, YWHAE) [153]. 
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5.2.1.9  G1/S Transition of the Cell Cycle (Appendix A5.1.10) 
 
During the G1 phase of the cell-cycle when cells are primarily involved in growth, the 
cells usually proceed to S phase, proliferate or exist in a quiescent state (G0) [163].  
 
This Tox List was only observed in the mouse dataset and comprised of 15 genes, of 
which the majority were up-regulated at Day 2 and some at Day 30. . IPA did not produce 
this Tox List from the datasets uploaded for both rat and the human datasets. 
 
 
A number of genes involved in S phase of cell growth (E2F, CCND) were up-regulated at 
Days 2 and 30. The latter are also involved in the G1/S phase transition, cell cycle 
progression and apoptosis.  
 
 
 
5.2.2  Mitochondrial Dysfunction (Appendix A5.1.11) 
 
The mitochondrion hosts many redox carriers that are able to transfer single electrons to 
oxygen leading to the formation of ROS. As well as being primary consumers of oxygen, 
the mitochondria also play host to an antioxidant defense system capable of detoxifying 
ROS. This defense system protects against oxidative damage to cellular components 
[164]. 
 
This Tox List was only identified in the mouse dataset which comprised of 33 genes and 
proteins. Phase I (COX, CYB5R3, GPD2, GPX4, SDH, PDHA1) and II (GSR) 
metabolizing enzymes were found to be mostly up-regulated at Day 2 or later, although 
some members of the cytochrome oxidase, oxidoreductase (COX) were also down-
regulated at a combination of one or more days. Some members of the family of NADH 
dehydrogenases were also down-regulated at one or more days.  
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5.2.2.1  Pro-Apoptosis (Appendix A5.1.12) 
 
Genes identified by this Tox List included those involved in pro-apoptosis signalling and 
regulation. External factors such as exposure to a foreign compound can trigger a cell to 
program its death by the process of apoptosis.  
 
Thirteen genes from the mouse dataset were observed to be part of the pro-apoptosis Tox 
List compared to one gene observed at Day 5 in the rat dataset and one gene observed in 
the human dataset. Most genes were down-regulated at more than one time point and all 
had a role to play in apoptosis and cell death. Apoptosis (killer genes) specific genes 
(BOK and BAD) were down-regulated at Day 2 and 4 respectively within the mouse 
dataset. The gene CASP3 up-regulated at Day 2 in the mouse is part of the caspase family 
that plays a central role in the execution phase of apoptosis. 
 
 
 
5.2.2.2  Anti-Apoptosis (Appendix A5.1.13) 
 
IPA identified 8 genes as part of the Anti-Apoptosis Tox List. All the genes in this list 
were associated with the inhibition of apoptosis signalling and regulation. Only three 
genes (BAG3, BIRC5, TMX1) were up-regulated at Day 2 or later. The gene changes 
were only observed in the mouse dataset. The up-regulated genes are known to inhibit 
apoptotic function.  
 
 
5.2.2.3  Hepatic Cholestasis (Appendix A5.1.14) 
 
Bile acids and their salts are produced in the liver and have an essential role in the 
digestion of fatty acids. Hepatic cholestasis occurs when bile produced in the liver is 
unable to flow to the small intestine. Hepatic cholestasis is clinically characterized by 
increased plasma concentration levels of cytotoxic biliary constituents such as bilirubin, 
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reduced absorption of fats and damage to the liver [165]. Exposure to foreign compounds 
may result in the development of hepatic cholestasis.  
 
Fifty genes were identified to be part of the hepatic cholestasis Tox List of which 34 were 
from the mouse dataset, nine from the human and seven from the rat dataset. The 
majority of genes within this list were from the family of transporters, kinases and ligand 
dependent nuclear receptors. The ABC transporter proteins (ABCC2, ABCC3, ABCB11) 
associated with transport of phosholipids from liver hepatocytes into bile were up-
regulated at one or more days and were found to be common between the rat, mouse and 
human datasets. Members of the solute carrier family (SLC), which are co-transporters of 
sodium/bile and aid in the circulation of bile acids, were found to be up-regulated 
predominantly in the mouse at day 2, although SLC10A1 was found to be common 
between the mouse and the rat.  
 
 
5.2.2.4  LPS/IL-1 Mediated Inhibition of RXR Function (Appendix A5.1.15) 
 
Eighty-nine genes/proteins were identified to be part of the LPS/IL-1 mediated inhibition 
of RXR function. The latter comprised of 31 genes from the rat dataset, 64 from the 
mouse and 26 from the human dataset.  
 
The genes involved in this Tox List were mostly up-regulated and included metabolizing 
enzymes (ALD, CYP, GST, FMO, SULT). The gene encoding the enzyme CYP2B6 
(CYP2B2/ CYP2B10 in the rat and human respectively) was observed to be up regulated 
across all species and time points investigated. Some members of the aldehyde 
dehydrogenase family (ALDH6A1, ALDH9A1) were down-regulated in the mouse at 
Day 2. Members of the ABC transporting proteins involved in the transportation of 
molecules within the intra- and extra-cellular membranes (and thought to be involved in 
biliary transport and members of the solute carrier family (SLC) known to be involved in 
ion transport and fatty acid transportation) were found to be common between the 
different species and were mostly up-regulated at the different time points. ABCA1 was 
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down-regulated at days 4 and 30 in the mouse and also at day 3 in the human dataset. In 
addition, proteins involved specifically in lipid transport- apolipoprotein (APOC4) and 
the phospholipids transfer protein (PLTP) were down-regulated at Days 2 and 30 
respectively in the mouse. 
 
Members of the acyl CoA synthase long chain family (ACSL) that play a key role in lipid 
biosynthesis and fatty acid degradation, were all down-regulated from Days 2 to 30 in the 
mouse and at Day 5 in the rat (ACSL1).  
 
There were observed differences between the expression of genes within the Tox List 
between the three species. Members of the glutathione transferase family (GSTT2, 
GSTM1) were observed to be down-regulated in the rat at 6hrs and Day 5 respectively in 
comparison to the mouse where the genes were up-regulated. Differences were also 
observed between the rat and the human dataset for genes belonging to the 
sulfotransferase family. SULT1A1 was down-regulated at Days 2 and 5 in the rat 
compared to being up-regulated in the human dataset at Day 3. SULT2A1 was down-
regulated in the rat at Day 5 while SULT1A2 was up-regulated at Day 3 in the human. 
SULT1A3 was however down-regulated in the human. The enzyme catalase (CAT) was 
observed to be up-regulated in the rat at Day 1 but down-regulated at Day 30 in the 
mouse.  
 
 
 
5.2.2.5  Negative Acute Phase Response Proteins (Appendix A5.1.16) 
 
Six genes were identified within this Tox List, which comprised of three genes from the 
rat dataset, 4 genes from the mouse and 2 genes from the human dataset. The genes 
involved in negative acute phase response were observed to be mostly down-regulated 
across all 3 species. 
 
The plasma proteins albumin (ALB) and alpolipoproteins (APOA1) were down-regulated 
in the mouse and human datasets, while APOA2 was observed to be up-regulated at 5 
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days in the rat.   The gene AHSG now known as fetuin A was also down-regulated in the 
mouse and human dataset at 2 and 3 days respectively. The latter exhibits pro-
inflammatory effects by playing a key role in the regulation of cytokine expression, most 
notably interleukin 6 (IL6) which is involved in the inflammation and maturation of B 
cells [166]. The inter-alpha trypsin inhibitors (ITI) a family of plasma serine protease 
inhibitors were also down-regulated in the mouse and rat dataset.  
 
 
5.2.2.6  Positive Acute Phase Response Proteins (Appendix A5.1.17) 
 
IPA identified 14 genes to be part of the positive acute phase response Tox List. This 
comprised of five genes from the rat, 9 from the mouse and 2 from the human dataset. 
The positive acute response proteins identified were mostly up-regulated across the three 
species.  
 
Key genes encoding acute phase response proteins observed to be up-regulated in the rat 
and mouse included the C-reactive protein (CRP) which is involved in a host of defence-
related functions, and orosomucoid proteins (ORM1, ORM2) that are known to increase 
due to inflammation. Most of the proteins encoded by the genes involved in this Tox List 
were plasma proteins. Genes that were down-regulated included the metalloprotein 
ceruloplasmin (CP) involved in iron transport, alpha 2-macroglobulin (A2M) a protease 
inhibitor and cytokine transporter and the plasma proteins serpin peptidase inhibitors 
SERPING1 and SERPINA3 involved in the regulation of the complement cascade and 
protease targeting respectively [153]. 
 
 
 
 
 
 
 
 
 
 
 
 
 128 
 
5.2.2.7  TGF-β-Signalling (Appendix A5.1.18) 
 
The transforming growth factor-β (TGF-β) signalling Tox List comprised of 18 genes, 
three of which were observed in the rat and 17 from the mouse dataset. The TGF-β 
involved in the regulation of growth and the proliferation of cells was expressed only in 
the mouse dataset where it was observed to be up-regulated at Days 2, 4 and 30. Genes 
encoding key proteins known to bind and activate TGF-β were also present in this Tox 
List and they included the bone morphogenic proteins (BMP2, BMPR2), observed to be 
down-regulated at Day 2 in the mouse and the SMAD family of  transcriptional 
regulators. SMAD1 was up-regulated at day 2 and down-regulated at Day 4 in the mouse 
while SMAD4 was down-regulated only at Day 4.  
 
Members of the mitogen-activated protein kinases (MAP2K1, MAP2K2, MAPK8) were 
also up-regulated in the mouse in addition to members of the Ras family of genes (HRAS, 
RRAS, RRAS2). HRAS and RRAS were both up-regulated at Day 2 in the mouse while 
RRAS2 was down-regulated at Days 2, 4 and 30, also in the mouse. Ras genes encode 
proteins that are involved in cellular processes that involve cell growth, differentiation 
and survival. They are also involved in the regulation of MAP kinases [153].  
 
 
5.2.2.8  Hepatic Fibrosis (Appendix A5.1.19) 
 
Hepatic fibrosis is a chronic liver disease associated with accumulation of extracellular 
(ECM) matrix proteins.  
 
IPA identified 18 genes as part of the Hepatic Fibrosis Tox List. This comprised of 14 
genes from the mouse, five from the rat and four from the human dataset. Most of the 
genes in this group were down-regulated at Day 2 or more and involved in cell migration, 
growth and proliferation.  
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The collagen-type proteins (COL), which are part of the extracellular matrix of proteins 
were up-regulated at Day 2 in the mouse. COL3A1 was, however, down-regulated in the 
rat at 6hrs in contrast to the mouse in which it was up-regulated at Day 2.  
 
 
5.2.2.9  Hepatic Stellate Cells Activation 
 
IPA identified 8 different genes encoding proteins associated with the process of hepatic 
fibrosis and hepatic stellate cell activation within this Tox List. The latter was made up of 
one gene from the rat, 6 from the mouse and 3 from the human dataset.  
 
Genes up-regulated included the growth factors PDGFA and TGFA at Day 2 and 30 
respectively in the mouse dataset. The gene encoding Cluster of differentiation 14 (CD14) 
able to detect lipopolysaccharide (LPS) and bind with apoptotic cells and LPS (in the 
presence of the LPS binding protein), was up-regulated in the human dataset. 
Transforming growth factor (TGF)-beta genes (TGFBR2, TGFBR3) were both present 
within the mouse data. TGFBR2 a member of the kinase family and TGFB receptor 
subfamily were up-regulated at Days 2, 4 and 30 in the mouse. TGFBR3, a 
multifunctional cytokine involved in extracellular matrix production was down-regulated 
at Day 2 in the mouse.  
 
The insulin-like growth factor (IGF1) was down-regulated in the mouse and human 
dataset at all days investigated. The gene encoding CYP2E1 was down-regulated in the 
rat at Day 5 and also in the human at Day 3 [153].  
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5.3 Toxicolgical Function (Tox Function) 
 
 
IPA Tox Function analysis enabled genes to be grouped according to their known 
associations with clinical pathology endpoints. Applying a similar approach as that 
carried for the selection of the Tox Lists, the Tox Functions results were selected on the 
basis of the association with postulated PB key events for liver tumour formation.  
 
Eight functional categories associated with hepatotoxicity clinical pathology endpoints 
were selected for further analysis. This included liver proliferation, hyperplasia/ 
hyperproliferation, hypertrophy, liver necrosis/cell death, liver damage, liver steotosis, 
liver cholestasis and hepatocellular carcinoma. The toxicity functions were selected for 
further analysis on the basis of a) the number of genes involved from the experimental 
datasets and b) the assigned statistical significance that measured the likelihood of 
association between the genes within the dataset and a particular clinical pathology 
endpoint as denoted by the functional toxicity. Table 5.3 summarises the toxicity 
functional analysis findings and the corresponding scores and statistical significance 
rankings for each function category from the individual datasets. 
 
The Path Designer tool function in IPA was used to generate functional networks for the 
different datasets to investigate the interactions and relationships of the molecules 
involved in the different toxicity functions. The results of the functional analysis carried 
out for each time-point were combined for each particular toxicity function. The 
functional network was built using the published dataset rather than data available within 
the IPA Knowledge base. The functional networks for the toxicity functions showed the 
interactions and relationships (direct or indirect) of molecules up- and downstream of the 
key genes. The network interactions were built to expand the key genes by 10 more 
molecules using data only available form the uploaded dataset. The generated networks 
for the different toxicity functions within the different species datasets are provided in 
Appendix V (A5.2 - A5.2.11). 
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Table 5.3: Toxicity Functions Related to Hepatotoxicity across all species 
 
 
Category 
 Rat 1 day Rat 5 days 
Occurrence 
No. of 
genes Occurrence 
No. of 
genes 
Hepatocellular Carcinoma X
* 
4   
Liver Cholestasis X
*
 9 X
*
 2 
Liver Cirrhosis X
*
 3   
Liver Hepatomegaly X
*
 1   
Liver Hyperbilirubinemia   X
*
 2 
Liver Steatohepatitis X 1   
Liver Steatosis   X
*
 1 
 
Category 
 Human 3 days 
 Occurrence 
No. of 
genes  
Liver Cholestasis X* 12 
Liver Hyperbilirubinemia X* 2 
Liver Cirrhosis X* 4 
Liver Fibrosis X* 4 
Liver Proliferation X 1 
Liver Steatosis X 1 
Liver Necrosis/Cell Death X 1 
Liver Steatohepatitis X 1 
Liver Hepatitis X 1 
 
 
NB: X
* –indicates statistically significant association (p-value ≤ 0.05) of the genes 
involved in the Tox Function indicated and genes known to be associated with that Tox 
Function in the IPA Knowledge base. 
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Table 5.4: Summary of Tox Functions According to the Different Hepatotoxicity Categories 
 
NB: X
* –indicates statistically significant association (p-value ≤ 0.05) of the genes involved in the Tox Function indicated and genes 
known to be associated with that Tox Function in the IPA Knowledge base.
Category  
Mouse 10 hrs Mouse 2 days Mouse 4 days Mouse 30 days 
Occurrence 
No. of 
genes Occurrence 
No. of 
genes Occurrence 
No. of 
genes Occurrence 
No. of 
genes 
Hepatocellular Carcinoma   X
*
 9 X
*
 6 X 3 
Liver Cholestasis X
*
 2 X
*
 3 X 1 X
*
 2 
Liver Cirrhosis         
Liver Congestion     X 1   
Liver Damage X 1 X 10 X 4 X
*
 4 
Liver Degeneration     X 2   
Liver Dysplasia   X 2     
Liver Hematopoiesis   X 1   X 1 
Liver Hepatomegaly   X 3 X 2 X 2 
Liver Hepatitis   X 1   X
*
 4 
Liver Hemorrhaging       X
*
 2 
Liver 
Hyperplasia/Hyperproliferation 
X
*
 
2 
X
*
 
11 
X
*
 
6 
X
*
 
7 
Liver Hypertrophy   X 1 X 1 X 1 
Liver Hypoplasia   X 1 X 1 X 1 
Liver Failure   X 1 X 1 X 1 
Liver Fibrosis X
*
 1 X 3 X 3 X
*
 3 
Liver Hyperbilirubinemia         
Liver Inflammation   X 4 X 2 X
*
 5 
Liver Proliferation X 2 X
*
 15 X 6 X
*
 8 
Liver Regeneration X 1   X 2 X 3 
Liver Necrosis/Cell Death X
*
 4 X
*
 23 X
*
 9 X
*
 14 
Liver Steatosis X 1 X
*
 11 X 5 X
*
 12 
Liver Steatohepatitis   X 2 X 2 X
*
 2 
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5.3.1  Liver Proliferation 
 
 
Nineteen genes combined from the mouse datasets (10hrs & 30 days) were associated 
with liver proliferation. These genes were used as the focus molecules from which the 
functional network for liver proliferation was built. A comparison of the network with 
the IPA knowledge base on relevant biological functions (cellular growth and 
proliferation) confirmed that all 19 genes were statistically associated (P value = 
2.2E-32) with the proliferation of liver cells when compared with genes within the 
IPA knowledge base. Most of the genes up- or down-stream from the key molecules 
were also identified to be involved the proliferation of the cells (P value = 1.61E-22).  
 
Only one molecule from the human dataset was identified by IPA to be associated 
with liver proliferation (IGF1). The Insulin-like growth factor is involved in the 
mediation of cell growth and development. The surrounding genes up- or down-
stream of IGF1 between the mouse and the human dataset were very different. In 
addition, only two of the genes (CAV1 & VTN) that interacted directly with IGF1 
were identified to play roles in the proliferation of particular types of cells.  
 
A search carried out in the IPA Knowledge base found 75 genes associated with liver 
proliferation. These genes were compared to those obtained from the Tox Function 
results for the mouse and human dataset (A5.3 and A5.3.1 in Appendix V). Nineteen 
genes were observed to be from the mouse and only one gene from the human dataset 
were found to be part of the IPA liver proliferation associated genes.   
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5.3.2  Liver Hyperplasia/ Hyperproliferation and Liver Hypertrophy 
 
IPA also grouped 13 genes within a separate Tox function category of hyperplasia/ 
hyperproliferation from the mouse datasets. This Tox function was identified in all 
mouse time points investigated. All molecules were combined to create the functional 
network (A5.2.3 in Appendix V). The key focus genes that included the ligand 
dependent nuclear receptors (AHR, PPARA), transcription regulators (MYC) and 
kinases (MAPK8, IKBKG, TGFBR2) were categorised in IPA Tox Function to have 
roles in proliferation and hyperplasia. The genes up- or down-stream of the key 
molecules were also shown to be involved in cell growth and proliferation.  
 
Genes associated with the liver hypertrophy Tox function were only observed within 
the mouse dataset at day 4. The gene encoding the enzyme CYP1A2 was categorised 
within IPA to play a role in liver hypertrophy. CYP1A2 was shown to interact directly 
with key ligand dependent nuclear receptors such as AhR and indirectly with NR1I2. 
It was also shown to interact directly with transcription regulators NFIA, PPARGC1A 
and indirectly with HNF4A.  
 
Only six genes associated with liver hyperplasia/ hyperproliferation were found 
within the IPA Knowledge base. Comparison of these genes with the mouse datasets 
(A5.2.3 in Appendix V) showed two genes in common with those identified by the 
IPA Knowledge base. Similarly, only three genes specifically associated with liver 
hypertrophy were identified within the IPA Knowledge base, of which only one was 
actually found in the mouse dataset.  
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5.3.3  Liver Necrosis/ Cell Death 
 
Changes in genes associated with liver necrosis/cell death for the mouse datasets, 
were observed to be statistically significant at all four time points. 33 key genes 
common to all datasets were identified from the toxicity function results to create the 
functional network showing the immediate interacting genes. Overlay of the network 
with the IPA functions and disease database identified only the key genes associated 
with death of liver cells (P value =7E-38) and necrosis (P value = 1.24E-9).  
 
A search for genes commonly associated with cell death identified 65 genes within 
the IPA Knowledge base. 35 of these genes were found to occur within the mouse 
dataset and were observed to be mostly up-regulated.  
 
 
5.3.4  Liver Cholestasis 
 
Genes thought to be involved in liver cholestasis were observed across all three 
species investigated. The gene encoding the transporter protein ABCC2 was the only 
common gene across the three functional networks. The genes encoding transporter 
proteins from the ABC and solute carrier family were mostly perturbed across the 
three datasets. 
 
A search carried out in the IPA Knowledge base identified 83 genes associated with 
liver cholestasis. Only four, 10 and 12 of the latter genes were found within the mouse, 
rat and human dataset respectively.   
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5.3.5  Liver steatosis 
 
The functional network for liver steatosis comprised of 19 key genes compiled from 
the four time points investigated in the mouse. Overlay of the functions and disease 
database in IPA identified the key genes to be associated with hepatic steatosis (P 
value = 2.68E -34).  
 
Fifty-six genes associated with hepatic steatosis were found within the IPA 
knowledgebase. Comparison of the latter with the mouse dataset showed that 18 of 
these genes were perturbed within the mouse datasets. Most of the genes from the 
mouse dataset were shown to be down-regulated. 
 
 
5.3.6  Hepatocellular Carcinoma (HCC) 
 
Genes associated with hepatocellular carcinoma were only identified in the results 
obtained from rat (Day 1) and mouse datasets (all time points investigated). 
Comparison of the functional network to the functions and disease database in IPA 
showed the key genes were statistically associated with molecules known to be 
involved in hepatocellular carcinoma (Mouse: P value = 4.8E -16; Rat: P value = 
1.49E -7).  
 
A search within the IPA Knowledgebase identified 107 genes associated with 
hepatocellular carcinoma. Comparison of the latter with the dataset showed that only 
five and 12 from the rat and mouse were common with the IPA genes. 
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5.4 Comparison of All Datasets with Published Multi-Gene Signatures for the 
Identification of Non-Genotoxic Hepatocarcinogens and Reference Genes 
for Hepatocellular Carcinoma as Identified by the Literature  
 
 
The DEGs from all time points investigated across the three species were combined 
and any duplicates observed were removed. The common genes observed were 
compared   to the 19 genes identified by Pei et al [156] to be associated with HCC. 
The comparison showed that there were no common genes between the different 
DEGs obtained from either the mouse or the rat.  The gene, paternally expressed 10 
(PEG10) was, however, identified from the human dataset (Table 5.5).  
 
There was no commonality between the multi-gene signatures identified by Fielden et 
al [154] and Nei et al [155] for the identification of non genotoxic hepatocarcinogens. 
In addition, the comparison of these multi-gene signatures with the grouped DEGs 
obtained from the datasets obtained for the three species investigated here showed that 
there was no commonality between the different lists of genes (Table 5.5).  
 
 
Table 5.5: Summary of results from the comparison of all datasets with literature 
derived biomarkers for non-genotoxic chemicals 
 
Source 
Multi-gene signatures 
for the identification of 
Non-genotoxic 
hepatocarcinogens 
Mouse 
(3466 DEGs) 
Human 
(831 DEGs) 
Rat 
(285 DEGs) 
Nie et al. [155] 6 0 0 0 
Fielden et al. 
[154] 
37 0 0 0 
 
 
 
Table 5.6: Summary of results from the comparison of all datasets with genes 
identified in the literature to be associated with hepatocellular carcinoma 
 
Source 
Genes Associated  
with HCC 
Mouse 
 (3466 DEGs) 
Human 
(831 DEGs) 
Rat (285 
DEGs) 
Pei et al. [156] 19 0 1 0 
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5.5 Canonical Pathways 
A similar approach applied for the selection of results obtained from the Tox Lists and 
Tox Functions, was employed for the selection of the canonical pathways. The focus 
was placed on observed signalling pathways and those considered to have a potential 
involvment in the MOA of PB were selected for further analysis. Selected signalling 
pathways included cellular growth, proliferation, apoptosis and cellular stress. For 
illustrative purposes, only one experiment was selected to represent each species (rat 
Day1, mouse Day 2 and human Day 3) for the evaluation of the MOA related 
pathways. The MOA related signalling pathways from the three different experiments 
are provided in Appendix V (A5.4 to A5.4.18).  
 
 
5.5.1  Cell Growth, Proliferation and Development 
The exposure of PB to all three species affected numerous signalling pathways 
involved in cell growth, proliferation and development. Although there was strong 
similarity between the pathways affected across the three species in relation to cell 
growth, proliferation and development, the percentages of genes involved in these 
different pathways were significantly higher in the experiment carried out in the 
mouse compared to the rat and human.  
 
5.5.2  Apoptosis 
The genes involved in the signalling pathways involved in apoptosis were mostly 
affected in the mouse and human compared to the rat. The percentage of genes in the 
mouse experiment was again shown to be higher when compared to the level of genes 
actually perturbed in similar pathways in the rat and human experiments. The AhR 
signalling pathway was however observed across all three species to be greatly 
affected by PB.  
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5.5.3  Cellular Stress and Injury 
 
The three species showed that similar pathways involved in cellular stress and injury 
were affected. Genes in the mouse were observed to be mostly affected by exposure 
to PB. The NRF2-mediated oxidative stress response pathway was observed to be 
significantly affected across all three datasets. This indicated that exposure to PB 
resulted in the induction of genes involved in the regulation of oxidative stress.  
Where available, the signalling pathways associated with the Tox Lists and Tox 
functions discussed previously, were examined to provide a better understanding of 
the levels of genes that were affecting the pathways of interest. The relevant 
pathways
15
 for the different time points across the different species datasets are 
displayed below as stacked bar charts in Figures 5.1.1 to 5.1.9. The figures also 
illustrate the overlap between the signalling pathways relevant for the MOA and the 
observed toxicities as depicted by the Tox List and Tox functions.  
The selected signalling pathways for the IPA Tox Lists included: NRF2-mediated 
Oxidative Stress Response, AhR Signalling, PXR/RXR Activation, LPS/IL-1 
Mediated Inhibition of RXR Function, PPARA/RXR Activation, Cell Cycle: G2/M 
DNA Damage Checkpoint Regulation, Cell Cycle: G1/S Checkpoint Regulation, 
Acute Phase Response Signalling, PPAR Signalling, p53 Signalling, Apoptosis 
Signalling, Mitochondrial Dysfunction, NF-KB Signalling TGF-Î² Signalling, Growth 
Hormone Signalling, Hepatic Cholestasis and Hepatic Fibrosis / Hepatic Stellate Cell 
Activation. The IPA Tox List for CAR/RXR was not included as a signalling pathway.  
 
 
 
                                                 
15
 The pathways represented by stacked bar charts show the number of up-regulated 
(red), down regulated(green), and unchanged molecules (grey) in each Canonical 
Pathway. The selected canonical pathways involved in the analysis are shown on the 
x-axis. The y-axis on the left shows the percentage of genes within the dataset that are 
involved in the relevant pathway, while the right y-axis shows the level of 
significance (P-value = 0.05). The total number of genes that make up the individual 
IPA pathway is displayed above each bar chart.  
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5.5.4 Tox Function: Rat 
 
The pathways most affected by PB treatment in the rat dataset were PXR/RXR 
Activation, NRF2-mediated Oxidative Stress Response, LPS/IL-1 Mediated Inhibition 
of RXR Function and AhR Signalling. At 6 hours, only the PXR/ RXR activation 
pathway was slightly affected. At Day 1 an increase in the involvement of the genes 
in all 4 pathways were observed and this increased further at day 5. The most affected 
pathway at Day 5 was the PXR/RXR activation (15%) followed by LPS/IL-1 
Mediated Inhibition of RXR Function (12%), NRF2-mediated Oxidative Stress 
Response (10%), and AhR Signalling (8%). At Day 1, 6% of the genes involved in the 
Acute Phase Response Signalling pathway were shown to be predominately down-
regulated and this was reduced to 3% at Day 5.  
 
 
5.5.5  Tox Function: Mouse 
 
Almost all the pathways selected were affected in the mouse compared to the rat. 
Similar to observations in the rat, the PXR/RXR Activation pathway was observed to 
be most affected at the earliest time point of 10hrs. In general, the highest percentages 
of genes involved in the selected pathways were observed at Day 2 with levels 
decreasing by days 4 and 30. At day 2, the Cell Cycle: G2/M DNA Damage 
Checkpoint Regulation was most affected by PB with about 44% of the genes in that 
pathway perturbed. More than 30% of the genes within the NRF2-mediated Oxidative 
Stress Response, Aryl Hydrocarbon Receptor Signalling, and LPS/IL-1 Mediated 
Inhibition of RXR Function were affected.  In general, the percentage of genes 
perturbed by the latter 4 pathways decreased significantly by Day 30. Interestingly, 
however, although the genes involved in the PXR/RXR activation pathway decreased 
from 34% at Day 2 to 14% at Day 4, the percentage of genes involved in this pathway 
increased again by Day 30 to 23%.  
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5.5.6  Tox Function: Human  
Only a small fraction of the selected pathways were significantly affected by PB 
within the human dataset. Similar to observations in the rat and mouse, the PXR/RXR 
Activation pathway was the most affected at the time point investigated showing that 
at least 15% of the genes involved in that pathway were perturbed. This was followed 
by the LPS/IL-1 Mediated Inhibition of RXR Function and NRF2-mediated Oxidative 
Stress Response pathways which showed 12 and 7% of the genes in their respective 
pathways were affected by PB treatment.  
 
 
Figure 5.1.1: Selected signalling pathways for Rat 6 hours 
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Figure 5.1.2: Selected signalling pathways for Rat Day 1 
 
 
Figure 5.1.3: Selected signalling pathways for Rat Day 3 
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Figure 5.1.4: Selected signalling pathways for Rat Day 5  
 
 
Figure 5.1.5: Selected signalling pathways for mouse 10 hours 
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Figure 5.1.6: Selected signalling pathways for mouse Day 2 
 
 
 
Figure 5.1.7: Selected signalling pathways for mouse Day 4  
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Figure 5.1.8: Selected signalling pathways for mouse Day 30  
 
 
 
Figure 5.1.9: Selected signalling pathways for human Day 3  
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5.6 Discussion  
 
The use of toxicogenomics in different biological disciplines has increased 
significantly in the past decade [167]. Numerous studies have been published to 
describe the use of toxicogenomics to predict toxicological outcomes such as 
carcinogenicity. In addition to the use of transcription data in a predictive capacity, 
numerous studies have also been published that have attempted to predict the mode of 
action of a chemical, solely on the basis of observed gene expression changes. A 
recent review by Waters et al [168] identified 11 studies that used toxicogenomics 
methods in their characterisation of modes of action for different chemicals, using 
transcription profiling and supervised clustering methods. In the latter review, the 
authors identified papers that had published signature genes/ biomarkers that appeared 
to discriminate between direct vs. indirect carcinogens and non-genotoxic and non-
carcinogens. 
 
To date, no toxicogenomics studies have been published that thoroughly examine the 
nature of a MOA through the examination of potential molecular pathway changes 
that may be indicative of toxicological end points/ pathologies that are key to a MOA 
[169]. Indeed, the extension of the IPCS framework to include additional types of 
information, such as that from toxicogenomics, has been highlighted as a key 
potential development. 
 
The availability of microarray data in public repositories has made it easier to obtain 
such data and for scientists to carry out toxicogenomics analysis. Problems relating to 
technological issues and quality control of data produced from microarray 
experiments are also being overcome through the development of internationally 
recognized standards for microarray experiments [167]. The latter includes the 
Minimum Information About a Microarray Experiment (MIAME) [140], External 
RNA Controls Consortium (ERCC) [170] and the Microarray Quality Control Project 
(MAQC) [149]. The majority of journals have made it compulsory for published 
experiments using DNA microarrays (and submissions of microarray data to be made 
publicly available in repositories) to meet MIAME standards [167].  
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A comparative assessment of MIAME compliant microarray data obtained from 
public repositories was carried out as part of this project to explore the use of 
toxicogenomics data in MOA analysis. Different analytical tools were used to analyse 
the transcriptional responses of liver tissues obtained for the mouse and rat in-vivo 
and for human hepatocytes treated with PB at dose levels (rat and mouse) that induce 
tumourigenic response in rodents.  
 
The functions, pathways and networks associated with the identified differentially 
expressed genes (DEGs), were investigated through the use of IPA Tox Lists, IPA 
Tox Functions, IPA Canonical Pathways and IPA Functional Networks.  
 
The diverse effect of exposure to PB was illustrated by the Toxicity List and 
Canonical Pathway analysis in IPA, which showed that the differentially regulated 
genes were grouped and associated with a wide range of Tox Lists and signalling 
pathways across all the experiments from the different species and time points 
investigated.  
 
Phenobarbital has been shown in experimental studies to induce hepatic drug 
metabolism as well as a range of pleiotropic effects on liver function that include cell 
proliferation, cell growth and communication, tumour promotion, glucose metabolism, 
inhibition of apoptosis, hypertrophy and development of hepatic foci (although this 
list is not exhaustive). Experimental studies carried out in rodents have shown that PB 
exerts many of its diverse effects on liver function through its activation of the nuclear 
receptor CAR [56, 59, 71].  
 
 
5.6.1.1  Evidence for CAR Activation and CAR-Related Effects on Liver  
Function 
 
The activation of CAR has been postulated to be an essential key step for PB-induced 
liver tumour formation [56]. The genes that encode the various enzymes and 
transporter proteins regulated by CAR have been shown to be involved in the 
excretion of steroid and thyroid hormones, bilirubin and bile acids. In addition to 
metabolism key toxicological responses to the observed tumourigenic effects of PB 
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(i.e. increased cell proliferation, hypertrophy, development of altered hepatic foci 
(leading to advanced liver tumours) have all been shown to be dependent on CAR 
activation [64, 72]. It has been suggested that the nuclear receptors CAR and PXR 
work together in a manner referred to as “crosstalk” to interact with hormone 
responsive transcription factors that work to repress the transcription of genes 
involved in glucose homeostaisis, lipid metabolism and inflammatory response [67, 
171]. Indeed the two nuclear receptors have been observed to share the same target 
genes such as phase I metabolising enzymes (CYP2B, CYP3A CYP2C) and phase II 
metabolising enzymes (GSTs, UGTs and SULTs) [68, 172].  
 
The CAR/RXR Activation Tox List was observed across all time points and species 
investigated. The direction of transcriptional regulation was observed to be the same 
across all the datasets investigated and as expected, genes affected were mostly those 
encoding metabolising enzymes (CYP2B & CYP2C) and transporter proteins. These 
genes were all up-regulated across all time points and species investigated. The genes 
encoding CYP2B10 (orthologous to human gene CYP2B6 and rat gene CYP2B2) and 
CYP3A1 (orthologous to human gene CYP34 and mouse gene CYP3A4) have been 
identified as the target genes for CAR and PXR respectively [68]. With the exception 
of Day 3 in the rat, the gene encoding the human gene CYP2B6 was observed to be 
up-regulated across all other time points across the 3 different species. PB induced 
CAR induction of CYP2B6 has been demonstrated in numerous experiments [67, 
173]. Honkakoski et al [68] investigated the time course for the induction of 
CYP2B10 in mice after exposure to PB and observed mRNA levels of was slightly 
induced after 1hr and was markedly raised after 24hrs. The authors demonstrated that 
the increase in levels of CYP2B10 occurred after the binding of mCAR1 with RXR 
following PB treatment. 
 
In an effort to elucidate the structural and functional relationship between CAR and 
PXR, Moore et al [174] tested the effects of PB on  mouse and human CAR (hCAR/ 
mCAR) and PXR (hPXR/mPXR) ligands. The authors observed that the hPXR ligand 
was induced to a much greater extent (9-fold change) compared to the mPXR (no 
change in expression compared the controls). It is therefore likely that the up-
regulation of CYP2B6 observed in the human dataset may reflect the effect of PXR 
rather than CAR on this target gene. Hariparsad et al, [175] employed PB as a positive 
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control in their investigation of the induction of CYP3A4 in human primary 
hepatocytes. The authors observed a marked increase in the mRNA and protein levels 
(1.9 ±0.3–fold increase) of CYP3A4 after treatment with PB. This increase in 
CYP3A4 activity level corresponded with an observed 30.9-fold increase in the 
expression level of hPXR following treatment with PB.  
 
Within the PXR/RXR Tox List, the gene encoding CYP3A4 was also observed to be 
up-regulated in all three species (rat Days 1 and 5; mouse Day 2 and human Day 3).  
Although all three species showed statistically significant transcriptional changes 
within the set of genes identified by IPA to be associated with this type of toxicity (A 
link to the full list of genes involved in all Tox Lists investigated is provided in 
Appendix V), the gene encoding CAR (NR1I3) was down-regulated and only 
observed in the mouse at 2 days, while RXRA was observed in the mouse at Day 2 
(down-regulated) and at Day 30 (up-regulated) and down-regulated in the human 
dataset (Day 3).  The observations for CAR here were similar to evidence obtained 
from in-vivo experiments which showed that CAR was down-regulated in both mouse 
and rat hepatocytes [176-178]. Moore et al [174] also observed mCAR and hCAR to 
be induced at very low levels (0.4 and 0.5 respectively) by PB.   
 
 
5.6.1.2  Evidence for Crosstalk between CAR and PXR: Glucose & Lipid  
Metabolism 
 
IPA identified a larger set of genes to be associated with PXR/RXR Activation 
compared with the number of genes identified to be associated with CAR/RXR 
Activation. All three species showed significant levels of genes involved in 
PXR/RXR Activation toxicity across the different time points. In addition to genes 
encoding drug metabolising enzymes and transporter proteins, genes known to encode 
proteins that play significant roles in hepatic energy metabolism were also observed to 
be perturbed by PB treatment. The latter was only observed within the mouse dataset 
at the different time points investigated. The gene encoding PXR, NR1I2 was only 
observed to be up-regulated in the mouse at 4 days, this result is consistent with 
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evidence from experimental studies in the mouse [178] which shows that PXR is up-
regulated in response to PB exposure.  
 
The gene encoding CAR was down-regulated at day 2 in contrast to PXR which was 
up-regulated at day 4. The genes identified within the PXR/RXR activation 
toxicological list were predominantly those involved in hepatic energy metabolism.  
 
Key genes known to be involved in hepatic energy metabolism that were perturbed by 
PB treatment within this Tox List included FOXO1, G6PC, HNF4A and PRKARIA. 
Experimental studies show that the pancreatic hormones insulin and glucagon, control 
the amount of energy available in the liver through the regulation of glucose-6-
phosphatase (G6PC) and phosphoenolpyruvate carboxykinase (PCK1/PEPCK1) 
which control the rate limiting steps in glucose and lipid metabolism [67, 179, 180]. 
The down-regulation of the gene G6PC (mouse day 30) is consistent with 
observations from studies carried out in using mouse hepatocytes [181, 182]. 
 
Insulin decreases the production of glucose by repressing the transcription of G6PC 
and PEPCK1 genes. This brings into play the forkhead transcription factor (FOXO1) 
which is able to activate insulin response sequence (IRS) bearing genes such as G6PC  
and PCK1, in the absence of insulin [67, 183, 184].  
 
Both CAR and PXR have since been shown to bind directly to FOXO1 thereby 
preventing its interaction with G6PC. It has been suggested that this crosstalk with the 
same gene is the underlying mechanism for the repression of the G6Pase in response 
to PB and the resulting repression of gluconeogenesis, an observed effect following 
exposure to PB [67]. A study carried out by Kodama et al [185] demonstrated that 
both CAR and PXR repressed FOXO1-IRS activity in cotransfected HepG2 cells after 
exposure to PB for 48 hours. 
 
In addition to the cross-talk between PXR and CAR to interact with the insulin 
responsive transcription factor FOXO1 to prevent gluconeogenesis, PXR has also 
been shown to interact with cAMP response element binding protein (CREB). Since 
G6PC contains CRE, interaction with PXR leads to the repression of glucagon [186].  
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Other key genes observed in this Tox List observed to be down-regulated at Days 4 
and 30 in the mouse were the nuclear factor hepatocyte nuclear factor 4, α (HNF4A) 
and the peroxisome proliferator-activated receptor γ co-activator 1 alpha (PRKAR1A) 
which were also down regulated in the mouse at Days 2, 4 and 30. Studies show that 
PRKAR1A which is activated by glucagon, binds to and co-activates HNF4α 
mediated transcription. Activation of CAR and/or PXR has been shown to lead to the 
dissociation of PRKAR1A from HNF4α resulting in the repression of G6PC and 
PCK1 (PCK1 was observed to be down regulated at Days 2, 4 and 30 in the mouse 
within the CAR/RXR Tox List). Ueda et al [67] investigated the effects of PB using 
CAR knockoutmice and observed that exposure of wild type mice after 12 hours of 
exposure to PB resulted in the repression of the gene PEPCK1 (among others) genes 
involved in glucose synthesis.  Kodama et al [185] also observed a decrease of 
PEPCK1 mRNA in CAR wild type mice after chronic treatment with PB (32 weeks).  
Both CAR and PXR therefore repress glucose production by directly binding to the 
transcription factors that activate genes involved in gluconeogenesis [67, 187]. 
 
It is important to note that insulin has been shown to reduce PB induction of CYP2B 
in rat hepatocytes [188]. The levels of CYP2B, CYP3A and CYP4A have also been 
shown to increase in diabetic rats and mice and return to normal levels after treatment 
with insulin [189]. It has been suggested that the repression of gluconeogenesis may 
actually serve the purpose of increasing the capability of hepatic cells to metabolise 
foreign compounds. Repression of G6PC leads to increased levels of hepatic glucose-
6-phosphate, an essential component of the pentose phosphate pathway. Glucose-6-
phosphate is converted to ribose-5-phosphate by glucose-6-phosphate dehydrogenase, 
generating NADPH in the process. It is therefore thought drug-induced CAR and 
PXR activation (as in the case of PB treatment resulting in repressed gluconeogenesis) 
may help hepatic cells maintain high enough levels of NADPH required for drug 
metabolism [67, 180]. 
 
Oxidation of fatty acid and ketogenesis occurs in response to low blood glucose to 
provide hepatic tissues with extra ketone bodies in the liver. The key enzymes 
involved in this process of β-oxidation and ketogenesis are carnitine 
palmitoyltransferase 1A (CPT1A) and mitochondrial 3-hydroxy-3methyl-glutarate-
CoA synthase (HMGCS2). Stearoyl-CoA desaturase 1 (SCD1) is the key enzyme 
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involved in the synthesis of unsaturated fatty acid and is regulated by glucose and 
fructose. The transcription factor FOXA2 activates both CPT1 and HMGCS2, 
however, in the presence of insulin both genes are repressed through the inactivation 
of FOXA2. Insulin has also been shown to increase the transcription of SCD1 through 
the activation of the sterol regulatory element-binding protein (SREBP). Studies 
carried out in mice have shown that the mRNA levels of CPT1A and HMGCS2 are 
down-regulated in wild-type mice but not in PXR-null mice. The opposite effect was 
observed for SCD1 which was shown to be up-regulated in wild-type mice but not in 
PXR-null mice. The drug-activated PXR was shown to bind directly to FOXA2 
thereby preventing its binding with CPT1A and HMGCS2. PXR activation was also 
shown to increase the transcription of SCD1. It is therefore thought that although 
mechanisms may differ, drug-activated PXR mimics the behaviour of insulin by 
repressing hepatic metabolism through the reduction of β-oxidation and ketogenesis 
and results in an increase of triglycerides. The pathway for the energy metabolism is 
depicted in Figure 5.2 [180].  
 
The key genes involved in lipid metabolism discussed above were identified within 
the PXR/RXR Tox List. CPT1A was down-regulated in the mouse at Day 2 while 
HMGCS2 was also down-regulated in the mouse at Days 2 and 30. SCD1 was 
however observed to be down-regulated at Day 1in the rat and also at Day 30 in the 
mouse and at Day 3 in human hepatocytes. This result was inconsistent with the 
experimental results described above. 
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Figure 5.2: Energy Metabolism in the Fasting Liver 
 
 
Source: Konno et al., 2008
 
 
 
The key genes discussed above were also identified within other Tox Lists in IPA. 
CPT1A was also grouped within genes involved in the LPS/IL-1 Mediated Inhibition 
of RXR Function, Hepatic Cholestasis and Mitochondrial Dysfunction. SREPF1 
which is involved in the activation of SCD1 was observed to be down regulated at 
Day 1 in the rat within the LPS/IL-1 Mediated Inhibition of RXR Function and 
Hepatic Cholestasis Tox Lists. The down-regulation of the latter gene by PB may 
explain why SCD1 was also observed to be down regulated in the rat and mouse.  
 
 
5.6.1.3  Inhibition of RXR 
 
Significant numbers of genes were observed to be involved in the LPS/ IL-1 Mediated 
Inhibition of RXR Function Tox List and Canonical pathway across the three species. 
Lipopolysaccharide (LPS) found on the outer membrane of gram-negative bacteria is 
known to bind to the CD14/TRL4/MD2 complex which promotes the secretion of 
pro-inflammatory cytokines [190]. Inflammation down-regulates the expression of 
hepatic genes involved in different physiological processes collectively known as 
negative acute phase response. Beigneux et al [191] demonstrated that mice injected 
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with LPS led to an 80% decrease in the level of mRNA for CYP2B10 after 4 hours, 
the effect was sustained for at least 16hrs and resulted in a 95% decrease in mRNA 
level compared to controls. Similarly the mRNA levels for CYP3A was markedly 
reduced by 99% (compared to controls) by 16hrs following treatment with LPS.  
 
Many of the genes involved in acute phase response are regulated by RXR. In 
response to the pro-inflammatory cytokines RXR undergoes a JNK-mediated CRM-1 
dependent nuclear export that leads to the reduction in the levels of nuclear RXR. 
When this occurs, the knock on effect is the reduction of the expression of hepatic 
transport proteins (e.g. ABC), metabolising proteins (e.g. CYP, GST) and 
biosynthesis (CYP7A1), leading to impaired metabolism, transport/ and or 
biosynthesis of lipid, cholesterol, bile acid and xenobiotics [192]. Beigneux et al [191] 
observed a 90% and 76% decrease in mRNA levels for both CAR and PXR 
respectively at 16 hours following  treatment with LPS. The authors observed that this 
reduction also coincided with a 76% and 81% decrease in the mRNA level of RXRa 
after 4 and 16 hours respectively following LPS treatment.  
 
Evidence for LPS/IL-1-mediated inhibition of RXR, included the observed up 
regulation of the CD14 gene in the human experiment. RXRA was down-regulated in 
the mouse at Day 2 and at Day 3 in the human experiment in addition to CYP7A1 
observed to be down-regulated in the rat at Day 1. Finally, members of the acyl CoA 
synthase long chain family (ACSL) that play a key role in lipid biosynthesis and fatty 
acid degradation, were all down-regulated from Days 2 to 30 in the mouse and at Day 
5 in the rat (ACSL1).   
 
A significant number of genes were categorised by IPA to be associated with the 
LPS/IL-1 mediated inhibition of RXR function pathway, to suggest the inhibition of 
RXR. The observed up regulation of metabolising enzymes (particularly the target 
genes for CAR and PXR; CYP2B and CYP3A) as observed in other pathways, 
suggests that this pathway is not relevant and does not illustrate a real effect from PB 
exposure among the datasets examined. In addition, AHSG (grouped with genes 
involved in the Negative Acute Phase Response Proteins Tox List) which exhibits 
pro-inflammatory effects by playing a key role in the regulation of cytokine 
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expression was also down-regulated in the mouse and human dataset at Days 2 and 3 
respectively.  
 
The evidence from the latter suggests that although a significant number of genes 
were shown to be involved in the LPS/IL-1 mediated inhibition of RXR function, the 
inhibition of RXR via this pathway clearly did not affect the ability of RXR to bind 
with either CAR or PXR. The up-regulation of target genes for PXR and CAR was an 
indication that these nuclear receptors were able to bind with RXR to induce the genes 
involved in the various physiological processes.  The observations from the genes 
categorised in this pathway illustrates the importance of interpreting the biological 
significance of the effects observed at both the individual gene level as well as at the 
pathway level. It also highlights the importance of not restricting the focus of the 
biological interpretation to only “top pathways/Tox Lists” as indicated by the level of 
assigned statistical significance.  
 
 
5.6.1.4  Evidence for Cell Proliferation and Growth 
 
Numerous signalling pathways associated with cellular growth and proliferation were 
affected by exposure to PB across the three species (see Appendix 4.1D). The genes 
involved in these pathways were also grouped within different Tox Lists that included 
PPARα/RXR Activation, G2/M Transition of the Cell Cycle, G1/S Transition of the 
Cell Cycle, Mechanism of Gene Regulation by Peroxisome Proliferators via PPARα, 
TGF-β Signalling, Aryl Hydrocarbon Receptor (AhR) Signalling and p53 Signalling.  
 
Key genes such the retinoblastoma-like 1, (RBL1/p107) and retinoblastoma-like 2 
(RBL2/ p130), D-type cyclins (CCND1, CCND3), cyclin-dependent kinase 4 (CDK4) 
and E2F transcription factors (E2F1, E2F2, E2F3, E2F4, E2F6), were observed within 
the G1/S Transition of the Cell Cycle Tox List. The latter genes have been associated 
with playing key roles in the regulation of cell proliferation.  
 
The D-type cyclins are known to interact with the kinases, CDK4 and CDK6 leading 
to the initiation of phosphorylation of the Rb family members p107 and p130 thereby 
preventing their interaction with the E2F transcription factors. The phosphorylation of 
 156 
 
p107 and p130 leads to the accumulation of the E2F transcription factors, particularly 
E2F1, E2F2 and E2F3 which are involved in the transcription of many genes involved 
in DNA replication and cell cycle progression. An additional consequence of the 
phosphorylation of p130 is the disruption of the formation of complexes with E2F3b, 
E2F4 and E2F5 found in quiescent cells which act as transcriptional repressors of S 
phase genes [193, 194].  
 
It is postulated that the deregulation of these key genes and others that encode 
proteins involved in this RB/E2F pathway which would result in the loss of the 
tumour suppressor protein Rb or over expression of D-type cyclins may be an 
important key step in the development of tumours [194, 195]. With the exception of 
RBL2 (p130), the key genes discussed above were all up-regulated in the mouse 
experiment at Day 2 within the G1/S Transition of the Cell Cycle Tox List. E2F2 and 
E2F3 were also observed in the mouse experiment at 30 days. The results observed 
here are also corroborated by observations in experimental studies. A two week in-
vivo study by Kinoshita et al [92] showed that rats administered with 0.05% PB led to 
the induction of cyclin D1 (CD1/ CCND1) and p21
WAF1/Clip1
 mRNA expression. The 
authors observed the highest induction of CD1 mRNA at day 4 of the experiment; this 
preceded the highest elevation of proliferating cell nuclear antigen (PCNA) indices 
observed on day 6 of the experiment. The induction of CD1 was followed by the 
induction of p21
WAF1/Clip1
 mRNA expression at day 6 during the significant increase of 
PCNA and prior to the observed elevation of 8-hydroxy-2‟-deoxyguanosine (8-OHdG) 
(a known marker for oxidative DNA Damage) and apoptosis.  
 
 
5.6.1.5  Evidence for the Inhibition of Apoptosis 
 
Within the Canonical Pathways produced for the different datasets, numerous 
signalling pathways were identified for apoptosis. Among the signalling pathways 
identified, the AhR signalling pathway was observed to be common across the dataset 
obtained from the 3 different species, and was observed to be particularly perturbed in 
the mouse Day 2 dataset.  
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The Anti-Apoptosis Tox List identified only eight genes that were associated with 
anti-apoptotic function. Only three of these genes BAG33, BIRC5, TMX1, known to 
play a role in the inhibition of apoptosis were observed to be up regulated in the 
mouse.  
 
As the results observed from the Canonical Pathways implicated the role of the AhR 
Signalling in apoptosis, some of the key genes observed to be up-regulated and 
identified to play a role in the inhibition of apoptosis within Tox List and Canonical 
Pathways included: CCND1, CDK4, CHEK1, MYC and MDM2 (as observed in the 
mouse data).  In addition TGFBR2 was observed to be up-regulated in the mouse 
experiments carried out at Days 2, 4 and 30 while SMAD4 was down regulated at 
mouse Day 4 within the TGF-β signalling Tox List.  
 
The ligand-activated transcription factor aryl hydrocarbon receptor (AhR) has been 
shown to be involved in the mediation of a wide range of toxicological responses 
through the activation of multiple signalling pathways upon exposure to xenobiotic 
chemicals. Evidence for AhR -mediated inhibition of apoptosis and cell-cycle 
progression has been obtained from studies carried out using 2,3,7,8-
Tetrachlorodibenzo-p-dioxin (TCDD) (reviewed in Marlowe & Puga [161]).  The 
effect of AhR on different signalling pathways results from its induction on genes that 
include MYC, MYB and members of the FOS and JUN family. Tumour promotion 
was not observed in AHR-null rats treated of with TCDD, suggesting that AhR was 
required for this effect [161, 196]. In addition, TCDD was shown to modulate MDM2 
protein levels which have been shown to negatively regulate p53 by promoting its 
degradation. It has been suggested that AhR may crosstalk with the p53 signalling 
pathway initiated by the activation of MDM2 by tumour promoters like TCDD, 
resulting in a reduced p53 response to deal with DNA damaging agents through either 
arrest of the cell cycle or apoptosis [194, 196] MDM2 was observed to be up-
regulated at Day 2 in the mouse and was grouped within genes associated with both 
p53 signalling and AhR Signalling pathways and Tox Lists. 
 
Evidence for the role of AhR-mediated inhibition of apoptosis as a result of PB 
exposure is however not corroborated by the experimental evidence. In fact, PB has 
been shown to have a low binding affinity for the AhR although it has been shown to 
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induce expression of CYP1A2 (an AhR target gene) in mouse liver [197]. The latter 
effects have been observed to occur in both wild type and AhR knockoutmice, which 
suggests that PB induces CYP1A2 independently of the AhR [197]. In addition, 
Nelson et al [162] observed a 2-fold increase in the mRNA levels of MDM2 in rats 
after single or repeated treatment (5 days) with PB this was in contrast to observations 
in the mouse where PB did not induce MDM2 mRNA in the liver. The authors did not 
observe any changes in other p53-dependent genes and concluded that the observed 
increase in hepatic protein levels of MDM2 demonstrated the nuclear localisation of 
MDM2 and confirmed its interaction with P53 resulting in its degradation. Indeed, the 
authors observed a 35% decrease in p53 protein levels after 5 days of PB treatment. 
The mechanism by which PB induces MDM2 is yet to be determined [162].  
 
Induction of the transcription regulator MYC plays a key role in cell proliferation 
control through the direct transcriptional activation of G1 cyclin D1 and D2 as well as 
the cyclin D partner CDK4. Over-expression of MYC has been shown to induce E2F 
binding of DNA. This activity is thought to be the result of the MYC mediated 
induction of the cyclin D/CDK4 which results in the phosphorylation of and 
subsequent inactivation of members of the Rb family leading to the accumulation of 
E2F [194, 198]. 
 
Another gene that plays a key role in the regulation of cell proliferation is the 
transforming growth factor-β (TGF-β) which is a potent cell growth inhibitor and 
inducer of apoptosis. TGF-β is initiated by the binding of the ligand to a 
heterodimeric complex of two transmembrane receptors namely TGF-β receptor type 
I (TGFBR1) and TGFBR2 both of which possess serine/threonine kinase activity. In 
the presence of a ligand, the two transmembrane receptors interact with each other 
resulting in the phosphorylation of TGFBR1 by TGFBR2. This event triggers the 
phosphorylation of the SMAD3 which forms a heterodimeric complex with SMAD4 
in the cytoplasm and later translocates to the nucleus where it represses c-Myc [199].  
 
The observed up-regulation of TGF-β and MYC were consistent with in-vivo studies 
in the mouse. The co-expression of c-Myc and TGF-β frequently expressed in human 
tumours including hepatocellular carcinoma [200] has been studied extensively. 
Studies carried out to investigate the synergistic effects of c-myc and TGF-α  using c-
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myc/ TGF-α double transgenic mice showed that co-expression of c-myc and TGF-α 
resulted in increased cell proliferation and a reduction of apoptosis in hepatic pre-
neoplastic cells postulated to be the result of  the disrupted the Rb/E2F pathway [201-
203]. Sanders & Thorgeirsson [201] showed that administration of PB in mice 
resulted in a decrease in TGF-β1 accompanied by a decrease in apoptosis. Dramatic 
increases in apoptotic activity were observed upon the removal of PB from the diet. 
These results, were supported by observations in studies carried out by Santoni-Rugiu 
et al [203], showed that the induction of c-Myc (presumably as a result PB treatment) 
disrupts cell cycle progression in the liver leading to the TGF-β acting as survival 
factor in hepatocytes. The reduced apoptotic activity therefore appears to be due to the 
increased levels of c-Myc and E2F and the induction of TGF-β1. It has been 
suggested that under these conditions, PB and TGF-β act via a common pathway to 
promote cell survival by inhibiting apoptosis leading to accelerated cell growth.  
 
 
5.6.1.6  Evidence for Cellular Stress (Oxidative Stress) 
 
The Tox List and Canonical pathway for Oxidative Stress Response Mediated by Nrf2 
was observed across all species to be significantly affected by PB treatment, the 
highest percentage of perturbed genes were however observed from the mouse dataset 
at day 2. 
 
In response to PB treatment, various cytoprotective enzymes involved in mechanisms 
of detoxification to reduce oxidative stress were perturbed and observed to be 
predominantly up-regulated across all datasets investigated. Antioxidant response has 
been shown to require the involvement of four key components that consist of NF-E2 
related factor 2 (NFE2L2/ NrF2), Kelch-like ECH-associated protein 1 (KEAP1) 
small musculoapo-neurotic fibrosarcoma (Maf) proteins (MAF & MAFG) and a cis-
acting enhancer known as the antioxidant response element (ARE) which is found in 
the promoters of the major detoxifying enzymes; glutathione S transferase A2 
(GSAT2) and NADPH: quinine oxidoreductase 1 (NQO1) [159, 160, 204]. All four 
components were affected by PB treatment and the four genes NQO1, KEAP1, 
NFE2L2, and MAFG were observed within the Tox List obtained from analysis 
carried out in the mouse and human datasets.  
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The transcription factor, NrF2 is an unstable protein with a half-life of approximately 
15 minutes [159]. It is located in the nucleus and is able to bind and activate the AREs 
to enable expression of the metabolising enzymes. NrF2 is constitutively expressed in 
the cell and is able to translocate directly to the nucleus. Under homeostasis, it is 
stabilized and targeted for proteasomal degradation through its interaction with 
KEAP1. KEAP1 thus represses NrF2 in a redox-dependent manner under homeostasic 
conditions [205].  
 
Under conditions of oxidative stress, the interaction between NrF2 and KEAP1 is 
antagonized, leading to the accumulation of NrF2. Although the mechanism of the 
disrupted NrF2-KEAP1 interaction is not fully understood, it is thought that the 
dissociation is likely to be due to mechanisms that either prevent or reduce access of 
KEAP1 to NrF2, by oxidation of key –SH groups on KEAP1 [159]. The accumulation 
of NrF2 in the nucleus is enabled through its stabilisation by the interaction with 
members of the small MAF family of transcription factors [204]. Li et al [160] carried 
out an in-vitro study using human cells and showed that NrF2 formed a heterodimer 
with MAFG. The MAFG gene has been shown to possess an ARE enhancer in its 
promoter region [206].  The stabilization of NrF2 through the formation of the NrF2-
MAFG heterodimer therefore amplifies NrF2 signalling [160] to enable the increased 
expression of ARE-driven genes such as NQO1.  
 
The gene encoding NrF2 (NFE2L2) was observed to be up-regulated in the mouse at 
Day 2 and also in the human experiment at Day 3. KEAP1 expression was only up-
regulated in the mouse dataset at Days 2, 4 and 30. Up-regulation of the ARE-driven 
gene NQO1 was observed in the rat experiments at Days 1 and 5 and also in the 
mouse experiment at Day 2. Increased expression of the MAFG gene was only 
observed in the human experiment, at Day 3. 
 
The observed up-regulation of KEAP1 in the mouse experiments was consistent with 
experimental observations of the transcriptional expression of KEAP1 in response to 
oxidative stress. A study carried out by Pi et al [207] to examine the effect of arsenic 
(a potent inducer of oxidative stress) showed marked increases of KEAP1 at both the 
transcriptional and protein levels after treatment of human cells with arsenic. The 
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increase in KEAP1 expression levels also occurred within the same time-frame as the 
observed maximum NrF2 production/nuclear accumulation and preceded the NrF2 
activation of NQO1.  
 
Although both NrF2 and MAFG were observed to be up-regulated in the human 
experiment the ARE-driven gene NQO1 was not observed to be differentially 
expressed. This was in contrast to the mouse experiment, which showed that NQO1, 
KEAP1 and NrF2 were all up-regulated. The latter suggests that the observed 
transcriptional changes were in response to dealing with cells under oxidative stress. 
The fact that NQO1 was not increased in the human experiment raises the question of 
whether the NrF2-ARE signalling pathway was indeed relevant in the human 
experiment. It is not possible to tell in the case of the human hepatocytes whether the 
observed changes are secondary to the toxic effect of PB exposure. 
 
A two-week study in rats carried out by Kinoshita et al [92] showed that PB 
administered at a high dose induced oxidative stress in the rat hepatocytes. The 
authors investigated the relationship and mechanisms involved between the induction 
of oxidative stress, cytochrome P-450 and hydroxyl radicals and the formation of 8-
OHdG. Kinoshita et al [92] measured the formation of oxidative stress using electron 
spin resonance (ESR) which showed statistically significant formation of OH
.
 by Day 
4 of PB exposure and reached a maximum by Day 8 of exposure (82.1 ± 6.0% 
p<0.001). A time-dependent significant elevation of total P-450 content and protein 
levels of CYP2B1/2 and CYP3A2 were also observed. The activity levels of the 
enzymes were also observed to increase rapidly until Day 8 at which point the levels 
remained constant, similar to the levels of OH
.
. The authors measured the effect of the 
observed oxidative stress on DNA damage by measuring the levels of 8-OHdG by 
immunohistochemistry. Statistically significant increases in 8-OHdG-specific 
immunoreactivity were detected from Day 4 following treatment with PB (this effect 
was observed to be reversible). The authors noted that the observed accumulation of 
8-OHdG in the nucleus and elevated levels of CYP2B1/2 and CYP3A2 in the 
cytoplasm were evidence that the observed increase in DNA damage post PB 
exposure in rat was a direct result of the production of oxidative stress. The authors 
suggested that this observed effect was related to the increase in protein and activity 
levels of the 2 P-450 isoenzymes, although this was not demonstrated unequivocally 
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by the authors. It should be noted however that neither KEAP1 or NRf2 changes were 
observed in the rat dataset examined here. 
 
 
5.6.2  Evidence for Hepatocellular Carcinoma (HCC) – Comparison with  
Reference Gene Lists 
 
The IPA Toxicity function, which groups the DEGs according to clinical pathology 
endpoints, enabled the overview of the dataset within the context of the toxicological 
endpoints. The Tox functions that could be associated with known key events in PB 
induced hepatocarcinogenesis included: liver proliferation, hyperplasia/hypertrophy, 
necrosis/cell death and hepatocellular carcinoma. The genes identified to be part of 
the selected Tox functions were compared with genes obtained from the IPA 
Knowledge Base for their association with the relevant toxicological end-points. The 
search within the IPA Knowledge Base identified large reference gene lists for liver 
proliferation (75 genes), cell death (65 genes) and HCC (107 genes). This was in 
contrast to the six reference genes obtained for hyperplasia/ hyperproliferation and 
hypertrophy (3 genes). The low numbers of genes obtained for the latter was most 
likely due to the focus on identifying liver only related genes.  
 
Cross comparison of the different datasets with the IPA reference genes showed that 
for most of the end points selected, particularly for liver proliferation, cell death and 
HCC, only the data from the mouse datasets (genes combined from all end points 
investigated in the mouse) showed some correlation with the IPA reference genes. For 
liver proliferation 25% of the IPA genes were observed within the mouse dataset. 
 
With regards to the IPA genes identified for liver proliferation, cell death and HCC, 
the most meaningful correlations were obtained by comparison of the reference gene 
lists with the mouse data, compared to 0.01% in the human dataset and 0% in the rat. 
38% of the IPA genes identified for cell death were observed in the mouse compared 
to no genes in the rat and human dataset. Finally, for HCC, 11% and 0.04% of the 
IPA genes were identified in the mouse and rat datasets respectively.  
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The above exercise was intended to identify IPA derived reference genes that were 
grouped according to biological functions that could be associated with key events 
that are related to the MOA for PB induced hepatocarcinogenesis. It was hoped that a 
comparison of the Tox function results (obtained from the Core Analysis of the 
different datasets) with the groups of genes categorised in IPA to be associated with 
the relevant key events would provide a better indication of the extent to which the 
datasets under investigation identified the same genes as those identified by the IPA 
Knowledge Base.  
 
The fact that meaningful comparisons could only be made from the mouse dataset 
highlighted some of the limitations (e.g. reliability of the datasets) associated with the 
rat and human dataset investigated. It also highlighted some of the problems 
associated with the categorisation of genes within biological functions. As illustrated 
by the example for the genes identified from the IPA Knowledge Base for liver 
hypertrophy (which identified only 3 genes), it is not always possible to identify genes 
that are associated with common pathways for the key events. In addition the 
identification of CYP1A2 as being associated with liver hypertrophy was somewhat 
odd as this gene isn‟t necessarily associated with liver hypertrophy and its induction 
may be more of a reflection of a more general response to the exposure to a foreign 
compound. The fact that liver hypertrophy which has been demonstrated in 
biochemical studies to be a real key event for PB induced hepatocarcinogenesis but 
was not represented among the pathway changes observed in IPA indicated that while 
many of the genes that are associated with liver hypertrophy were probably present 
within the dataset investigated, they may have been categorised under different 
biological functions and so they were not identified as a significant pathway.  
To enable a more objective comparison of these datasets, the DEGs obtained from the 
3 species were compared to genes that had been identified to be associated with HCC 
and biomarkers that had been identified to show predictive capability for non-
genotoxic MOAs. The comparison of all the datasets from the 3 species with the 
genes obtained from the 3 studies [154-156] showed  that 1 of the HCC associated 
genes was identified from the human dataset but overall, none of the reference genes 
or biomarkers were observed across the different species. This result was somewhat 
surprising considering PB is a classic non-genotoxic chemical and PB was also 
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selected as a reference compound by Fielden et al [154] to verify the MOAs of their 
test compounds using clustering methods.  
By their own admission, Fielden et al [154] acknowledge that the accuracy of 
prediction of their identified gene signatures for nongenotoxic hepatocarcinogens are 
only as good as the accuracy of the results being modelled. The latter is especially 
true of the different datasets investigated here particularly for the rat datasets for 
which significantly lower numbers of DEGs were obtained when compared with those 
obtained from the mouse and human datasets. The experimental variability between 
the different datasets is also likely to have had a significant impact on the results 
obtained from the different data sources. As such IPA was used to run a comparison 
analysis between the DEGs obtained from the data at the different time points 
investigated for each species. No genes were found to be common between the rat, 
mouse and human datasets or between the rat and mouse datasets. The gene, UDP 
glucuronosyltransferase 2 family (UGT2B4) was the only molecule found to be 
common in the combined rat datasets. In contrast, 35 genes were found to be common 
among the combined mouse datasets. A full list of the genes and the results of a 
functional analysis is provided in Appendix V. 
 
A comparison of all the datasets investigated in the mouse identified 35 common 
genes from the four time-points investigated. A Core Analysis run on the identified 35 
genes enabled the categorisation of the genes according to the different Tox Lists, Tox 
Functions and Canonical pathways as shown in Figures 5.3 to 5.5. As expected, the 
results showed that the genes are associated with a wide range of pathways and 
toxicities as already discussed above.  
 
While the pathways and Tox Lists identified are characteristic of compounds like PB, 
it would be premature at this stage to refer to these 35 genes as biomarkers for PB 
induced toxicity. However, the fact that the analysis of these genes show that they are 
involved in a cross section of toxicities that are indicative of a wider range of 
functions associated with for example CAR/PXR activation, as observed from the 
analysis of the full datasets is reassuring evidence for the methodology applied in this 
investigation.  
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Figure 5.3: Tox List Analysis of genes common between all mouse datasets. 
 
 
 
 
NB: 
In IPA the significance of the association between the dataset and the different 
pathways were measured in 2 ways:  
 
1) Fisher‟s exact test was used to calculate a p-value determining the probability that 
the association between the genes in the dataset and the pathway is explained by 
chance alone (left Y-axis). 
 
2) A ratio
16
 of the number of molecules from the dataset that map to the pathway 
divided by the total number of molecules that map to the pathway (right Y-axis) [153]. 
 
 
 
 
 
 
 
 
 
 
                                                 
16
 The ratio is the number of molecules in a given pathway that meet the cut criteria divided by the 
number of molecules that make up that particular pathway. 
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Figure 5.4: Canonical Pathway Analysis of genes common between all mouse datasets. 
 
 
 
 
 
Figure 5.5: Tox Function Analysis of genes common between all mouse datasets. 
Tox function 
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5.6.3 Discussion of Applied Methodology: Application of evidence from 
transcriptomics analysis to MOA analysis – learning points and 
recommendations 
 
 
One of the main challenges of this transcriptomics analysis was on the presentation of 
the result output produced by IPA and the presentation of the information within the 
context of MOA analysis.  
 
The approach taken for the analysis of the results obtained from IPA is summarised in 
Figure 5.6 below. A key learning point from this investigation was that information 
obtained from the different result outputs produced by IPA could not be viewed or 
interpreted in isolation. The Core Analysis carried out in IPA enabled the assessment 
of the signalling, metabolic pathways, molecular networks and biological processes 
that were most significantly perturbed in the PB datasets (based on the DEGs 
uploaded to IPA) investigated. The evaluation of the results focused on the analysis of 
the canonical pathways, Tox Lists and Tox functions.  IPA suggest that the results 
produced are intended to facilitate a better understanding of the relative impact of the 
gene changes within the context of well characterised pathways (descriptions of the 
different result outputs can be found in chapter 4, section 4.3). The collective 
evidence from the three result outputs will be referred to as simply as “pathways” for 
the ease of discussion 
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Figure 5.6: Strategy for Pathway and Network Analysis of Transcriptomics Data for 
MOA Analysis.  
 
Analysis of  DEGs using 
IPA™ or similar software
Identification of pathways 
that are indicative of key 
biological events or that 
support already known  key 
events for a MOA
Biological relevance of 
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Correlation of transcriptional 
changes with results from  
experimental studies
Literature search to identify 
key genes known to be 
associated with the 
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Significance of affected pathways 
or functions 
Canonical 
Pathways
Tox 
Function
Tox List
Supporting evidence for the 
identification of key events  
for MOA analysis or risk 
assessment 
Results output: 
“Pathways”
Chemical X:
Obtain background 
knowledge about the key 
events in the MOA for the 
end point of interest
 
 
 
 
5.6.4  Identification of Toxicologically Informative Pathways 
 
Regardless of the assigned statistical significance, pathways were selected for further 
analysis on the basis of plausible mechanisms and MOAs for hepatoxicity. An 
important factor for the consideration of the biological significance of a pathway of 
interest is the extent to which the genes identified to make up a pathway are perturbed 
by the compound under investigation.  
The CAR/RXR Activation pathway for example was heavily perturbed by PB 
treatment as illustrated by almost 80% of the genes being perturbed (mouse Day 2 
experiment). This observed effect as a result of PB treatment was an indication that 
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the effect on this pathway was extremely unlikely due to chance alone. Although the 
consideration of data from other species datasets investigated showed that the same 
pathway was affected to a lesser extent, the fact that similar target genes (e.g. 
CYP2B6, RXR and other metabolising enzymes) were observed to be affected across 
all species indicated that the involvement of less genes from the rat and human 
datasets on this pathway may be due to the lower number of DEGs available for 
analysis more than the reduced impact on this pathway.  
The effect of a compound on a pathway, as indicated by the number of affected genes 
within that pathway, is a good indication that the pathway is affected. However that is 
not to say that this pathway would play a critical biological role in the toxicity but it 
does provide a good indication of pathways that should not be ignored and that should 
be considered for further investigation. In the face of overwhelming evidence such 
observations, particularly from unsupervised analysis, can be used to develop 
hypotheses about a compound‟s MOA.  
 
 
5.6.5 Identification of Key Genes within a Pathway that are Indicative of 
Key Biological Processes for a MOA 
 
 
Owing to the sheer volume of genes involved in some of the pathways investigated 
across all the datasets examined, it was impossible to consider all the genes 
individually. Instead, the focus was placed on some of the key genes within the 
pathways that were known to co-ordinate or be involved in key biological processes. 
 
For the purposes of this risk assessment led exercise, the identification of key genes 
involved focusing on signalling pathways within the identified Canonical Pathways 
and Tox Lists that were observed as being associated with the biological processes of 
interest and key events postulated to be part of PB‟s possible MOA e.g. CAR 
activation, apoptosis, cell proliferation, hypertrophy or oxidative stress. For example, 
PXR/RXR Activation was observed as one of the Canonical Pathways and separately 
as a Tox Lists. The genes involved in both these pathways were observed to be highly 
perturbed across the different time points investigated across the three species. This 
observation was considered to be significant as there has been considerable 
documentation on the effects of PB on nuclear receptors, most notably CAR and PXR.  
 170 
 
 
As both CAR and PXR were identified within the Tox Lists, the search within the 
literature focused on the identification of key genes regulated by these two nuclear 
receptors upon exposure to PB. The search enabled the identification of mechanistic 
studies that provided evidence for the cross-talk between PXR and CAR and the 
induction of key genes involved in the regulation of hepatic metabolism. The key 
genes identified by the literature were then examined to determine whether the same 
genes were observed in the different time points investigated within the studied 
datasets and whether the perturbed changes observed were consistent with the 
evidence suggested by the literature.  
 
 
 
5.6.6 Biological Relevance of Transcriptional Changes Observed for Key 
Genes; Consideration of Experimental Evidence 
 
 
Once the key genes had been identified, an important factor for consideration was the 
biological relevance of the observed transcriptional changes. In general it is important 
to consider studies that have investigated the genes of interest using the compound of 
interest or a compound with a similar MOA. Where available it is helpful to correlate 
transcript levels of genes of interest and also consider the protein levels for the 
corresponding genes to establish weight of evidence. While it may not always be 
possible to find results for the compound of interest, a search for results on the basis 
of similar pathways, endpoints (or effects from other published studies from 
compounds with similar MOAs) can sometimes prove useful. In addition, it is often 
useful to obtain evidence on mechanistic studies that have sought to investigate the 
toxicological effect in relation to the key event for the compound under investigation. 
This was illustrated with results compiled for oxidative stress in which the transcript 
levels for the gene KEAP1 were obtained from studies carried out using arsenic. 
Although no evidence for the induction of KEAP1 by PB was found in the literature, 
it was possible however to obtain mechanistic studies investigating the effect of PB 
on oxidative stress. Mechanistic studies carried out by Kinoshita et al [92] showed 
that high levels of PB in the rat induced DNA oxidative base modifications in rat 
hepatocytes via the generation of oxidative stress.  
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The pathway for Oxidative Stress Response Mediated by NrF2 (as observed from the 
Canonical Pathways and Tox Lists) was significantly perturbed in the human 
experiment, similar to observations in the mouse. Although the key genes identified 
from the literature were common between the two species, the expression of NQO1 
did not change in the human experiment. Therefore, regardless of whether the other 
key genes were observed in the human, the fact that one of the target genes for this 
pathway did not show a change in expression, led to the biological relevance of this 
observed pathway being questioned in the human experiment. A search within the 
literature however identified  an experiment carried out by Lambert et al [208] which 
showed that NQO1 is up-regulated in human hepatocytes following exposure to PB. 
This study raised issues of consistency among different toxicogenomics studies; it is 
clear that different study approaches will inevitably affect the repeatability of results 
and potential reliability of the output from one study. It also raises the issue of the 
extent to which any one dataset can be used to form conclusions about potentially 
significant pathways (as informed by the presence of perturbed key target genes).  
Similarly, results obtained from the pathway changes observed in the three species 
pointed to a potential role for the AhR in the regulation of apoptosis related events. 
Although evidence for the role of AhR for the mediation of the observed effects of 
inhibition of apoptosis was obtained from mechanistic studies carried out in 
compounds such as TCDD; mechanistic evidence in studies carried out with PB 
showed that it has a low binding affinity for the AhR. In this situation, although the 
results obtained in IPA pointed to a potential role of AhR in the mediation of this key 
event, mechanistic evidence obtained from the literature showed that while PB 
induced the same key genes as those mediated by hAHR, the inhibition of apoptosis 
by PB was achieved via a different mechanism, although the manner in which it does 
this is still unknown [162].  
While it is important to pay close attention to pathways that are shown to be highly 
perturbed by the compound under investigation, inferred pathways should be verified 
with evidence obtained from mechanistic studies of the chemical of interest. 
Examination of the presence of key genes that are involved in the regulation of the 
key biological processes is also essential. Where possible, it is also useful to consider 
the correlation of the transcriptional changes observed with results from experimental 
 172 
 
studies to ensure that the observed transcriptomics results are as would be expected in 
experimental studies and not the result of false positives of false negatives from the 
microarray techniques applied.  
 
 
5.6.7  Study Limitations 
 
As the discussions of the results show, most many of the results interpreted as 
evidence for the key event were findings from the mouse datasets. The lack of 
adequate rat datasets rendered it impossible to carry out a thorough species 
comparison analysis.  
 
The availability of PB data for analysis was a major limitation in this investigation, 
particularly for studies carried out in rat and human hepatocytes. As this investigation 
illustrates, the application of toxicogenomics evidence to aspects of chemical risk 
assessment like MOA analysis, can be very much dependent on the availability of 
public microarray data such as those stored in public microarray repositories. The 
availability of data at more varied time points for the different species would have 
enabled a more in-depth analysis of the temporal relationship to examine the effect of 
PB on the observed gene changes.  
 
There were also shortcomings in relation to the statistical manipulation of the 
microarray data. For smaller datasets like those obtained from the rat, the statistical 
filter applied to identify if deferentially expressed genes (DEGs) had to be relaxed 
quite substantially, in some cases a p-value cut off of 0.25 was applied in order to 
obtain enough genes to proceed to the next stage of analysing the DEGs in IPA. While 
the lack of uniformity in statistical analysis increased the likelihood of obtaining false 
positives in the genes identified to have been affected by PB treatment, the practice is 
justified given that the investigation sought to conduct the analysis as an illustration 
of the use of toxicogenomics data in risk assessment. The use of such a high p-value 
cut off in this instance therefore served the purpose to enable the availability of 
enough data for the assessment in IPA. While this was a major limitation with some 
of the datasets, this relaxed statistical approach for some of the datasets enabled the 
evaluation of some genes rather than none at all. It is however acknowledged that this 
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increases the uncertainties in the results obtained. One would imagine, however, that 
this is likely to be the same approach that a risk assessor with limited toxicogenomics 
data would apply, as this would probably be the case for many chemicals. 
The data was insufficient to carry out a thorough analysis of the similarities or 
differences between in-vivo and in-vitro studies as well as an in-depth assessment of 
the temporal relationships for the individual species. However, the similarities 
observed between the mouse and rat dataset was an indication of the possibility to 
interpret findings for MOA using a combined data approach.  
 
5.6.8  Problems encountered using IPA 
 
The use of IPA in this transcriptomics analysis was essential for the consideration of 
the biological relevance of the gene changes observed as a result of PB treatment. 
Notwithstanding the benefits of applying this tool for the analysis, many challenges 
were encountered with using the software.  
 
One of the minor difficulties encountered using IPA was the inability to change the 
gene symbol output from the default of human, regardless of the dataset specified in 
the analysis settings. This meant that for the mouse and rat dataset analysed, for which 
the settings for mouse and rat were selected respectively, IPA instead provided the 
human equivalent gene symbol for that gene. In the case of the lists of genes obtained 
from the Tox List analysis, care had to be taken to ensure the correct names for the 
genes from the different species were obtained and interpreted correctly.  
 
This investigation illustrated that while various microarray datasets can be evaluated 
for risk assessment purposes such as MOA evaluation, the experimental variability 
inherent (such as those obtained from different sources in this investigation) in the 
experimental derivation of the datasets means that some datasets will provide more 
informative results than others. However all datasets need to be considered to help 
paint a better picture of the biological functions involved in the evaluation of the 
compound of interest. 
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The genes within the IPA Knowledge base are curated manually by scientists. The 
categorisation of the genes into their biological functions and, therefore, the relevant 
pathways and networks that they are involved in, relies on the consistency of IPA 
database with the most up-to-date evidence from the literature.  
 
While the assignment of groups of genes to various Tox Lists and Canonical 
Pathways enabled the consideration of the observed gene changes within the context 
of the key events for PB-induced liver tumour formation, the suggested results were 
interpreted with caution, particularly when the results were cross-referenced against 
mechanistic evidence available for PB. A noteworthy example of the latter case was 
the implication of the AhR signalling pathway in apoptosis on the basis of the 
significantly perturbed pathways observed from the results obtained in IPA (discussed 
above).  
 
In addition, the categorisation of some genes as being involved with particular 
toxicological endpoints (as suggested by the Pathways) had the potential to allow the 
user to wrongly interpret some of the findings as being biologically relevant. This was 
illustrated by the large number of genes that encode transporter proteins that were 
grouped within the pathways for hepatic cholestasis. The changes observed for the 
genes that encode the transporter proteins may have been the result of other effects of 
PB that are not necessarily associated with hepatic cholestasis. Another example of 
this was the identification of CYP1A2 from the mouse dataset as being involved in 
liver hypertrophy. A search within the IPA Knowledge Base for genes associated with 
liver hypertrophy identified only 3 genes (that included CYP1A2) for this 
toxicological effect. It was notable that IPA did group many genes into the Liver 
Hyperplasia/ Hyperproliferation and Liver Hypertrophy Tox List. This was somewhat 
surprising as this constitutes a main key event for PB induced hepatocarcinogenesis. 
Without prior knowledge about the key events for PB MOA, the results obtained 
would now have led to the identification of this pathway as being important for 
further investigation.  
 
When considering evidence for cell proliferation for PB, it was interesting to note that 
the RB-E2F pathways cited across numerous publications as being an important 
pathway for cell proliferation was not categorised within IPA as either a signalling 
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pathway or as a Tox List. While key genes such as E2F1, RBL1, RBL2, MDM2, 
MYC and the D-type cyclins were grouped into Tox Lists such as G1 and G2 
Transition, P53 signalling and AhR signalling and various other signalling Canonical 
pathways, the interpretation for the involvement of these genes within key pathways 
involved in the regulation of cell proliferation was rendered a lot more complicated 
than it had to be. While it is not being suggested here that the results from IPA were 
incorrect, it was merely an observation that the categorisation of the pathways/Tox 
Lists were perhaps not as up-to-date as they ought to have been. For example, in 
addition to the signalling pathways grouped under the category of “Cellular Growth, 
Proliferation and Development” within the signalling Canonical pathways, a pathway 
relating to genes involved in the RB-E2F pathway highlighted in the literature could 
also be considered. The interpretation for key events within the context of risk 
assessment would be made a lot easier if the pathways and Tox Lists are grouped in 
such a way as to take into account some of the main key events that commonly occur 
in carcinogenesis.  
 
Attention must also be drawn to the changing nomenclature for genes, which was a 
considerable source of confusion during the analysis. In an attempt to compare the 
datasets from this investigation with biomarkers identified for non-genotoxicity and 
hepatocellular carcinoma, each gene identifier provided for the biomarker first had to 
be converted to the correct gene symbol to enable comparison. Secondly, the different 
synonyms for each gene symbol pertaining to the species of interest also had to be 
obtained to ensure that no relevant genes were missed out. In the era of developing 
biomarkers for endpoints of interest, it seems logical that the issue of gene 
nomenclature should also be addressed. The availability of so many synonyms for a 
single gene is a cause for confusion in this field. Until there is more harmonisation in 
this area and the issue of nomenclature is resolved, it is important that risk assessors 
consider all the different synonyms for their gene of interest. 
 
As a Pathway Analysis software, IPA is an extremely powerful and essential tool for 
the evaluation of genes that have been obtained using high throughput technology. It 
would be otherwise impossible to consider biological and functional relevance of 
thousands of genes and the use of such a tool enables the genes to be grouped together 
within their functional contexts. That said care has to be taken in the interpretation of 
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the results suggested by the analysis output. It is important that the results obtained 
are not interpreted in isolation from other sources of evidence obtained in the 
literature.  
 
 
5.6.9 Summary of Toxicogenomics Evidence for PB Key Events  
 
As outlined in Chapter 2, the key events postulated for the MOA for PB liver tumour 
formation include: activation of CAR, liver hypertrophy, development of altered 
hepatic foci, cell proliferation and inhibition of apoptosis. Other associated 
toxicological events include oxidative stress and inhibition of gap junction 
intercellular communication. The analysis of publicly available transcriptomics data 
for PB provided evidence for CAR activation, cell proliferation, inhibition of 
apoptosis and oxidative stress. The evidence for the key events directly inferred from 
the results outputs from the Tox Lists, Tox Functions and Canonical Pathways are 
briefly summarised below.  
 
 
CAR Activation 
 
The induction of the gene encoding the CYP2B enzyme, one of the characteristic 
effects elicited by the nuclear receptor CAR in response to exposure to PB was 
observed across the data examined from all species investigated.   
 
Although the gene encoding CAR (NR1I3) was observed to be down regulated in the 
mouse, the up-regulation of key genes such as PXR, CPT1, G6PC, FOXO1, 
HMGCS2, HNF4A and PRKAR1A provided evidence for the cross-talk between 
CAR and PXR for the regulation of hepatic metabolism as suggested by evidence 
reviewed from the literature. Evidence interpreted for this cross-talk between the two 
nuclear receptors was only observed in the dataset obtained from the mouse 
experiments. The observed gene changes were consistent with evidence obtained from 
mechanistic studies carried out in the mouse. 
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Cell Proliferation and Growth 
 
The evidence for cell proliferation and growth was obtained from the results observed 
from gene changes across different perturbed pathways that included: PPARα/RXR 
Activation, G2/M Transition of the Cell Cycle, G1/S Transition of the Cell Cycle, 
Mechanism of Gene Regulation by Peroxisome Proliferators via PPARα, TGF-β 
Signalling, AhR Receptor Signalling and p53 Signalling.  
 
The key genes identified from the literature to be associated with playing a key role in 
the regulation of cell proliferation included D-type cyclins (CCND1), E2F 
transcription factors (E2F1, E2F2, E2F3), cyclin-dependent kinase (CDK4) and 
retinoblastoma like genes (RBL1, RBL2). The latter perturbed genes identified in the 
literature to be associated with the regulation of cell proliferation were observed to be 
up-regulated in the mouse dataset only.  
 
Inhibition of Apoptosis 
 
Evidence for the PB-induced inhibition of apoptosis was obtained predominantly from 
the perturbed genes grouped within the AhR signalling pathway. Although the latter 
pathway was identified across the datasets obtained from the three species, which was 
suggestive of a role for AhR in the mediation of the observed effects of apoptosis, 
evidence obtained from the literature suggested that PB has a low binding affinity for 
AhR and therefore the gene changes observed occurred independently of the AhR. 
 
Key genes identified by the literature to play key roles in the regulation of cell growth 
and the inhibition of apoptosis included: CCND1, CDK4, MYC, MDM2 and 
TGFBR2. With the exception of TGFBR2, all the genes were grouped within the AhR 
signalling pathway. Therefore, although the literature provided evidence that allowed 
the exclusion of role of the AhR ligand as suggested by the results obtained by IPA, 
the relevant key genes were observed within this pathway of genes. The five key 
genes whose role provided evidence for the PB-induced inhibition of apoptosis were 
all observed to be up-regulated in the mouse dataset only. 
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Oxidative Stress 
 
Evidence for oxidative stress was obtained from the gene changes observed from the 
perturbed pathway for Oxidative Stress Mediated by NrF2. Four key genes identified 
from the literature as being involved in oxidative stress included NrF2, KEAP1, 
MAF(G) and NQO1.  
 
A search in the literature identified four genes considered to be essential component 
for antioxidant response. All four genes were present in the mouse dataset (NrF2, 
MAF, NQO1 and KEAP1). While only three of the genes (NrF2, MAFG and KEAP1) 
were observed within the human dataset. The key genes within the mouse and human 
datasets were observed to be up-regulated. In the absence of the antioxidant response 
element responsive gene (NQO1) in the human dataset, it was not possible to 
conclude with certainty that the gene changes within this dataset were caused by 
oxidative stress or as a result of the more general toxicity effects exerted by the 
exposure of the human hepatocytes to PB. 
 
The expression of the gene changes observed within the mouse and human datasets 
were consistent with observations in experimental studies.   
 
 
 Liver Hyperplasia/ Hypertrophy 
 
Only a small number of genes were observed to be associated with the 
Hyperplasia/Hyperproliferation and Liver Hypertrophy pathways. The results were 
interpreted as being insignificant and insufficient as evidence for this key event. 
Based on the categorisation of the genes in IPA, the gene encoding the CYP1A2 
enzyme was identified in the mouse Day 4 dataset to be associated with liver 
hypertrophy. Based on the known function of this gene as a drug metabolising 
enzyme, this result was disregarded as it was more likely that the induction of this 
gene was more the result of the inducing effects of PB exposure rather than as a true 
indication of the effects of hypertrophy.  
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Observed Species Differences (mouse in vivo dataset vs. Human in vitro dataset) 
 
The gene changes observed across the datasets obtained from all three species showed 
that many biological pathways were perturbed as a result of exposure to PB. Of 
particular interest were the observed differences observed between the mouse in vivo 
dataset and the human in vitro dataset.  
 
Whilst it was possible to identify biological pathways of interest that were indicative 
of some of the key events (and associated toxicological events) for the MOA for PB 
liver tumour formation, a thorough examination of the genes involved in the perturbed 
pathways, indicated that the key genes identified by the literature to play key roles in 
the key events of interest, were predominantly observed in the mouse (in vivo) dataset 
only.  The only exception was for the evidence obtained for PB-induced oxidative 
stress, whereby some evidence for this associated toxicological event was also 
observed in the human (in vitro) dataset. 
 
PB exposure was observed to result in the up-regulation of many of the genes 
encoding some of the phase I and II drug metabolising enzymes (predominantly CYP 
family, GST family) as well as the genes encoding transporters proteins 
(predominantly ABC and SLC family) in both the mouse and human datasets.  In 
contrast, changes in the key ligand dependent nuclear receptors (CAR and PXR) were 
only observed in the mouse and not in the human dataset. RXR was, however, 
observed in both the mouse and human dataset. Similarly, most of the key 
transcription regulators (JUN, E2F1, MYC, MDM2 and SMAD) were only observed 
to be up-regulated in the mouse dataset and were not differentially expressed in the 
human dataset. A change in only NrF2 was observed to occur in both the human and 
the mouse dataset.  
 
Similarly, many of the pathways selected for investigation were observed in both the 
mouse and human datasets. To determine the biological relevance of the observed 
perturbed pathways, where possible the key genes observed were cross referenced 
with information on the mRNA levels for the relevant genes from mechanistic or 
biochemical studies obtained from the public literature. In most cases examined, the 
mRNA levels for most of the key genes were found but the gene changes were 
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observed to occur predominantly in the mouse. This was particularly true for evidence 
obtained for the evidence obtained for CAR/ RXR activation, evidence for the cross 
talk with PXR, cell proliferation and the inhibition of apoptosis. 
 
A lack of change in the expression of the key genes in pathways thought to be 
involved in the key events for the MOA for PB in the human dataset could be an 
indication that these effects in humans do not occur. However, owing to the problems 
encountered in interpreting the results obtained from this transcriptomics analysis, 
such a conclusion would be premature without further analysis of a much larger 
human dataset. Indeed, a recent gene expression profiling study carried out by 
Lambert et al [208] showed that primary human hepatocytes exposed to various 
concentrations of PB, led to the induction of genes such as MYC, CAR, PXR (albeit 
at low levels of induction at some doses after quantification using reverse 
transcription polymerase chain reaction (RT-PCR) and many other drug metabolising 
enzymes similar to results observed in the data investigated here. The observed 
induction of some of the genes as a result of PB exposure of the human primary 
hepatocytes contradicts some of the results obtained in the human dataset analysed 
here. It is therefore essential that a wider human in vitro dataset be evaluated using a 
comparative approach similar to that applied here, before any conclusions can be 
drawn about the differences between the in vitro and in vivo datasets in relation to the 
potential effects of PB on the key events for the MOA for liver tumour formation. 
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5.7 Conclusions 
One of the main challenges of this transcriptomics analysis was on the presentation of 
the result output produced by IPA and the presentation of the information within the 
context of MOA analysis.  
Based on the evaluation of the different pathways, Tox Lists and Tox functions, 
evidence for some of the key events for PB-induced hepatocarcinogenesis including 
CAR/PXR activation, cell proliferation, inhibition of apoptosis and associated the 
effects of oxidative stress were obtained from the combined datasets obtained from 
the mouse. 
A sensible approach to deal with the large lists of genes obtained and grouped 
according to functionality, was to focus on key genes or groups of genes as informed 
by the available literature. This approach enabled the focus to be placed on particular 
sets or groups of genes that were indicative of some of the key events that have been 
postulated to be part of the PB MOA for liver tumour formation.  
Similar to observing groups of genes within a network of genes, one of the benefits of 
examining the results of the Tox Lists in the form of simplified heat maps was that it 
facilitated an easier examination of the temporal relationships among the observed 
gene changes involved across the different pathways. This was exemplified by the 
interpretation of the results collated as evidence for proliferation and inhibition of 
apoptosis, which showed the involvement of key genes across different Tox Lists and 
pathways.  
Overall, the results obtained from the analysis were difficult to interpret. The analysis 
in IPA produced an overwhelming amount of results and in order to make sense of the 
results output created from the analysis, focus had to be placed on selected key genes 
(on the basis of information obtained from literature) within pathways considered to 
be potentially relevant for the MOA for PB. It would be a cumbersome task to 
consider all the many functions of a single gene and such an approach would be 
counterproductive, particularly from a risk assessment point of view. However, the 
approach used to select genes to interpret findings for a biological effect risks being 
criticised over its subjective nature owing to the fact that the assessor chooses what 
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the focus for the interpretation will be. Regardless of the potential subjectivity of the 
approach applied here, it is the only practical solution to evaluating transcriptomics 
data derived from using high throughput technologies when conducting a risk 
assessment. 
It was hoped that the examination of the individual gene changes associated with the 
different Tox Lists would provide insight into the temporal relationship of potentially 
significant genes and enable the identification of differences between the different 
species at the time-points investigated. Owing to the limitations in the datasets 
available however, no meaningful significant temporal or species differences could be 
found.  Regardless of the shortcomings of the available dataset, the majority of the 
Tox Lists reviewed showed that most of the genes that were present at the different 
time points had similar directions of transcription.   
The comparison of the datasets with biomarkers for non-genotoxicity obtained from 
the literature showed that there were little or no similarities between the different 
datasets and the identified biomarkers from the three different sources. Comparison of 
the DEGs with functionally related genes identified from the IPA Knowledge base 
showed that where it was possible to categorise the genes into the biological processes 
of interest, many of the genes from the mouse dataset were observed to have been 
affected by PB treatment.  
Although 35 genes (from the combined mouse dataset only) were found to be 
common from the studies carried out at the different time points investigated, these 
have deliberately not been referred to as biomarkers in this investigation. The genes 
identified were representative of a wide range of biological processes affected by PB 
and as such illustrated some of the characteristic gene changes that represented the 
overall results obtained from the analysis with the full datasets.  
The analysis carried out here has demonstrated that the molecular basis of some of the 
key events in the MOA for PB can be determined from published toxicogenomics 
data. However, this was not achieved using an unsupervised approach and a 
meaningful interpretation of the results within the context of the key events for MOA 
analysis was only achieved on the basis of the information obtained from the literature 
and through verification of the observed gene changes with evidence from 
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mechanistic studies. Indeed, interpretation of some of the observed pathway changes 
or individual genes on the basis of the results produced by IPA could have led to the 
misinterpretation of the significance of particular genes in the regulation of pathways 
that were indicative of potential key events for PB‟s MOA. 
 
While it is clear from the results discussed here, that toxicogenomics can enable the 
MOA to be described on the basis of some of the key events (through the 
identification of key genes that are indicative of the involvement of a particular 
biological pathway), it would be premature to conclude that the potential effects for a 
chemical like PB can be deduced using MOA consideration, without the need to 
conduct long term studies, as suggested by Waters et al [168]. The experience of this 
transcriptomics analysis indicates that many more hurdles need to be overcome to 
improve the confidence placed in the results obtained from toxicogenomics data. 
More importantly, more publicly available datasets for case study compounds like PB 
need to be evaluated to improve the weight of evidence for the interpreted findings in 
order to reduce the level of uncertainties associated with the interpreted results.  
 
The analysis described in this chapter has illustrated that to some extent it has been 
possible to explain key events in terms of Toxicity pathways provided in IPA. 
However it was not possible to predict key events and MOA on the basis of the 
pathways observed. In the future it would be helpful to examine the toxicogenomics 
data using specific MOA assessment criteria. This would facilitate the identification 
of data gaps and enable a more thorough assessment of the weight of the 
toxicogenomics evidence for a particular key event. In addition such an analysis 
would not only focus on the evaluation of the time-response but also on the dose-
response, consistency and plausibility of observed gene expression changes.  
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Chapter 6  
 
General Discussion and Conclusions 
 
 
The chemical risk assessment process requires the thorough consideration and 
evaluation of a variety of scientific evidence deemed appropriate to evaluate the 
hazard from a chemical of concern as part of the effort to mediate against any 
potential risks to human health and the environment [54].  
 
In the past decade the use of the MOA approach in risk assessment has been promoted 
widely and adopted by many regulatory and advisory bodies as a means to harmonise 
approaches to chemical risk assessment and to improve transparency. In this same 
period, the simultaneous growth of genomics data generated within the public domain 
has provided the impetus to investigate the extent to which such data can be 
considered as part of the WOE in a MOA analysis and more generally in chemical 
risk assessment. Alongside this, the increased need for transparency in risk 
assessment means that more effort needs to be put into the application of techniques 
that facilitate transparent evaluation of the WOE as part of MOA/HRF and risk 
assessment in general. 
 
This thesis aimed to address two important aspects of the WOE analysis process 
pertinent to the application of the IPCS HRF and more generally risk assessment. An 
attempt to conceptualise these two aspects is illustrated in Figure 6.1 and includes: 
 The types of data compiled and considered as evidence as part of the WOE 
analysis for MOA or human relevance analysis. 
  The presentation of evidence to improve the transparency of the decision 
making process for MOA or human relevance analysis. 
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Figure 6.1: Conceptual illustration of fundamental aspects of a WOE-based approach 
applied for MOA analysis in risk assessment and current drivers for the further 
development of the IPCS HRF as a risk assessment tool.  
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6.1 Techniques to Improve the Transparency of the use of a WOE-Based Approach 
in MOA and Human Relevance Analysis: Systematic Review 
 
Conclusions on the human relevance of the MOA for PB, and therefore for other 
compounds sharing the same MOA, rely heavily upon epidemiological studies on its 
carcinogenic potential in patient populations.  PB was therefore used as an illustrative 
example, in which systematic review techniques were applied for the evaluation of 
available epidemiological evidence for a potential association between PB and liver 
cancer. The methodology and results of the review are detailed in chapter 3. 
 
The systematic review was undertaken broadly applying the guidelines provide by the 
NHS Centre for Reviews and Dissemination [43] and recommendations for systematic 
reviews provided by Peters et al [101] and Weed et al [103]. A key feature of this 
review was the initial statement of the intent and purpose of the review. The 
methodology developed, detailed the efforts to develop a search strategy to identify 
all relevant epidemiology papers from different electronic databases. Inclusion and 
exclusion criteria for the selection of epidemiological papers considered to be relevant 
for the review were also elaborated and clearly stated. 
 
A key component of the systematic review was the development of a quality 
assessment scoring system (also described within the methodology) that enabled the 
transparent assessment of the quality of the selected studies. The studies were 
assessed on the basis of how well the authors addressed and dealt with issues of bias, 
confounding and different aspects that related to the exposure, classification and 
assessment of epileptic patients exposed to PB. The criteria used to assess the quality 
of the different studies and the basis for the assigned scores was stated explicitly. The 
latter ensured a transparent critique of the different studies and made transparent, the 
basis for the conclusions and interpretations of the results obtained from the studies.  
 
One of the main advantages of this approach to the evaluation of evidence for the 
HRF was the identification of areas of uncertainty for the assessment of the evidence. 
Most notably, the review highlighted some of the methodological difficulties 
encountered with trying to investigate the association between PB and liver cancer.  
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It was not possible to reach a conclusion about the association between PB and the 
occurrence of liver cancer on the basis of the epidemiological evidence reviewed in 
Chapter three. Although the English and Danish cohort studies [109, 110] were 
assessed to be of a high quality as they were the only studies to have adequately 
identified a group of patients that were treated unequivocally with PB predominantly, 
the findings reported by the authors were based on a very small cohorts of patients. In 
contrast the larger Finnish cohort (almost 30,000 patients) described by Lamminpaa et 
al [112] found a positive association but were unable to identify patients treated 
predominantly with PB. The results reported by Lamminpaa et al [112] were assessed 
to be unreliable on the basis of the limitations inherent in their study design.  While 
the focus of any conclusions about the association of PB and liver cancer should be 
placed on this larger study, the uncertainty associated with the Finnish cohort study 
suggest that the results reported should be interpreted with caution. A refinement of 
the Finnish study (such as setting up a nested case control study on the cohort already 
identified) would go a long way to improving the reliability of the study and would 
add to the WOE and enable more definitive conclusions to be drawn about the 
potential association between PB and liver cancer. 
 
The routine application of systematic review techniques such as that described above 
and in Chapter 3 would go a long way to improving the transparency of decisions 
reached using a WOE-based approach to the IPCS MOA/HRF and other components 
of the risk assessment paradigm.  One of the cited advantages of applying the IPCS 
HRF is that it improves the transparency of aspects of the hazard characterisation 
stage of risk assessment [9]. It achieves this objective by facilitating the consideration 
of the WOE within the context of causal criteria
17
 as articulated by Hill [29]. What 
remains to be seen is how the WOE compiled for the different aspects of the 
individual criteria for causality can be made more transparent, particularly if they are 
used as the basis for key decisions about a chemical of interest. 
 
It is worth considering how feasible it is to conduct an exhaustive systematic review 
for every process that applies a WOE-based approach to the narrative review as part 
                                                 
17
 Hill emphasised that the issues he proposed useful for consideration of causality of an association 
identified in an epidemiological study should not be considered as criteria.  However, the term „Hill 
criteria‟ is now widely used, and has been used in this thesis for convenience and consistency with 
current literature. 
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of the risk assessment. Clearly the process of compiling and evaluating the WOE for 
MOA analysis can be quite labour intensive let alone the evaluation of WOE for every 
aspect of the risk assessment for a single chemical under evaluation. If it is envisaged 
that it may not be possible to apply a thorough and detailed systematic review 
approach to every aspect of the Framework then perhaps more guidance is needed to 
identify the key areas of the HRF to which a more thorough application of systematic 
review techniques for the evaluation of the WOE would be most beneficial. 
 
This issue was recently addressed in a guidance document produced by EFSA on the 
application of systematic review methodology in food and feed safety risk assessment 
[42]. The EFSA guidance document states that while it may be suitable to carry out a 
systematic review to address a research question, it may not always be worthwhile or 
practically feasible. Some of the factors stated as having an impact on the feasibility 
of carrying out a systematic review included the consideration of the quality and 
quantity of the evidence to be reviewed, the availability of resources and the potential 
costs of applying such techniques (taking into consideration the time, budget and the 
expertise that would be required). To decide on whether or not to engage in a 
systematic review process, the guidance document recommends the use of a scoping 
technique to initially survey the extent of the literature. This process of assessing the 
extent of literature to be evaluated would enable the estimation of the amount of 
resources that may be required to carry out a systematic review process.  
 
There is however the contrasting view that there is no excuse for not carrying out a 
systematic review using the many guidelines that are now available (e.g. Guzelian et 
al. [209]). Even when the evidence for a particular review question is overwhelming, 
it may still be possible to apply systematic review methods. The transparency of the 
risk assessment process is fundamental to credible risk assessment [40] and this can 
be facilitated by techniques such as systematic reviews applied in the evaluation of 
the WOE. In situations where there is overwhelming evidence for a review question, 
the emphasis should be placed on the thorough consideration of the criteria for the 
eligibility of studies for inclusion in the review. Therefore if the scoping process 
identifies a significant volume of evidence for a review question, the criteria for 
inclusion could be restricted to include only e.g. key studies, pooled studies, narrative 
reviews or meta-analyses etc [210]. It is the explicit description of the process behind 
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the evaluation of the evidence and the stated rationale for the selection of studies used 
as the basis for risk assessment conclusions that render the risk assessment process 
more transparent and the decisions credible.  
 
An additional key issue is the consideration of the quality of toxicological studies 
which form the bulk of the WOE assessed as part of MOA analysis. From a UK 
perspective, the current approach to evaluating such data and the formulation of 
decisions relies on a combination of the WOE considered and application of expert 
judgment to draw conclusions about whether the substance under evaluation is 
considered to have adverse affects on human health [43].  Klimisch et al [211] 
proposed guidelines for a systematic approach for evaluating the quality of 
experimental toxicological and ecotoxicological data. The authors proposed reliability 
categories which varied depending on the level to which the study conformed to good 
laboratory practices (GLP) or other defined criteria. While such factors are already 
taken into account by experts who make their judgement about particular 
toxicological studies (quality assurance and GLP are commented on explicitly for all 
studies cited in JMPR monographs), this is often implicit, and the adoption of a more 
formal approach would render the process far more transparent and credible, a desired 
outcome articulated by an ILSI/HESI expert committee [40].   
 
 
6.2 Consideration of Toxicogenomics data as part of the WOE for MOA 
analysis 
 
The PB case-study 
 
The results and data from relevant toxicogenomics studies are being made 
increasingly available for potential inclusion in risk assessment. There is therefore a 
need to develop a structured framework for the evaluation of such data in WOE 
considerations. PB was used as a case study to explore some of these issues. The 
methodology developed for the analysis of the transcriptomics data was described in 
Chapter 4 and the results of the analysis and a discussion of the results obtained were 
detailed in Chapter 5.  
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Toxicogenomics data on PB were obtained from 2 public microarray repositories 
(ArrayExpress and Gene Expression Omnibus). The toxicogenomics datasets obtained 
for PB were from both studies that had focused on investing PB as the primary 
compound and those that had generated data on PB through its use as a positive 
control. Although it would have been more useful to consider only datasets in which 
PB was employed as the primary compound for investigation, the datasets compiled 
from the use of PB as a positive control had to be included owing to the limited 
number of datasets available for the analysis.  
 
The pre processing of the data obtained and the statistical strategy were devised in 
consultation with a genomics expert from the USEPA. Differentially expressed genes 
(DEGs) were identified from data collected from 9 investigated time points in the 
mouse (4 time points studied in vivo), rat (3 time points studied in vivo and 1 time 
point studied in vitro) and human hepatocytes (1 time point studied in vitro). The aim 
was to carry out a comparative analysis of publicly available toxicogenomics data for 
PB to determine the extent to which such information could be meaningfully 
interpreted as part of the MOA analysis to form part of the weight of evidence for a 
chemical of interest. A further objective was to explore the value added by such 
studies to such an analysis. 
 
To facilitate the biological interpretation of the observed gene changes, the 
commercial pathway analysis software Ingenuity Pathway Analysis™ (IPA) was 
employed for analysis of the data. Analysis of the data in IPA produced results in the 
form of pathways (IPA Tox Lists and Canonical Pathways) and functional networks 
which were interpreted within the context of the known key events for the MOA for 
PB induced liver tumour formation as described in Chapter 2 of this thesis. Novel 
insights into the MOA for PB from these data were also sought. 
 
Based on the observed results from the Tox Lists and Canonical Pathways, evidence 
for PB induced CAR activation, cell proliferation, inhibition of apoptosis, and 
hepatocellular carcinoma was obtained, on the basis of the perturbed gene changes 
within the selected pathways. In addition evidence was described for associated 
toxicological events like oxidative stress. The results were also suggestive of 
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pathways that were unlikely to be involved in the MOA for PB hepatocarcinogenesis 
(e.g. AhR and PPAR). 
 
Owing to the sheer volume of the results obtained, a strategic approach had to be 
adopted to enable a manageable but efficient interpretation of the results within the 
desired MOA context. The focus was therefore placed on describing the changes 
observed for the principle genes identified from the literature to play critical roles in 
the regulation of genes within the pathways identified to be essential for the key 
events of interest. Where possible, experimental evidence for the observed gene 
changes was obtained from the literature and discussed; this was done as part of an 
effort to determine whether the gene changes observed from the constructed 
microarray experiments correlated well with experimental observations. In most cases, 
the key genes selected for further investigation and discussion from the microarray 
experiments were consistent with the experimental evidence for PB. The only 
exception (among the genes selected) to this was for the gene SCD1 which is involved 
in the regulation of lipid metabolism. This gene was observed to be down regulated in 
the rat and mouse dataset investigated even though the gene has been demonstrated to 
be up regulated in studies carried out using PXR knock-out mice [180]. The gene 
encoding AhR was however observed be up regulated in all the mouse time points 
investigated even though mechanistic studies have shown that PB has a very low 
binding affinity for this transcription factor. In addition there is little evidence for the 
involvement of the AhR signalling pathway in PB MOA yet this pathway was 
observed to be significantly perturbed in the results produced in IPA.  Such issues of 
reliability of the results obtained will be discussed further in the following sections.  
 
A clear limitation of this comparative analysis of publicly available toxicogenomics 
data was the amount of evidence available for PB. A thorough species comparison 
could not be carried out as the data was limited for the rat and human. Although there 
was some observed commonality between the perturbed genes across the different 
pathways selected, the majority of the pathways compiled as evidence for the key 
events were based on the data obtained from the mouse datasets particularly the 
mouse data generated from the study at 2 days. The evidence for the key events 
directly inferred from the results output from the Tox Lists, Tox Functions and 
Canonical Pathways provided some evidence for PB induced CAR activation, cell 
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proliferation, inhibition of apoptosis and oxidative stress. With the exception of 
evidence considered for oxidative stress (in which key genes were observed to be 
differentially expressed in both the mouse and human dataset) which showed 
consistency between the two datasets, it was not possible to evaluate the consistency 
of the results observed across the datasets obtained for the three species. This was 
because the majority of the evidence obtained for the key events were on the basis of 
results obtained from the mouse dataset.  
 
 
6.2.1 Generalisation from the Case-study  
 
The comparative analysis of the transcriptomics data for PB identified a number of 
methodological issues associated with trying to interpret the biological relevance of 
the results obtained within the context of the key events for the MOA for PB induced 
liver tumour formation. These issues fell into two main categories that included: 
 
1. The inability to apply an unsupervised (i.e. without the need to be led by 
information in the literature) approach to the identification of key events on 
the basis of the observed perturbed genes or pathways alone. 
 
2. The inability to have confidence in some of the results obtained without cross 
referencing mechanistic data available from the published literature (e.g. 
interpretation of the relevance of AHR in the regulation of apoptosis for PB 
induced effects). 
 
 
The Inability to Apply an Unsupervised Approach to the Identification of Key  
Events on the Basis of the Observed Perturbed Genes or Pathways Alone 
 
One of the advantages cited for the application of omics technology to MOA analysis 
is the lack of bias towards a particular MOA [212]. While this may be true, one of the 
main limitations observed from the comparative analysis carried out in this thesis, was 
that it was very difficult to identify where the focus of the results interpretation should 
be placed in order to determine which molecular pathways were most relevant for the 
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PB MOA. Therefore the experience of carrying out the transcriptomics analysis was 
that one needed to have prior knowledge of the possible MOA for PB induced 
hepatocarcinogenesis in order to decide how best to interpret the results and to decide 
on which molecular pathways were most likely to be relevant. While it is appreciated 
that an unbiased approach to determining a MOA is preferred, in the case of 
toxicogenomics data, a balance has to be struck between striving for an objective 
approach to determining the key events on the basis of the vast amount of data 
generated and being able to obtain definitive answers to inform the risk assessment 
process.  
 
The experience encountered from the comparative analysis carried out in this thesis 
has been that one needs a sense of direction when trying to interpret the vast amount 
of data that have been generated and some prior knowledge about a chemical of 
interest certainly aids the process of interpreting the data and getting a better sense of 
what information is relevant and to provide direction for the interpretation of the 
results. Therefore it is essential that mechanistic data about the key events in the 
MOA for either the chemical of interest or a chemical known to operate via a similar 
MOA are assimilated prior to the toxicogenomics analysis in order to have a better 
understanding of the observed pathway changes in order to fully appreciate the 
biological relevance of observed perturbed pathways.  This has obvious implications 
for the nature of toxicity testing required, at least in the short to medium-term studies. 
 
General background knowledge about the key events involved in the MOA for PB 
induced hepatocarcinogenesis was found to be essential (provided in Chapter 2) for 
the interpretation of the toxicogenomics results. Review of the evidence for the PB 
key events and associated toxicological events enabled a more targeted evaluation of 
the toxicogenomics results produced in IPA. In addition it was helpful to have some 
knowledge about general mechanisms of hepatotoxicity in order to consider the 
involvement of different MOAs. This enabled the selection of specific pathways for 
further investigation rather than placing the focus on only the significantly perturbed 
pathways identified in IPA. This was illustrated by the selection of 18 Tox Lists 
(pathways) out of the 46 produced for hepatotoxicity in IPA as the focus for the 
analysis (the selected Tox Lists included significantly changed pathways and non-
significant pathways).  
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Evidence gathered from biochemical and mechanistic studies were also essential to 
help interpret the significance and relevance of the gene changes observed. These 
included mechanistic data obtained from genetically modified animals (e.g. CAR and 
PXR knockout mice) and mechanistic studies on specific target genes known to be 
involved in the regulation of specific pathways. Mechanistic studies demonstrating 
the effect of PB on transcript and protein levels were also reviewed to help determine 
the biological relevance of some of the gene changes observed. An important 
consideration for microarray studies is that not all gene changes observed will prove 
to be biologically relevant.  
 
The comparative analysis demonstrated that a range of supportive evidence is needed 
to facilitate the interpretation of toxicogenomics results. It is clear that the type and 
amount of supportive data needed for the interpretation of toxicogenomics results 
would be completely dependent on the intended application of the results. As 
illustrated in the attempt to apply the toxicogenomics data to key events for PB MOA, 
it was necessary to consider a whole range of evidence.  
 
In cases where toxicogenomics data is available to enable a more targeted 
consideration of different factors that could affect the response observed (e.g. dose, 
time, species), it is clear that more supportive mechanistic data would be required. 
The attempt to carry out a thorough species and temporal comparison of the PB 
dataset was limited by the lack of available DEGs to facilitate such analysis 
particularly within the rat and human datasets.  
 
In cases where there is insufficient mechanistic data to address particular aspects of 
the risk assessment, toxicogenomics data could prove potentially useful in helping to 
bridge some of the data gap about responses at particular time points or responses at 
specific doses or in particular species. The experience encountered here however 
suggests that this particular application can only be realised in cases where there is 
already sufficient mechanistic information available for the compound under 
investigation and the toxicogenomics results would be used for addressing very 
specific and targeted aspects of the missing knowledge. Such an approach would also 
require the consideration of the appropriate study design. 
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An outcome of this thesis was the development of a logical framework for the 
evaluation of toxicogenomics data within the context of MOA analysis. As illustrated 
in Figure 5.6 (shown in chapter 5), it is necessary to apply a constant iterative process 
to the evaluation of both the mechanistic data (obtained from available literature) and 
pathways identified as relevant from the toxicogenomics results. Interpretation of the 
biological relevance of the observed gene changes (as evidence for a key event) 
requires the verification of the observed expression changes with the mechanistic 
evidence that has examined the relevant end point and also the transcript changes 
(including protein changes) for the critical genes exposed to the relevant compound. 
While attempts have been made to do this in the analysis carried out in this thesis, the 
consideration of a more comprehensive dataset across the three species would reduce 
the uncertainties in the toxicogenomics evidence described here for PB. Where the 
mechanistic data have been obtained from in vivo studies, these can help confirm the 
consistency and predictability of toxicogenomics data developed using in vitro 
systems. 
 
Inability to Have Confidence in Results Obtained Without Cross Reference with 
Mechanistic Data  
 
The method by which individual genes are categorised in IPA into the biological 
functions and subsequently into biological pathways can result in a single gene being 
categorised under multiple functions. This can therefore make it very difficult to 
determine a priori which particular function and therefore which key event for the 
MOA is most relevant for the chemical of interest.  
 
An evaluation of the different outputs (Tox Lists, Canonical Pathways and Tox 
functions) was required to collate the evidence for the different key events for PB 
MOA. Crucially the pathways selected (on the basis of known mechanisms of 
hepatotoxicity) and considered to be relevant for the key events of interest were not 
necessarily identified by IPA to be the most statistically significant or dominating 
pathways. While it is known from experimental studies that PB induces a range of 
definitive biological effects in different species that can be identified as the key events 
that lead to liver tumour formation, it was difficult to obtain the same clear indications 
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from the microarray experiments carried out at the different time points across the 
different species.  
 
A targeted approach to interpreting the vast amounts of results obtained would not 
have been possible without prior knowledge about the key events of PB. Indeed the 
interpretations about the potential key events of PB on the basis of the results 
observed in IPA alone could have led to systematic misinterpretations of some of the 
results. An example of this was the identification of the LPS/ IL-1 Mediated 
Inhibition of RXR Function as a significantly perturbed Tox List and Canonical 
Pathway across all datasets from all species investigated. Although the evidence 
provided by the pathways were suggestive of the inhibition of RXR function as a 
potential effect of PB exposure, the fact that the target genes (CYP2B6 and CYP3A4)  
for the binding partners of RXR (CAR and PXR respectively) were up regulated 
suggested that this was clearly not a real effect of PB. While evidence from the 
literature was reviewed that confirmed the role of RXR inhibition of CAR and PXR in 
the presence of LPS, evidence from the same dataset examined confirmed that this 
was clearly not a real PB induced effect.  
 
Similarly the pathways for Hyperplasia/ Hyperproliferation and Liver Hypertrophy 
were not observed to be significantly perturbed. CYP1A2 was categorised to be 
associated within liver hypertrophy on the basis of evidence obtained from the mouse 
data. This was interpreted to be more as a reflection of the inducing effects of PB 
rather than a true indication of the key role of this gene in liver hypertrophy. This 
example suggested that many of the genes involved in both liver hyperplasia and 
hypertrophy were probably categorised and grouped within other pathways and so this 
pathway (confirmed to be key event on the basis of evidence from mechanistic studies) 
was not identified as significant. Without prior knowledge about the key events for 
PB, this pathway would not have been selected for further investigation and would 
have been disregarded as insignificant on the basis that the pathway was not 
significantly perturbed.  
 
Both these examples illustrated the importance of not placing the focus on only “top/ 
significant” pathways as the basis for any conclusions about the suggested effects of a 
chemical under consideration. It also highlighted one of the limitations of Pathway 
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Analysis programs like IPA, in that the results of significantly perturbed pathways do 
not always point to real effects and so have to be interpreted with caution and the 
biological relevance has to be thoroughly considered. It is effectively the case that a 
program like IPA throws up lots of results and the user of the program has to decide 
on the basis of scientific knowledge and expertise which pathways are actually, or 
likely to be, biologically relevant to the compound under consideration.   
 
It has been suggested that molecular pathways can be verified in vitro to identify and 
verify pathways considered to be associated with a proposed MOA in addition to 
developing assays that correspond to these toxicity pathways for use in modelling 
[212].   
The experience encountered from this research whereby publicly available 
toxicogenomics data was analysed to see how the results correlated with experimental 
observations, makes it very difficult to imagine how an untargeted approach could be 
applied to identifying the key events on the basis of the toxicogenomics data alone, 
without the unnecessary commitment of large amounts of resources. The experience 
encountered here suggests that the identification of pathways or functions as a key 
event on the basis of the functional classifications identified by pathway analysis 
software may not be achievable from standard microarray studies alone. Attempts to 
try to do this would not only be a cumbersome process, but could potentially lead to 
the misinterpretation of the data where adaptive toxicological responses could be 
wrongly interpreted as being key events in the carcinogenic process.  
  
 
6.2.2 Challenges for the Application of Toxicogenomics Data in Regulatory Risk 
Assessment 
 
The Health and Environmental Sciences Institute (HESI) Committee on the 
Application of Genomics to Mechanism-based Risk Assessment has highlighted that a 
measure of the successful impact of toxicogenomics data in risk assessment would be 
the inclusion of such data in regulatory submission and subsequent consideration in 
risk assessment applications.  The vast amount of toxicogenomics data being 
generated has put increasing pressure for such data to be incorporated into 
toxicological risk assessment [213]. The goal for the intended move in this direction 
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was formally addressed in the report by the US National Research Council which puts 
forward their vision for the future of toxicity testing in the 21
st
 century (Tox-21c). 
Tox-21c has formalised the intentions of what is expected from genomics 
technologies and puts forward a vision of how these expectations might be realised.  
 
The landmark report by the NRC: Toxicity Testing in the 21
st
 Century: A vision  and 
Strategy (Tox-21c) was commissioned by the US EPA (and the collaborating agencies) 
and their co-ordination of this work includes their ToxCast program [214] which has 
been developed to improve their capabilities to predict toxicity based on bioactivity 
profiling. The Tox-21c report sets out the vision (Figure 6.1) for the future of toxicity-
testing system that would rely more on the improved understanding on “toxicity 
pathways” to take into account the increased understanding of biological processes to 
chemical stressors and also to enable the incorporation of evidence obtained using 
high throughput technologies (e.g. genomics) and evidence from other emerging 
fields such as systems biology and bioinformatics. It is envisioned that such 
technologies would be used in a focused way rather than for broad-based genome 
wide studies [215, 216].   
 
 
Figure 6.1: The vision for the future of toxicity testing proposed by the National 
Research Council [216]  
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The identification and use of the toxicity pathways as the basis for new approaches to 
toxicity testing and dose response modelling was stated as one of the long term aims 
of the proposed vision [216]. In addition, the vision highlighted the need to use high-
throughput assays to evaluate relevant perturbations in key toxicity pathways that 
eventually result in disease. The latter links in closely with the requirements for MOA 
analysis (description of the key events for a MOA) as it highlights the need to focus 
on the evaluation of the key pathway changes that are obligatory for an observed 
effect.  
 
While regulatory agencies like the US EPA have been keen to encourage the 
submission and use of toxicogenomics data and have even gone as far as to 
incorporate guidelines for the use of toxicogenomics data in the form of policy [52], 
they remain cautious, highlighting crucially that such data cannot be used in isolation 
as the basis for a decision [51, 52]. 
 
Similarly in the UK, the potential for the future use of toxicogenomics data has been 
acknowledged but caution has been expressed over its use in regulatory risk 
assessment. A symposium was organised by the expert advisory Committee on 
Toxicity of Chemicals in Food, Consumer Products
 
and the Environment (COT) and 
its sister Committees on Carcinogenicity
 
and Mutagenicity (COC and COM) to 
discuss the current state of science for the use of genomics and proteomics in 
toxicology. The outcome of the symposium resulted in the production of a joint 
statement from these committees that concluded that research and validation in these 
technologies were required before such data could be considered for routine use in 
regulatory risk assessment [213, 217]. 
 
Many challenges remain to be addressed for the validation of toxicogenomics based 
test systems [218] before data generated using these technologies can be more widely 
accepted and trusted by regulatory bodies responsible for risk assessment. Indeed the 
vision for Tox-21c has identified validation as one of its key areas for research and 
development. The research and development needs highlighted in Tox-21c are split 
into 4 phases that include: 
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1. phase I: the elucidation of toxicity pathways; development of data storage, 
access and management systems; development of standard protocols for 
research methods and reporting. 
2. phase II: development and validation of toxicity pathway assays and 
identification of markers of exposure, effect and susceptibility. 
3. Phase III: evaluation of assays by comparison with traditional toxicity tests 
and on chemical with large datasets. 
4. Phase IV: the use of validated assays in place of traditional toxicity tests [216]. 
 
 
6.2.3 Practical Considerations for Use of Toxicogenomics Data in Risk Assessment 
 
The vision of Tox-21 to identify key toxicity pathways links closely with the 
requirements for MOA analysis. This suggests that a more targeted approach would 
be necessary for toxicogenomics study designs in order that this vision be fully 
realised. In this respect it is very different to the suggested use of programs like IPA 
which focuses on the user identification of significantly perturbed genes/ pathways 
that may or may not be suggestive of a toxicological effect.  
 
The move towards the increased use of toxicogenomics data in risk assessment would 
rely heavily on the increased use of in vitro tests. Under the proposal for Tox-21c this 
would involve the use of a wide range of in vitro tests to identify biological 
perturbations using cellular and molecular systems based on human biology. It is the 
aim of the Tox-21c vision that these tests would eventually replace whole animal 
testing and provide improved mechanistically predictive tools for human health risk 
assessments [216, 219]. It is important to consider the extent to which data obtained 
from in vitro studies can be informative and reliable for MOA analysis. As illustrated 
with the PB case study, the data obtained from the study in human hepatocytes 
showed that some key genes (NQO1, MYC, PXR, CAR) identified as critical for 
certain pathways (e.g. oxidative stress pathway, cell proliferation and inhibition of 
apoptosis) were not observed to be differentially expressed within the dataset 
examined but were reported to be up regulated in another study identified within the 
literature.   
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The Tox-21 vision shares similarities with the vision promoted in Europe for 
alternative testing methods, based on the concept of the 3Rs (reduction, refinement 
and replacement) to strive for greater animal welfare and minimise and eventually 
phase out animal use [220]. The experience of striving for the 3Rs in Europe suggests 
that while there may have been a 60% overall reduction (spanning over 3 decades) in 
the use of animal usage in experimentation, this reduction has been attributed to the 
increased use of genetically modified mice [221] rather than the introduction of  
formally validated 3Rs alternatives [220]. The continued reliance on the use of whole 
animal models for toxicity testing in human risk assessment are attributed to the many 
challenges cited for the shortcomings of the use of in vitro testing. The latter include:  
 the inability of cell-based assays to pick up some metabolic effects, for 
example studies carried out in hepatocytes may miss out toxicities that only 
occur in the whole liver. 
 Adequate testing of metabolites: cell-based assays may not always provide a 
true reflection of the actual toxicity as the toxicity from some compounds is 
caused by a metabolite of the parent compound (this is also an issue in vivo) 
[222].  
 Adequacy of cell models, often based on tumour-derived immortal cell lines. 
 
It is interesting to note that most animal tests carried out for human risk assessment 
have not changed significantly in the last 40 to 80 years [220]. While rats and mice 
may not be the most predictive models for human, they are relatively inexpensive to 
use in terms of breeding and maintenance [220].  
 
The vision for Tox-21c promotes a paradigm shift towards the increased use of human 
primary cells. The costs of generating toxicogenomics data obtained from in vitro or 
short term in vivo techniques are considered to be relatively low when compared to 
long term testing animal testing [223], however the costs of running numerous 
microarray experiments and analysing the data produced can render them quite 
expensive. This therefore hinders their use in more detailed microarray studies to 
consider dose and time course relationships. It also means that current microarray 
studies can only provide limited information and a snapshot of information [224].  
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A more important consideration is the costs for the validation of both methodologies 
and identified genomic biomarkers to enable increased acceptance of toxicogenomics 
data by regulatory bodies. Although advocates for the use of high throughput 
technologies highlight their potential to identify biomarkers for use in human risk 
assessment, there is currently little motivation from private companies to validate 
safety biomarkers partly because they do not know how they will be used by 
regulatory bodies but mostly because the high costs of validating identified genomic 
signatures [224].  
 
One of the advantages of applying a WOE-based approach to the IPCS HRF is that it 
facilitates the identification of data gaps to potentially inform toxicological study 
design and the identification of biomarkers. The routine application of 
toxicogenomics data to inform more targeted testing could prove potentially 
expensive not least because of the inability of toxicogenomics studies to specifically 
answer key questions.  
 
 
6.2.4 General Considerations and Identified Areas for Future Work  
 
Expectations are high for the use of data generated from omics technology for 
addition to the WOE for MOA analysis and risk assessment in general. The 
comparative analysis of publicly available toxicogenomics data for PB has identified 
many challenging areas that remain to be resolved and it is clear that we are still very 
much in the early part of phase I of the vision for Tox-21c and may be here for a 
while yet. The experience encountered here suggests that current microarray study 
designs (such as the studies obtained from the public microarray repositories) may not 
be fit for the purposes envisioned by Tox-21. Indeed the Tox-21 report suggests that a 
major investment in mechanistic and method development will be required to 
accomplish their objectives. However if the expectations of omics technologies are to 
be realised, then more case studies are needed to help in method development on the 
applicability of such data particularly when using publicly available data.  
 
If toxicogenomics data (or other forms of omics data) are going to be routinely 
generated and deposited in public databases for the intended application in risk 
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assessment analysis, effort needs to be put into the development of more thorough 
methodology on how such results should be interpreted. This is especially true when 
trying to determine what the focus of such interpretations should be, particularly when 
considering several endpoints at one time, as in the case of MOA analysis which often 
requires the identification of several key events. As illustrated by the comparative 
analysis, exposure to PB leads to the perturbation of many pathways (as would be the 
case for other compounds) and the challenge here was on the identification of the 
pathways that were most likely to inform the toxicological effect of interest.   
 
 
6.2.4.1    Future work 
 
One of the advantages of applying a WOE-based approach to the IPCS HRF is that it 
facilitates the ability to read across information to other compounds that are thought 
to act via the same MOA. The potential to read across toxicogenomics information 
about a particular compound should also be explored and is potentially very powerful.  
 
For prototypical compounds like PB, it would be beneficial to explore the extent to 
which perturbed gene(s) or pathways can be read across to other compounds known 
or postulated to act via the same MOA. Again using publicly available data, it would 
be particularly useful to investigate the potential for species extrapolation for 
compounds where there is available toxicogenomics data but insufficient mechanistic 
data.  
 
Finally, it would be beneficial to develop guidance on the extent to which 
toxicogenomics pathways can be verified. The verification of pathways of interest 
could be undertaken via independent confirmation or through the systematic 
evaluation of mechanistic evidence for the involvement of the pathways in 
toxicological effects of interest. The latter approach could be undertaken by applying 
the Hill criteria as appropriate (e.g. dose, time, plausibility etc.) and this approach 
would relate directly with the strategic framework proposed in this thesis for the 
analysis of toxicogenomics data for MOA analysis.  
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6.3 Final Conclusions 
 
 
Weight of evidence analysis is an essential component of the application of the IPCS 
Human Relevance Framework in cancer and non-cancer hazard identification. 
Application of a framework approach as an analytical tool in cancer hazard 
identification encourages the use of harmonised approach to risk assessment and aims 
to improve the transparency of the risk assessment process. While the framework 
currently provides the means to facilitate the systematic evaluation and presentation 
of available evidence, the use of more formal systematic review techniques to 
evaluate the weight of evidence as illustrated in this thesis through the evaluation of 
epidemiological evidence for PB, would improve the capability of the framework to 
provide more transparent conclusions about an animal MOA and the human relevance 
(both qualitative and quantitative) of the MOA.  
 
As demonstrated by evaluation of the epidemiological evidence for PB, the use of a 
systematic approach to evaluating evidence for risk assessment, particularly when it 
includes a quality assessment of the evidence under consideration, enables a more 
transparent identification of areas of uncertainty associated with the conclusions made 
and provides justifications for the basis of any resulting decisions.  
 
The illustration of the potential application of toxicogenomics data as part of the 
weight of evidence in MOA analysis has demonstrated that while it is important to 
include and thoroughly consider all types of available evidence about the potential 
hazards of a chemical of interest, interpretation of toxicogenomics data within the 
context of MOA analysis, through the use of pathway analysis software is difficult. A 
suggested framework for the evaluation of toxicogenomics data has been proposed to 
facilitate a logical evaluation of toxicogenomics data within the context of MOA 
analysis as proposed by IPCS.  
 
The implication of gene(s) or pathway changes as potential indicators of key events 
also needs to be interpreted with caution after thorough consideration of how these 
changes reflect changes observed or expected to occur in experimental studies. While 
the potential to read across the toxicogenomics evidence obtained for PB to other 
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compounds postulated to act via the same MOA needs to be explored, such an 
approach would be useful for providing supportive evidence for the results obtained 
here but would be dependent on the availability of public data. The experience from 
this comparative analysis however suggests that at the present time, the observed 
perturbed pathways are not robust enough to be used as stand alone evidence in MOA 
analysis or in general risk assessment. In addition the evidence obtained from the 
analysis of the perturbed pathways did not add weight to the evidence currently 
available for the MOA of PB induced hepatocarcinogenesis.  Even though many of 
the “right” pathways were sometimes observed to have changed, “wrong” pathways 
were also observed to be perturbed  
 
There is a clear need to improve the transparency of the communication of the 
interpreted findings of the results obtained from the analysis of toxicogenomics data 
(and more generally omics data) and users of pathway analysis software need to make 
explicit the basis for which they have interpreted their results as evidence for a key 
event. Where such data is used as supportive evidence as part of the weight of 
evidence in MOA analysis, it should be made clear how consistent such data is with 
what is already known from experimental studies. Guidance from IPCS in this area 
would be particularly useful. More importantly, genomics investigators need to be 
more transparent and explicit about the methodology that they have applied to 
investigating the biological relevance of their findings as illustrated in the analysis 
carried out in this thesis.  
 
While there is a current drive to promote the use of omics data in the risk assessment 
process, a global commitment is needed from scientists to develop best practices for 
the interpretation of the data being generated. Such a move would go a long way to 
address the current disconnect between the expectations of what omics technologies 
will deliver and the practicalities from a risk assessment perspective of how easily it is 
to interpret the results being generated to gain a full appreciation of the pledges that 
have been made for these technologies.   
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Summary of the Outcome of the toxicogenomics comparative analysis: 
 
 Currently, prior mechanistic knowledge about a compound under investigation 
is essential to enable efficient interpretation of the biological relevance of 
perturbed pathways identified using Pathway Analysis software. 
 
 An untargeted approach to evaluating toxicogenomics evidence within the 
context of MOA analysis can lead to misinterpretation of findings for the 
association of significant genes/ pathways with potential key events.  
 
 To realise the true potential for the application of toxicogenomics data in risk 
assessment, future toxicogenomics study designs will have to be a lot more 
targeted (i.e. in their considerations of dose-response, time-response and 
species analysis) before they can be applied to help fill in the current gaps in 
mechanistic knowledge.  
 
 Current analysis based on “standard” microarray studies are unlikely to be fit 
for the purposes envisioned by Tox-21 to effectively assess key pathways that 
would be indicative of key events in the MOA for a compound of interest. 
Such studies are essentially a means to an end, so that the information 
generated is currently only of limited value in MOA analysis. 
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